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“ It is the magician that does the magic, not the wand.” 
 
Andrew Brill
Voor mijn Moeder
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Introduction
 Female sterilization, by tubal ligation or tubal occlusion, is the most commonly 
used method of family planning in the world. Overall, in developed regions 8.1% 
of women between the ages of 15 and 49 years, married or in a union, currently 
use female sterilization for contraception, compared with 22.3% of those in less 
developed regions. More than 180 million couples rely on tubal sterilization for 
contraception (1). Approximately 75% of these people live in Asia (China and India). 
The majority of procedures are abdominal, by laparotomy or laparoscopy.
 Approximately 50% of all female sterilizations are performed during Caesarean 
Section or in the puerperal period. The other 50%, which is called “interval 
sterilization”, is performed at least six weeks after the last pregnancy or delivery (2). 
Pomeroy in the 1930s made tubal sterilization well known but, because a laparotomy 
was needed, it was still considered a major procedure. The mini-laparotomy, an 
abdominal incision of 2 -3 cm in length, was first described by Uchida and colleagues 
in 1961, offered a reduced recovery time and a better cosmetic result (3). Colpotomy, 
a technique that dates back to the early 19th century, began to attract new interest 
in the 1970s. Through a small in incision in the anterior or posterior vaginal 
fault a modified Pomeroy technique or fimbriectomy was done. Surprisingly the 
complication rates in Europe and the US were much higher than those in India and 
the method was abandoned. 
Laparoscopic sterilization 
Techniques and settings of sterilization have progressively changed since the 
1960s with the introduction of minimally invasive surgery. While in developing 
countries mini-laparotomy remains the most common approach, in developed 
countries nearly all interval sterilizationsand an increasing proportion of postpartum 
sterilizations are performed by laparoscopy (4). Various laparoscopic methods 
have been introduced since 1936. Unipolar coagulation was the first method of 
laparoscopic tubal occlusion to achieve widespread use. Although highly effective, 
it was associated with early reports of thermal injuries, including thermal bowel 
lesions and deaths. In 1972 bipolar electrocoagulation of the tubal isthmus was 
first introduced, which eliminates the need for a ground plate and was safer for the 
patient (5). The first laparoscopic sterilization in the Netherlands was performed in 
Leiden in 1972 by Prof. van Hall (6). Several alternative laparoscopic techniques were 
introduced in the early 1970s. The elastic rubber band was developed by Yoon. The 
band is introduced with a specially designed laparoscopic applicator. The application 
of the band onto a tubal loop is associated with 2-3% incidence of haemorrhage 
from stretching the vessels underneath the tube or tearing the tube itself (7). 
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Approximately 3 cm of constricted tube undergoes necrosis. An advantage of the 
spring/Hulka clip was that it only compresses 3 mm of the mid-isthmus of the tube. 
As a result, anastomosis for reversal of sterilization is fairly successful. Another 
technique, described by Filshie and colleagues, uses a silicone rubber-lined titanium 
clip that is applied to the mid isthmus and must include the entire circumference of 
the tube (8). The Filshie Clip has been used around the world for the past 20 years 
and was approved by the Food and Drug Administration in the United States in 1996. 
All methods currently in use are highly effective when performed properly, 
although pregnancy can occur in spite of optimal application. Such failures are often 
due to tuboperitoneal fistula formation. When pregnancies do occur they are much 
more likely to be ectopic than pregnancies during use of other methods or when no 
method is used. The risk of pregnancy persists during the fecund period and it is 
therefore important to consider the long-term cumulative probability of pregnancy 
with any contraceptive method -or methods- over time. Unfortunately there are no 
controlled trials comparing the different laparoscopic techniques with a follow-up 
period long enough to provide evidence on long term failure rates (1,9). Pregnancies 
can and do occur even many years after sterilization, as has been documented by the 
U.S. Collaborative Review of sterilization (CREST study) (10) in which pregnancies 
occurred in the 10 years after each of the four methods of laparoscopic sterilization 
studied (unipolar coagulation, bipolar coagulation, silicone rubber band application, 
and spring clip application). An analysis of the experience of 10,685 women followed 
prospectively for up to 8 to 14 years in the CREST study identified 143 sterilization 
failures (pregnancies other than luteal phase pregnancies) and found that the risk 
of pregnancy after sterilization varied by age at sterilization and method of tubal 
occlusion. The 10-year cumulative probability of pregnancy was low for most women 
aged 34-44 years at sterilization but was as high as 5% for women aged 18-27 years with 
two methods (bipolar coagulation and spring clip application). Another noteworthy 
finding from this analysis is that the risk of pregnancy accumulated over time. The 
timing of sterilization failures varied by method; for example, a high proportion of 
pregnancies after clip application occurred in the first three years after the procedure, 
whereas pregnancies after bipolar coagulation occurred at approximately the same 
rate year after year. A total of 47 (32.9%) of the 143 pregnancies identified were ectopic. 
The cumulative probability of ectopic pregnancy, like that for pregnancies overall, 
increased over time and varied by method of occlusion and age at sterilization (11).
The findings from this review of sterilization techniques should be interpreted with 
some precaution, keeping in mind that they were based on procedures performed 
more than 20 years ago and that a substantial number of the procedures were 
performed shortly after the introduction of laparoscopic sterilizations in the USA. 
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A subgroup analysis of women undergoing bipolar tubal coagulation showed that 
the cumulative failure rate during the period 1978 – 1982 (19.5 per 1,000) was three 
times higher than during the period 1985 – 1987 (6.3 per 1000). In addition, those 
women who had three or more sites coagulated had a very low probability of pregnancy 
(3.2 per 1,000) compared to women with fewer sites coagulated (12.9 per 1000).
The Filshie Clip was not available in the United States until 1996 and was not 
included in the U.S. Collaborative Review of sterilization. However, published data 
suggest that the clip is, like the other methods of tubal occlusion, highly effective. 
Four studies from the Family Health International (FHI) were designated pivotal 
evaluations: all were prospective, randomised and multicenter investigations of 
interval sterilizations. A 12-month cumulative pregnancy rate of 0.1-0.2 per 100 
women for the Filshie Clip were reported (12). Long-term follow-up data for the Filshie 
Clip such as those obtained by CREST are limited. A five-year follow-up study from 
Kovac and Krins involving 30,000 women revealed a failure rate of 73 per 30,000 (2.4 
per 1,000) (13).
Hysteroscopic sterilization 
The idea of utilising hysteroscopy for tubal occlusion goes back for more than a 
century. In the last 100 years transcervical approaches were studied and promoted 
during four separate periods, beginning in the early 1920s. During World War 
II, in 1942, Clauberg started his criminal research in Auschwitz on thousands of 
imprisoned Jewish and Gypsy women, looking for a cheap and efficient method 
to sterilise women. He injected acid liquids in to their uterus without the use of 
anaesthetics. After the war Lindemann continued sterilization experiments with the 
Claubergs technique of coagulating the fallopian tubes (14). The fourth period started 
at the beginning of this century (15). Hysteroscopic sterilization techniques have been 
sought because they avoid the risks of the laparoscopic route, they allow women a 
quicker return to normal activities and are especially useful in women for whom 
laparoscopy is contraindicated. The methods for tubal closures include chemical 
applications, mechanical devices and thermal methods where electrosurgery, 
cryocoagulation, radiofrequency and laser are used. 
Thermal
In 1934 the first hysteroscopic sterilization with electrocoagulation was performed 
in two patients. Both procedures were unsuccessful. In the 1970s an overall bilateral 
tubal occlusion rate of 83% was achieved, but pregnancies including ectopics were 
reported (16). Finally the method did not prove to be reliable and suffered from serious 
complications due to bowel injury (17). Other methods with cauterization of the tubal 
openings have not been developed further (18,19,20).
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Chemical
Quinacrine sterilization is used in many developing countries because of good results 
and low costs. The technique requires two insertions of quinacrine into the uterine cavity. 
This can be done “blind” or by hysteroscopic guidance and direct tubal instillation by a 
specially developed catheter (21). The procedure is reported to have a 1-2% failure rate, 
although the rates for ectopic pregnancy and serious complications are equal to or less 
than those for transabdominal sterilization (22,23,24). Drawbacks from the procedure 
include the need for multiple applications and the problem of reliably confirming tubal 
occlusion. An HSG is not recommended, because of the risk to blow out the delicate 
occluding scars (25). The need to make this procedure simple, safe, inexpensive and 
thereby more acceptable, even in countries with limited surgical facilities is well 
recognized. Use of quinacrine pellets has become the most widely adopted method of 
non-surgical female sterilization (26). The Family Health International has recently 
decided not to pursue further research on quinacrine, partly because of the relatively 
high pregnancy rates after quinacrine compared to other contraceptive methods 
(27). The 10-year pregnancy probability is approximately four times higher than after 
laparoscopic tubal sterilization (bipolar coagulation) as reported by CREST.
Mechanical
To avoid the risk of complications many different device were developed and 
have been tried during the second half of the last century. Most of the devices were 
unsuccessful (24). Three devices became commercially available and were introduced 
on the European Market.
Ovabloc Intra-Tubal Device
The concept of blocking the fallopian tubes with silicone was first introduced by 
Crofman (28). The first studies performed on rabbits, proofed an efficacy of 100% if 
the silicone material was applied up to the isthmic part of the tubes. Erb developed 
a technique for hysteroscopic intratubal administration of liquid silicone, mixed with 
a catalyst and cure-in-place to form rubbery implants, with the aim of producing a 
non-incisional, non-scarring method for permanent contraception with minimal 
discomfort for the patient (29).
This Ovabloc method has been in use since 1978. Phase II and III studies were 
performed in the late 1970s and early 1980s in Belgium and the USA (30). These FDA 
trials were stopped when the initially assumed reversibility was poor (31,32). In 1985 the 
Ovabloc procedure became commercially available in the Netherlands (Ovabloc Europe 
BV, Alphatron Medical Systems, Rotterdam, later Advanced Medical Grade Silicones BV, 
Beverwijk, the Netherlands), where its use has mainly been confined to a few centers 
(33). A CE Mark for the European market is achieved in 2001. 
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The insertion is an outpatient procedure. The procedure involves high pressure 
injection of viscous silicone into the ostium with a catheter placed in the tubal 
ostium through a hysteroscope with a 7 French working channel. The silicone 
conforms to the shape of the ampoule of the tube and solidifies in approximately 
five minutes. The silicone contains radio-opaque silver powder, which enables a 
radiological check for correct placement at completion of the procedure. Bilateral 
placement takes around 30 minutes. The woman is asked to use contraception for 
three months, at which point a second plain X-ray is performed to exclude migration 
and expulsion. Published data report a high failure rate, expulsion to the abdominal 
cavity and complete expulsions. The method never became very popular, probably 
because it was too complicated. It was stopped in 2009. In 2012 CE approval was 
obtained for Ovalastic (Urogyn BV, Nijmegen, the Netherlands), which is the result 
of a technical upgrade of Ovabloc. With this upgrade the manufactory claims a less 
time consuming, more reliable and safe procedure.
Essure
In November 2002 the Food And Drug Administration approved the Essure 
sterilization while it has been available on the European market since 2001 (Conceptus 
Inc. Mountain view, CA, USA). The device is a dynamically expanding insert that 
consists of a stainless steel innercoil, a nickel titanium (nitinol) expanding outercoil 
and Polyethylene Teraphtelate (PET) fibres. The device, with a length of 4 cm, is placed 
into the fallopian tube using a modern standard hysteroscope with a 5 French working 
channel. After placement the device will be anchored in the tubo-cornual junction by 
the expanded nitinol coil. The PET fibres induce an inflammatory reaction that causes 
scarring and occlusion of the tubes. The exact time that it takes for tubal occlusion 
of the tubes to allow the patient to rely on the devices as permanent contraception is 
unknown (34). Obliteration of the tubal lumen was demonstrated histologically in four 
of nine tubes removed within four weeks after device placement and five of five tubes 
removed within four to eight weeks after placement. Functional occlusion confirmed 
by hysterosalpingography (HSG) was already confirmed one week after placement 
(35). Patients are instructed to use alternative contraception until a three months 
confirmation test has shown adequate bilateral localization and tubal occlusion. In 
the US a HSG is required for confirmation according to the FDA approval while in 
other countries, scout X-ray or transvaginal ultrasound is used for confirmation. The 
ESS205, a modification of the former ESS105 device, with higher insertion rates was 
introduced in 2004. In 2007 the ESS305 with automatic release mechanism of the 
introducer catheter and a special introducer was introduced.
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Successful placement is achieved in 95-99% of the cases in an office setting 
(36,37). Worldwide more than 500,000 women rely on Essure sterilization. 
The cumulative nine years failure rate is 0.2% on the basis of follow-up data 
from 449 women included in the phase II and pivotal trials (34) More than 700 
unintended pregnancies are reported (38). Data analysis of patient files shows that 
44% of the pregnancies are attributed to patient non-adherence to the protocol or 
misreading of the confirmation test. Shavell reported a 12.7% compliance with the 
three months HSG in a general clinic population in an urban environment, despite 
both preoperative and postoperative counselling and a follow-up rate of 70% for the 
one-week postoperative control (39). 
Adiana
Adiana’s complete transcervical sterilization procedure (Adiana Inc., Redwood 
City, CA purchased by Hologic, USA) is a two-stage procedure. First, a superficial 
lesion of the epithelium of the intramural part of the tube is created with bipolar 
radiofrequency energy. The second step is placement of a 3.5 mm porous, silicone, 
non-biodegradable implant (matrix) into the tubal lumen. The implant provokes a 
fibrous reaction that occludes the tube over a period of weeks. Patients must use 
alternative contraception for three months until an HSG is performed. A CE Mark 
for the European market was obtained in December 2008 and the FDA approved 
the application in July 2009. The Evaluation of Adiana System (EASE trial) was 
completed in 2005 (40). It was stated that 611 women were treated, with a 95% 
bilateral insertion rate. Almost half of the patients (47%) received conscious sedation 
with an intravenous agent. The HSG confirmation test after three months showed 
tubal patency of one or both tubes in 8.8% of the patients. During the first four years 
of this trial, 15 pregnancies have been reported. Five of the pregnancies occurred 
while subjects were instructed to rely on an alternate contraceptive: two pregnancies 
following placement failure, and three pregnancies after successful placement, 
but during the waiting period (patient non-compliance). Ten pregnancies occurred 
following successful placement and HSG showing tubal occlusion. Six of these 
pregnancies occurred in the first year of rely. Retrospective review of HSGs for three 
of these subjects suggests that the diagnosis of tubal occlusion was in error (misread). 
The six pregnancies contributed to a one-year failure rate of 1.1%. In March 2012, 
the manufactory decided Adiana was not generating the expected revenue and the 
manufacturing of Adiana was stopped. At that moment a long-standing battle over 
patent infringement between the two companies was going on.
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Hysteroscopy
Between the 1970s and 1980s modern hysteroscopy was introduced. Procedures 
for distending the uterine cavity were introduced, with carbon dioxide and 
high-molecular weight fluids to allow visualization of the uterine cavity and tubal 
ostia (15). The Ovabloc ITD procedure was performed with a single flow hysteroscope 
with an Alberan deflexion bridge, initially with Hyskon (32% Dextran 70 in 10% 
glucose) or carbon dioxide as distension medium. From 1991, a continuous flow 
8.0 mm hysteroscope with a 2.2 mm (7 French) working channel and an Alberan 
deflexion bridge, fitted with a 4.0 mm 300 fore-oblique telescope was used with 
sorbitol for uterine distension (33).
At the beginning of the 1990s, scopes were used with operative sheats with a 
diameter equal or less than 5.5 mm with a working channel of 1.7 mm (5 French) 
and telescopes with a diameter ranging between 1.2 and 3.0 mm. With the use of 
these smaller instruments the use of a speculum and tenaculum and dilatation 
of the cervix was no longer necessary: the vaginal cavity can be distended with a 
distension medium to facilitate location of the cervical canal. The anatomy can be 
followed by gentle movements of the hands that correctly drive the hysteroscope 
into the cervix and through the internal cervical os (41). This method has been 
defined as the “vaginoscopic approach”, the patient discomfort associated with the 
traditional approach to the uterus has been eliminated (42).
As anesthesia and analgesia are not required for hysteroscopy, women now have 
the option of permanent contraception while avoiding the risk associated with 
laparoscopy and general anesthesia. Some physicians are still hesitant to perform 
the procedure in an office setting, most commonly citing patient discomfort as the 
major concern, but several studies support high tolerability and satisfaction with 
an office approach (43).
One study indicates that patients undergoing hysteroscopic sterilization experience 
significantly less pain than those undergoing laparoscopic sterilization (44).
Paracervical block with 1% lidocaine provides effective pain relief for cervical 
manipulations during office hysteroscopic sterilization, but does not reduce the pain 
associated with upper uterine/tubal manipulation when placing the devices (45). 
Pain scores were associated with procedural time. A likely explanation for this 
is that procedural time is a marker for difficulty of the procedure or skills of the 
hysteroscopist. In general, the more difficult the Essure placement is, the longer it 
will take to achieve correct placement, and frequently additional manipulations are 
needed to assist in appropriate placement, the more cramping of the fallopian tubes 
will be induced. An important finding is that the largest difference in observed pain 
scores was 2.3 on the VAS. Even though for the purposes of this study a relatively 
conservative difference of 0.9 on the VAS was used to be clinically relevant to prevent 
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under powering, some studies indicate that the clinically relevant VAS difference is 
around 2.5. Therefore, although a difference was observed and found to be statistically 
significant, this may not represent a clinically relevant difference. When examining 
the placebo group, we observed that pain was not significantly greater than reported 
menstrual pain. This is critical when counselling patients regarding the pain from 
the Essure procedure, as well as likely other office hysteroscopy procedures that 
require less manipulation than Essure. Because pain is one of the most common 
patient concerns when choosing to undergo an office procedure, the ability to tell a 
patient that the pain will be similar or less than a typical menstrual period can be 
very reassuring for many patients (45).
According to a Cochrane review from 2012 the available literature is insufficient 
to determine the appropriate pain regimen for outpatient sterilization by 
hysteroscopy. Neither paracervical block with lidocaine nor conscious sedation 
significantly reduced overall pain scores during sterilization by hysteroscopy with 
Essure. Although paracervical block with lidocaine did not reduce overall patient-
reported pain, it did reduce pain during some portions of the procedure, particularly 
with injection into, or manipulation, of the cervix. Since paracervical anesthesia is 
safe and inexpensive it may be a reasonable option. The provision of intravenous 
conscious sedation did not reduce the total pain score but did significantly reduce 
pain at the time of insertion of the second tubal insert; this is one of the most 
painful parts of the procedure. Thus, it may have some benefit (46).
Confirmation test
In the late 1970s the hysterosalpingography (HSG) was abandoned as a routine 
follow-up after laparoscopic sterilization because of discordance between tubal 
patency and pregnancy rate. In a study of 250 women with laparoscopic tubal 
fulguration the patency rate with HSG was 3.6% while the pregnancy was only 
0.62%. A review of additional contemporary studies confirmed discordant patency 
and pregnancy rates (47).
The results of the CREST review did not change the policy of confirmation of 
laparoscopic sterilization. The CREST review reported an overall cumulative failure 
rate of 1.9%. This was more than double what has been accepted as the standard 
failure rate for tubal sterilization. This failure rate contrasted sharply with previous 
studies of common tubal occlusion techniques that cited figures lower than 1%. 
Until then, comparisons of contraceptive failure rates had reported the probability 
of failure during the first year after sterilization ranging between 0% and 0.4% 
(48). These failure rates, however, were based on investigations having only one or 
two years of follow-up. Alternative diagnostic tests for confirmation of laparoscopic 
sterilization have not been described.
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An HSG is also not recommended after transcervical sterilization with quinacrine, 
because of the risk to blow out the delicate scars (25). No other tests have been evaluated.
For all hysteroscopic techniques initially a HSG was recommended. For the 
Ovabloc method finally two X-rays images were required to evaluate the effectiveness 
of the device: one X-ray immediately following instillation to check the integrity and 
shape of the plug and a second X-ray at three months post-instillation to check the 
proper location of the Ovabloc devices. This decision that patients could not rely on 
the sterilization for three months was an arbitrary point in time (49).
In the US, according to the FDA, an HSG is required after hysteroscopic 
sterilization with Essure, while in Europe and other countries initially X-ray was an 
accepted alternative. In February 2011 the Conformité Européene Mark approved to 
use Transvaginal Ultrasound (TVU) to confirm proper placement of the microinsert, 
three months following the procedure. Available data confirm that proper location 
of the microinserts correlates very well with tubal occlusion and high effectiveness 
(50). Evaluation of data from 745 patients with unintended pregnancies showed a 
high incidence of misreading of the HSGs and patient non-compliance to the HSG 
confirmation test (38). In an urban clinic population in Michigan the compliance 
to a protocol with HSG revealed only 12.7%, despite correct counselling and a 70% 
follow-up rate for the post-operative visit (39). Studies with confirmation tests other 
than HSG report higher patient compliance (36,37,43, 50).
The first and only study available data for the Adiana method reports 53 of 604 
patients with unilateral or bilateral tubal patency with the three months HSG. By 
six months post-procedure, 26 still showed at least unilateral patency. With TVU, 
598/604 subjects had devices visualized bilaterally. There have been a total of 10 
pregnancies among 553 women who were told to rely on Adiana for contraception 
based on the three-months HSG, two pregnancies of which were ectopic. It is unclear 
how the TVU imaging correlates with these unintended pregnancies. The devices are 
not radiopaque, therefore pelvic X-ray is not useful for the confirmation (40). 
There is a need for other tests to confirm proper position and tubal occlusion 
after sterilization. HSG is still the gold standard. The procedure is invasive and 
uncomfortable for the patient. In addition it is associated with infection, vasovagal 
reaction and anaphylactic shock. Also uterine bleeding and perforation may occur. 
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Alternative ideas are suggested and are subject of research: 
-  Contrast Infusion Sonography (CIS) or Saline Infusion Sonography (SIS). NaCl 
infusion in the uterine cavity while inspecting for real time flow within the tube 
or unequivocal dye spill in the adnexa (51).
-  Hysterosalpingo Contrast Sonography (HyCoSY) with the use of an ultrasound 
contrast agent to examine tubal patency.
-  Volume Contrast 3D Ultrasound produces a 5 mm thick volume image in the 
C-plane (VCI-C) similar to HSG. The images yield more detail with regard 
to the relationship of the device to the uterine cavity than conventional (2D) 
ultrasound or HSG. Like 2D US it gives information about the position of the 
microinsert but not about the integrity of the fallopian tubes. A Classification 
has been developed to assess the position of the microinsert. Four positions 
are described: perfect, proximal, distal and very distal. Only the last one is 
associated with a higher chance of tubal patency on HSG (52,53).
Tubal occlusion prior to IVF
Hydrosalpinx is associated with poor in-vitro fertilization outcome but the actual 
mechanism is not yet fully understood. The passage of hydrosalpingeal fluid into the 
endometrial cavity might create an unfavourable environment for embryo implantation 
or development (54). Laparoscopic salpingectomy prior to IVF in patients with ultrasound-
visible hydrosalpinges is recommended. Hysteroscopic sterilization techniques offer 
the possibility of an alternative for salpingectomy by proximal tubal occlusion prior to 
IVF. Previous reports estimated the efficacy of proximal tubal occlusion in patients with 
hydrosalpinges and shows excellent reproductive outcomes after Artificial Reproduction 
Techniques (ART). The presence of nickel in the Essure device is cause of concern related 
to embryologic development, but Nitinol showed no cytotoxic, allergic or genotoxic 
activity in animal studies (55). Second look hysteroscopy after Essure placement showed 
that the devices are encapsulated and the devices may therefore be compatible with 
implantation and successful pregnancies outcomes after IVF (56).
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Aims of this thesis
- To review the history and current practice of hysteroscopic sterilization.
-  To review placement rates, effectiveness and safety of current  
hysteroscopic sterilization methods.
-  To validate different diagnostic tests for the three months confirmation after 
hysteroscopic sterilization.
-  To evaluate the outcome of unintendend pregnancies and IVF pregnancies 
after regret or pre-procedure closure of hydrosalpinges.
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Outline of the thesis
Chapter 2  determines the placement rate, efficacy and safety of hysteroscopic 
sterilization methods that are currently available or has 
been available.
Chapter 3  determines the diagnostic characteristics of  X-ray and transvaginal 
ultrasound to localize Essure microinserts after successful 
bilateral placement.
Chapter 4  determines the reproducibility and inter-observer agreement 
of pelvic X-ray 3 months after hysteroscopic sterilization 
with microinserts.
Chapter 5  describes different types of incorrect position of microinserts 
after successful bilateral placement.
Chapter 6  estimates the causes of unintended pregnancies after hysteroscopic 
sterilization and determines whether this can be prevented.
Chapter 7  evaluates the protocol for confirmation of satisfied position of 
microinserts after hysteroscopic placement based on first-line 
examination with transvaginal ultrasound.
Chapter 8  determines the success rate of proximal tubal occlusion with 
microinserts in subfertile women with hydrosalpinges.
Chapter 9  evaluates the obstetrical outcome of intended and unintended 
pregnancies after Essure hysteroscopic sterilization.
Chapter 10  summarizes the results of the studies presented in this thesis and 
gives clinical implications and implications for future research.
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Introduction Broad implementation of hysteroscopic sterilization techniques has resulted in questions 
about its clinical value compared to laparoscopic sterilization techniques. This systematic review was 
conducted to evaluate the feasibility, safety and efficacy of different hysteroscopic sterilization techniques 
and to identify risk factors for failure. 
Methods This systematic review was conducted according to the PRISMA guidelines. Medline, 
EMBASE, Web of Science and the Cochrane library were searched for articles on hysteroscopic 
sterilization. Two reviewers independently selected cohort studies that evaluated placement rate, 
rate of confirmed correct placement 3 months post procedure complications and risk factors for 
failure of hysteroscopic sterilization. Main outcome data were probability of successful placement 
at a first placement attempt, probability of confirmed correct placement after successful placement, 
incidence of pregnancy after confirmed correct placement and identified factors that influence the 
rate of successful placement. 
Results A total of 45 original articles were selected. Six articles concerned Ovabloc, 37 Essure and two 
Adiana sterilization. The placement rates for Ovabloc, Essure and Adiana, were respectively: 80% (95% 
CI: 76-83%), 92% (95% CI: 91-94%) and 94% (95% CI: 91-95%). The percentages of women that could 
rely on successful bilateral placement confirmed at three-months follow-up were respectively: 96% 
(95% CI: 93-96%), 97% (95% CI: 96-98%) and 91% (95% CI: 89-93%). The chance that a patient 
could rely on a successful bilateral placement of Ovabloc in one attempt and confirmed after three 
months was 77%, for Adiana 86% and for Essure 89%. Twelve pregnancies occurred in 1,212 patients 
who were sterilised with Ovabloc method (10/1,000), 8 pregnancies occurred in 7,706 women after 
Essure sterilization (1/1,000). The 36 months cumulative pregnancy rate of Adiana was 16/1,000. 
Procedural and post-procedural complications were mainly related to placement failures including tubal 
perforation, expulsion or migration of the tubal device. Complications other than failed sterilization 
were rare and of minor clinical importance. 
Conclusion This systematic review demonstrated that all three hysteroscopic sterilization methods were 
feasible, safe and highly effective. The range of pregnancy rates are comparable to other sterilization 
techniques fromthe CREST study. The Essure method had the highest probability of successful 
placement in a first attempt, confirmed at three months and the lowest pregnancy rate. According to the 
results in this review, hysteroscopic sterilization is an attractive alternative for laparoscopic sterilization.
Abstract
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Introduction
The hysteroscopic approach to female sterilization has been studied for more 
than a century. The initial techniques often proved to be difficult, inefficient and 
dangerous. Failure rates were high and serious complications by perforation and 
thermal bowel lesions were reported in clinical trials (1,2). Nevertheless there was 
continuing belief that hysteroscopic sterilization would be a suitable method for 
permanent contraception. This was prompted by the facts that the hysteroscopic 
route avoids the transabdominal route, the risks of entering the peritoneal cavity 
are evaded resulting in less morbidity, a reduced need for anaesthetics and a quicker 
return to normal activities. Hysteroscopic sterilization can be fitted in an ambulatory 
setting and provides an option for women who whish to avoid incisional surgery or 
general anesthesia.
In the past decades, three systems became available on the commercial market: 
the Ovabloc Intra Tubal Device (Advanced Medical Grade Silicones BV, Reeuwijk, 
the Netherlands) in 1988 (3), the Essure system (Conceptus Incorporated, Mountain 
View, CA, USA) in 2002 (4,5) and the Adiana Permanent Contraception system 
(Hologic, Inc, Bedford, MA, USA) in 2009 (6). The Ovabloc device is a silicon 
mixture that is instilled into the tubal ostium and solidifies within five minutes into 
a rubber plug. The Essure device is a 4 cm expanding spring made of a nitinol outer 
coil and stainless steel innercoil with PET fibres, placed in the proximal section 
of the fallopian tube. Adiana is a combination of 60 seconds of radiofrequency 
appliqued to the mucosa of the fallopian tube followed by deployment of a 3.5 mm 
matrix into the created lesion. These distinct mechanisms of action, may lead to 
differences in feasibility, safety, required confirmation test and efficacy.
The above described techniques all require a so called ‘confirmation test’ three-
months post-procedure to verify proper placement. While conventional laparoscopic 
approach and abdominal approaches are effective immediately, hysteroscopic 
systems require a period of three months after the procedure for fallopian tubes 
to undergo fibrosis leading to occlusion and contraceptive efficacy (5,6,7). During 
these three months women have to use additional or alternative contraception. A 
hysterosalpingogram (HSG), pelvic X-ray or ultrasound is used to verify correct 
placement. For some techniques, it is argued that the post-procedure imaging 
should be eliminated based on the fact that in the original clinical trials, 96% of 
patients with successful bilateral placement had complete tubal occlusion at three 
months and 100% at six months (4,5).
Data from phase II and III clinical trials with Adiana and Essure have shown high 
feasibility, safety and efficacy (4,5,6). It remains questionable if daily practice results 
are comparable with these earlier results. Identifying risk factors for placement 
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failure will be important in patient selection and for identifying cases at risk for 
failure of hysteroscopic sterilization.
A Cochrane review published in 2011 on interruption of tubal patency for female 
sterilization indicated no randomised controlled trials comparing sterilization by 
laparoscopy or mini-laparotomy to sterilization by hysteroscopy (8). A pilot study 
to assess the feasibility of conducting a comparative study in a randomised fashion 
showed that less than 8% of the women included were willing to be randomised 
(9,10). This was explained by a strong personal preference to undergo either a 
hysteroscopic or a laparoscopic procedure.
While long-term studies on large cohorts of women have assessed sterilization 
after abdominal and laparoscopic approaches, less is known about the feasibility 
and efficacy of the hysteroscopic approach. Data on rare and long-term outcomes 
are available from cohort studies, rather than from randomised controlled trials. 
Further comparative trials are not considered to be high priority for research (8).
We conducted a systematic review to examine the feasibility, efficacy and risk 
factors for failure of hysteroscopic sterilization techniques. Secondary we aimed to 
determine if confirmation tests are still necessary for sterilization by hysteroscopy.
Methods 
This systematic review was conducted according to the PRISMA guidelines. All 
longitudinal studies addressing hysteroscopic sterilization were considered for 
inclusion, both prospective and retrospective. Studies were included if (successful) 
placement rate, efficacy, safety or risk factors for failure of hysteroscopic sterilization 
was investigated. Only original studies with > 20 consecutively included participants 
were selected, to allow pooling of data. Descriptive articles, case-series (with 
non-consecutively included participants), reviews, surveys, technical reports and 
congress abstracts were excluded. No language restriction was applied. All types 
of participants undergoing tubal sterilization by hysteroscopy were included. 
Animal studies were excluded. Excluded were studies wherein electrocoagulation 
or chemicals (e.g. quinacrine) was used to obliterate the tubes.
To assess feasibility, we consider successful placement rate, percentage of confirmed 
proper placements and the occurrence of procedural complications as outcomes. As 
efficacy refers to the ability to prevent conception from occurring, we evaluated the 
rate of unintended pregnancies after confirmation of correctly placed devices. 
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Hence we formulated the following research questions:  
1.  What is the probability of a successful placement at the first  
attempt of sterilization by a hysteroscopic procedure?
2.  What percentage of women have a confirmed correct placement  
of the devices three months after the procedure?
3.  What are the risk factors for placement failure of the devices used  
for hysteroscopic sterilization ?
4.  What are the complications of hysteroscopic sterilization and what  
are their incidences?
5.  What is the incidence of pregnancy after confirmed correct placement?
We defined (successful) placement rate as the percentage of women that had 
successful bilateral procedures in a first attempt. For Ovabloc a successful 
placement is defined as a successful bilateral instillation immediately followed by a 
satisfactory X-ray showing adequate filling, continuous from the tip to the ampulla. 
In the Pivotal Essure trial, a pelvic X-ray was performed 24 hours following device 
placement to serve as baseline evaluation of device location. Unless the microinsert 
had a trailing length greater than 18 expanded outer coils the placement was 
considered successful. For Adiana this means confirmation of placement at 
one-week post-procedure using transvaginal ultrasonography. Confirmed correct 
placement rate was recorded as the percentage of women with bilateral correct, 
unaltered positioned devices three-months post-procedure, out of the total number 
of women who had a successful placement. The related risk factors for placement 
failure were abstracted from both uni- and multivariate analyzes. We studied safety 
by recording intra- and post procedural complications other than failed sterilization. 
We defined complications as an unanticipated problem possibly causing harm to 
the patient that arises following the procedure (6,7,16,34,36,37,38). Symptoms 
related to patient tolerance of the procedure (e.g. pain, vasovagal reaction, nausea, 
vaginal spotting or post procedure bleeding) were not classified as complication. 
Efficacy was recorded as the cumulative pregnancy rate per specified unit of time 
as part of the total number of participants. All outcomes were evaluated per specific 
sterilization technique.
Search methods for identification of studies
Medline (PubMed version), EMBASE (OVID version), Web of Science and the 
Cochrane library were searched by a clinical librarian up to January 2013, without 
language restriction or methodological filters. The exact search is appended to 
this article (appendix 1). 
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Two reviewers (CC and SV) independently screened titles and abstracts for 
relevance. The bibliographies of included articles were then hand-searched for 
other relevant references. 
The same reviewers independently extracted study and patient characteristics 
and outcome data. The methodological details, number of included patients 
and descriptive study characteristics (for example country where the study was 
conducted, recruitment modality, source of funding), characteristics of the 
participants (for example age, body mass index parity), description of the device 
(type, version), description of the procedural setting (in-office or Operation 
Room, type of anesthesia, experience of the physician), co-interventions (for 
example polypectomy, endometrial ablation), and outcomes (types of outcomes, 
documentation of drop-outs, follow-up, standardization of outcome assessment) 
were extracted. Disagreements were reconciled by discussion with an arbiter (FWJ 
or HAMB). Data related to the defined outcomes were assessed for inclusion in 
the meta-analysis. 
The methodological quality of the included studies was assessed using a 
pre-defined checklist. Study limitations were reviewed for appropriate eligibility 
criteria; adequate measurement of outcomes: successful placement rate, confirmed 
correct placement, complications and pregnancies; selective reporting and other 
bias (e.g. confounding factors). Pooled probability of successful placement, 
confirmed placement and pregnancy were conducted using ‘R’ version 3.0.2. (11). 
The probabilities are shown with their 95 per cent confidence interval (CI).
Results 
The search produced 429 unique references, of which 66 were considered 
relevant to the topic based on title and abstract. A total of 11 case reports or series 
and one descriptive study were excluded. Nine eligible articles were excluded 
because of indistinctness about uni- or bilateral successful placement or double 
publication of data. Figure 1 shows the flow diagram of the selection process. 
Finally, a total of 45 articles were eligible for our analyzes: six articles concerned 
Ovabloc, 37 Essure and two Adiana sterilization. 
Ovabloc
Of the Ovabloc Intratubal Device study characteristics are shown in the table 
of Characteristics of included Ovabloc studies (3,7,12,13,14,15) (appendix 2). 
A total of 2,039 women were included in two prospective and four retrospective 
studies. The articles were published between 1983 and 1999.
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All participants were consecutively included. Two studies were multicenter and 
four were single-center. Two articles included cohorts that had overlap with each 
other (7,15). None of the studies reported a potential conflict of interest. The 
number of participants in each trial ranged from 115 to 438. The age range was 
18 to 46 years. The exclusion criteria were clearly defined in five articles. Three 
studies included nulliparous women (3,12,15). There are considerable differences 
in exclusion criteria between studies. In one study tubal patency was tested with 
perfusion of diluted methylene blue dye (MBPT) before instillation. Women with 
no tubal patency in one or both tubes were excluded for an installation attempt (12). 
All procedures were performed with a paracervical block. One study reported 
pre-medication of naproxen 12 hours and 2 hours before the procedure with 
atropine 30 minutes before the procedure (3). In three studies office hysteroscopy 
was performed with a 8 mm single flow (SF) system (Hyskon or CO
2
) (7,14,15), 
while in two studies a continuous flow (CF) system with low viscosity distension 
medium was used (12,13). In one study both SF and CF techniques were used (3).
Figure 2 shows the risk of bias graph for included Ovabloc studies. Follow-up data 
for pregnancies and complications other than failed sterilization were undefined, 
mainly based on self-reporting, and probably incomplete.
Feasibility of Ovabloc
The number of successful Ovabloc placements at first attempt was reported in 
five studies (n=1,601 women)(3,12,13,14,15). The probability varied between 78% 
and 84% with a pooled probability of 80% (95% CI: 76-83%) in a random effects 
model (figure 3). In one study, the lower success rate was explained by the inclusion 
of women with retroflected uterus, minor intrauterine pathology and nulliparity, 
resulting in a more difficult catherization of the tubes. Also the use of single flow 
hysteroscopy was cited as explanation (3). In a second study with a lower probability 
for successful placement, 50/411 (12.2%) of women were refrained from an 
installation attempt (12).
After successful bilateral placement the pooled probability for confirmed correct 
placement three months post-procedure is 96% (95% CI: 92-98%). One study 
reported uterine wall perforation five times in 438 cases (7).
Efficacy of Ovabloc
Approximately 100/1,312 (7.5%) of women could not rely on Ovabloc after 
successful placement, based on results of three-months confirmation tests. A total 
of 12 pregnancies were reported in women that had passed a proper three-months 
confirmation test, with good results (n=1,212)(3,7,12,13,15). The pooled prevalence 
of pregnancy is 1% (95% CI: 1-2%) (figure 5). 
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The majority of pregnancies (n = 8; 67%) occurred in the first three to 24 months after 
the procedure. Other reasons for discontinuation of reliance on Ovabloc sterilization 
were spontaneous expulsions (n=65) and removal or migration of the silicon plugs 
(n=30). One study reported a total of 18 women with normal plugs damaged by D&C 
and plugs removed in hope of becoming pregnant (15). In 47 women expulsion and 
removals were reported after the three-months confirmation X-ray (9,12,13)
Risk factors for placement failure
Univariate analyzes for risk factors were performed in two studies (3,12). Van der 
Leij et al compared 71 failed to 340 successful procedures and found nulliparity, 
intrauterine pathology and an asymmetric cavum to be associated with failure 
(12). De Blok et al. compared Ovabloc sterilizations performed with single flow to 
continuous flow hysteroscopies. Ovabloc procedures performed with continuous 
flow hysteroscopy had lower failure rates due to failed instillation of silicon in the 
tubes or insufficient visualization. The failed procedure rate decreased from 29% 
to 12% when continuous flow hysteroscopy was used, this was not statistically 
significant. Three other studies explained placement failures through technical 
difficulties with silicon instillation in the fallopian tubes, tip separation and silicone 
infiltration as a result of improper alignment, tubal spasm, intrauterine synechiae, 
fragments and bleeding, inadequate uterine distension, myomata or insufficient 
anesthesia during instillation (7,12,14).
Essure
The included Essure studies are described in detail in the tables Characteristics; 
appendix 3. A total of 14,126 women were included in 37 studies. It concerned 26 
prospective, eight retrospective, one partly retro- and partly prospective and one 
study with unclear relation between enrolment and occurrence of the outcomes. 
The articles were published from 2003 to 2012. All participants were consecutively 
included. Ten studies were multi-center, 27 were single-center. Nine articles 
studied a cohort that overlapped with a cohort in another article: seven studies were 
performed in centers in France (17-23) and two in Spain (24,25). In thirteen studies 
a potential conflict of interest was reported, in four studies it was stated there was 
no potential conflict and in twenty studies this remained unclear. 
The number of participants in each trial ranged from 24 to 4,306. The age ranged 
from 19 to 57 years. The exclusion criteria were not described in 26 articles, in 
11 articles the exclusion criteria were reported, in three (17,26,27) was referred to 
the criteria defined in the instructions for use (55). The version of the device used 
were not defined in 29 articles, ESS 305 in four (23,27,29), ESS 205 in one (30), 
and the first type know as STOP (Selective Tubal Occlusion Procedure) in two (4,5). 
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In two articles two Essure versions were used the ESS 205 and 305 (23) and the 
ESS 105 and 205 (31). In one study concomitant procedures were excluded (26), 
Seven studies included patients whom received concomitant procedures (19,20,21, 
22,23,32,33), all other studies did not report on concomitant procedures. The type 
of analgesics differed from only pre-medication, paracervical block, intravenous 
analgesics or general anesthesia. 
Figure 3. shows the risk of bias graph of included Essure studies. The methods of 
assessment for follow-up data on pregnancies were unspecified and mainly based 
on self-reporting thus probably incomplete. In some studies the risk of bias was 
judged high for assessment of confirmation because it was unclear whether single 
placements were also included in the evaluation (17,19). 
Feasibility of Essure
The data of 37 cohort studies were pooled to calculate the probabilities for 
successful placement and successful confirmation. The pooled probability for 
successful placement at first attempt is 92% (95% CI: 91-94%) with a range 
from 81% to 96% (figure 7). There seems to be a tendency for higher successful 
placement rates for studies published since 2007. The chance of confirmed correct 
placement after successful bilateral placement is 97% (95% CI: 96-98%) (figure 8). 
The chance a patient has a successful bilateral placement in one attempt and correct 
confirmation after three months is 89% (table 2). One cervical perforation (36) and 
one fundal perforation (37) during the procedure were reported. In one case the 
microinserts were removed because of a nickel allergy (38).
 
Efficacy of Essure
In figure 9 the number of pregnancies after a confirmed and Essure procedure are 
shown. Eight pregnancies occurred in 7,706 patients who relied on the sterilization 
after a satisfactory confirmation. In one women who became pregnant 32 months 
after the procedure, the three-months control pelvic X-ray and vaginal ultrasound 
scan suggested that the devices were well placed, and the HSG performed after 
delivery showed an apparent bilateral occlusion. Though, laparoscopy demonstrated 
a unilateral tubal perforation. In a second patient, after delivery, radiographic 
examination demonstrated complete expulsion of one device. In the third patient 
during laparoscopic sterilization after termination of pregnancy, one device was 
located intramural under the serosa due to partial perforation. In the fourth 
patient, device placement was unsuccessful on one side, and only one device was 
placed. On HSG, the contralateral tube seemed to be occluded, and the patient was 
instructed incorrectly to cease alternative contraception. In the fifth patient, during 
laparoscopic examination after termination of pregnancy, 1 device was intramural 
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under the serosa due to partial perforation. No data were available for analysis of the 
other three pregnancies. In all analyzed cases, pregnancy was related to incorrect 
position of at least one device. 
Patient related risk factors
In 12 studies risk factors for placement failure of Essure microinserts were 
analyzed (5,12,26,27,29,30,31,32,36,39,40,41). Age was investigated as a risk factor for 
placement failure of microinsert in six studies. Only in one prospective multicenter 
study with 578 women seeking hysteroscopic sterilization a statistically significant 
difference (P<0.01) in the age of patients was observed, with patients with successful 
placement averaging 35.3 years (±6.4 SD) and patients with failures averaging 39.4 
years (±5.3 SD) (27). Five other studies did not find any relation between age and 
placement failure (12,26,29,30,36).
According to the study of Rosen, an initial study of the first 80 procedures with 
Essure, nulliparity was associated with a longer procedure time (11.2 versus 16.7 
min, P < 0.01). However it was not predictive for placement failure (40). Five other 
studies found that parity is not a predictor of successful placement (12,26,29,30,36).
In the majority of the studies women were excluded if they had abnormal bleedings 
and/or the procedures were scheduled to be performed in the follicular phase unless 
they were taking oral contraceptives. In a phase II study of Kerin and phase III study 
of Shavell et al., 48-50% of the failed placements were due to anatomical reasons 
and not related to timing in the menstrual cycle. In a case control study Panel et al. 
found no lower placement rates in patients with concomitant bipolar resection and 
a history of abnormal bleeding. 
In a prospective study to determine feasibility, Sinha et al reported that cycle 
phase at the time of surgery (OR 11.2, 95% CI: 1.35-92.6) and an enlarged uterus 
(OR 15.7, 95% CI: 3.19-77.1) were both significant predictors of successful bilateral 
placement (36). In other studies menstrual phase timing and hormonal endometrial 
suppression did not improve successful bilateral placement. Cases performed in the 
follicular phase of the cycle had a shorter procedure time compared to the luteal 
phase procedure (9.3 versus 16.6 minutes) (40). A thin endometrium is less prone 
to congestion and makes it easier to see the tubal orifice (5,30,40,41).
According to several authors uterine axis is no predictor to placement failure (5,29,36).
Leyser-Whalen et al. used an electronic medical record database to assess risk 
markers associated with inability to place Essure coils in the tubal lumen using 
the new ESS 305 design (29). A total of 310 attempted procedures were analyzed. 
Patients with an history of Sexual Transmitted Disease (STI) were found to have a 
higher risk of placement failure (OR 2.64, 95% CI: 1.01-6.90). 
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Five studies analyzed the influence of BMI on the success rate of hysteroscopic 
sterilization. BMI was no risk factor for placement failure (27,29,30,36,39).
Many authors reported that increasing experience does not improve successful 
procedures but progressive decrease in time for the procedure showed the benefits 
of experience (5,27,39,40). Levie et al. compared 37 newly trained and 39 experienced 
physicians: in 652 patients, overall successful placement was 97.2%, with 98% 
successful placement rate versus 96.1% for experienced versus novice physicians, 
respectively. Mean procedure time was 9 minutes (± 7 SD; P< .01), with experienced 
physicians completing it on an average quicker at 7.9 minutes (±5.8 SD; P< .01) and 
novices completing it in 10.7 minutes (±8.3 SD; P< .01) (27). 
In almost all studies patients received some kind of premedication, mostly 
a combination of non-steroidal anti-inflammatory medications combined with 
diazepam. In a comparative study of Nichols et al. comparing hysteroscopic 
sterilization performed in-office versus a hospital operating room (26), NSAIDs 
before the procedure was significantly related to higher bilateral placement rates. 
Among cases with successful bilateral placement, only 18% did not receive NSAIDs 
before the procedure, whereas 33% of unsuccessful bilateral placements involved no 
NSAIDs (X2=4.78, p=0.03). Chern et al. reported a lower placement failure in the 
group that received pre-operative analgesia (Voltaren) and smooth muscle relaxant 
(Buscopan) compared with the group with no pre-medication (44). Another case 
controlled study did not find a difference in successful sterilization rate between the 
group with local anesthesia (paracervical block) and the group without anesthesia (18). 
Anesthesia type was not significantly associated with failure (30). 
Two studies compared the influence of the setting (on the success of placement. 
Nichols et al (26). compared procedures performed in-office versus a hospital 
operating room (OR) among newly trained physicians. They found no differences 
in placement rates between the two groups, but the OR group (n=252) was much 
larger than the Office Group (n=67). Savage et al. however reported a significantly 
higher successful placement rate in the outpatient setting. (97.3% compared 
with 92.8%, P=0.004) (39). More authors support the idea that office-based 
hysteroscopic sterilization is easily performed in an outpatient setting without the 
need for general anesthesia (18,32,36). 
Adiana
The included articles for Adiana both concerned the Evaluation of the Adiana 
System for Transcervical Sterilization (EASE) trial from 2002 through May 2005, a 
prospective, single-arm, international study, involving 18 investigators at 16 sites (6,16). 
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A total of 645 women participated in the study. Women were eligible to participate 
if they were 18-45 years of age, generally healthy, had established fertility, and 
were seeking permanent contraception. Exclusion criteria included major medical 
conditions, use of cortisone or cytostatic medication, any underlying health 
condition that would adversely affect the ability to undergo surgical procedures (e.g, 
cardiovascular conditions), pelvic inflammatory disease, intrauterine conditions 
that may affect tubal access (eg, synechiae), significant cervical or uterine pathology 
such as an abnormal Pap test or large leiomyomas, or any condition that might 
compromise compliance or long-term study follow-up. Each participant underwent 
a complete physical examination, with documentation of normal cervical cytology, 
negative testing for sexually transmitted diseases, and negative pregnancy test to 
confirm study eligibility. The mean age was 31 years, with a mean parity of 2.2 
(range (0-7). Analgesia used during the procedure ranged from topical or local only 
to intravenous sedation. Three months post-procedure a HSG was performed to 
confirm bilateral occlusion. Thereafter, women were evaluated by brief office visits 
at three, six, and nine months into the reliance phase and assessed with a complete 
examination at one, two and three years. Women with an unsuccessful sterilization 
(n=75) were excluded from the study or were followed for safety evaluation only. 
The assessment of successful placement was clearly defined. A small number of 
women was lost to follow up for the three-months HSG (7/611). Of the 570 women 
that were able to rely on the sterilization, 97% (n=547) were compliant with the 1 
year, 92% (n=523) with the two year and 89% (n=505) with the three year follow 
up. Concerning safety, the method of assessing and recording of complications is 
unclear. Additionally, it remains unclear how many women that could not rely on 
the Adiana sterilization were followed up for safety evaluation. We judged there was 
a low risk of bias for the outcome measurements successful placement, confirmed 
correct placement and incidence of pregnancy and an unclear to high risk of bias 
for outcome complications.   
Feasibility of Adiana
The results on feasibility and efficacy are presented in table 1. Successful 
bilateral placement in a first attempt was achieved in 607 of 645 women (94%). 
In seven women successful placement was achieved after with a second attempt. 
Hysterosalpingography was used to confirm reliability in 604 women. In 91% 
(n=551) bilateral occlusion after a successful first placement was confirmed three 
months post procedure. Re-evaluation of the remaining women by HSG at six 
months confirmed bilateral occlusion in 19 women aditionally. According to the 
protocol 611 women with successful bilateral placement, 93.3% (n=570) were able 
to rely on Adiana for pregnancy prevention and cease additional contraception. 
40 Hysteroscopic Sterilization
2
No uterine or tubal perforations or injuries related to RF energy or matrix placement 
were reported. No analysis for risk factors in placement or failures or learning curve 
were performed in the selected studies.
Efficacy of Adiana
A total of six pregnancies were reported in the first 12 months of the reliance 
phase, three in the second year and none in the third year. In retrospect, three 
pregnancies that occurred during the first year were determined to be due to 
misinterpretation of the HSG. 
Discussion
Modern hysteroscopic sterilization methods are feasible, safe and can be fitted in an 
ambulatory setting. The hysteroscopic approach provides an option for women who 
whish to avoid incisional surgery or general anesthesia. It particularly benefits women 
with (relative) contraindications for laparoscopic sterilization. Since 1988 three methods 
have become commercially available Two of them were withdrawn from the market. 
Ovabloc in 2009 after reports with disappointing results, technical problems with 
the cold storage of the silicon and the claim of reversibility of the technique could 
not be confirmed in a histological study (8). Adiana was withdrawn as part of a deal 
to settle ongoing patent infringement litigation in March 2012 (8). 
In this systematic review we analyzed the feasibility, safety and efficacy of Ovabloc, 
Essure and Adiana. Additionally we evaluated risk factors for placement failure of the 
different techniques. We did not evaluate patient tolerance and satisfaction because 
the characteristics of the studies we found, were too heterogeneous. We anticipated 
no conclusions could be drawn since patients’ experiences are multifactorial e.g. 
influenced by setting, type of anesthesia, A Cochrane review in 2012 concluded that 
the available literature insufficient is to determine the appropriate pain regimen 
for outpatient sterilization by hysteroscopy. In this systematic review feasibility was 
expressed as successful bilateral placement rate in the first attempt. We decided to 
exclude successful single placements in patients with a history of salpingectomy, 
because the higher chance for successful single placement would confound the 
outcome successful placement. For Ovabloc, Essure and Adiana, placement rates 
were respectively: 80% (95% CI: 76-83%), 92% (95% CI: 91-94%) and 94% (95% 
CI: 91-95%). The percentages of women that could rely on successful bilateral 
placement confirmed at three-months follow-up were respectively: 96% (95% 
CI: 93-96%), 97% (95% CI: 96-98%) and 91% (95% CI: 89-93%). We observed a 
tendency towards higher successful placement rates of Essure for studies published 
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since 2007. This can be explained through the introduction of the ESS 305 with 
automatic release mechanism of the introducer catheter and a special introducer in 
2007, which facilitated placement of the devices. 
Pregnancy rates may be calculated by either life table analysis or the Pearl Index. 
The latter, also called the Pearl rate is the most common technique used in clinical 
trials for reporting the efficacy of a birth control method but it assumes a constant 
failure rate over time. All studies included had an unspecified and incomplete 
follow-up beyond three months. In most studies data collecting for pregnancies was 
based on self-reporting rather than an active form of data collecting. Patients were 
instructed to report complications and pregnancies after the initial three months 
post-procedure. Few studies reported a specified time interval between procedure 
and occurrence pregnancy. Because of the unclear length and completeness of 
follow-up periods, it was not possible to calculate reliable cumulative failure rates. 
Complications during the hysteroscopic procedures were incidentally reported and 
were mainly related to unsuccessful procedures. Based on this systematic review it 
seems that Adiana and Essure methods have the highest successful placement rate 
at first attempt. Both methods were performed with smaller, 5-5.5 mm continuous 
flow hysteroscopes, while the majority of Ovabloc procedures were performed in an 
earlier time with 8 mm single flow hysteroscopes. 
Limitations
Only cohort studies were included in this review, because RCTs or good 
methodological comparative studies on this topic are missing. Long-term data for 
outcome pregnancies are lacking. Long-term data are needed to compare the efficacy 
of hysteroscopic sterilization with cumulative 10-years probabilities of pregnancy of 
laparoscopic sterilization studied by the Collaborative Review of sterilization Study 
Group (49). 
The Adiana and Essure method were both introduced when office hysteroscopy 
with continuous flow, 5.5 mm hysteroscopes already was accepted as standard 
procedures while the Ovabloc method was performed with older techniques with 8 
mm hysteroscopes combined with cervical dilatation. This could be an explanation 
of higher risk of placement failure caused by tubal spasm. According to the results 
in this review, hysteroscopic sterilization seems to be an attractive promising 
alternative for laparoscopic and abdominal permanent contraception.
Future perspectives
An important disadvantage of hysteroscopic sterilization methods versus 
laparoscopic procedures is the need for a three months confirmationtest and 
additional contraception. This implies extra costs and inconvenience for the 
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patients with a higher risk for non-compliance. Two new sterilization methods with 
launched in the near future. Both methods are based on an intra-tubal device with 
immediate mechanical occlusion of the fallopian tubes, which eliminates the need 
for a three-months confirmations test. (56,57)
A third new hysteroscopic sterilization method has been announced (58). It is 
described as a redesigned Ovabloc Intratubal Device System. Challenges related 
to the design included the storage of material under room temperature conditions 
achieving reliable curing times and incorporating a contrast agent to facilitate 
visibility for evaluation.
From our meta-analysis we calculated that 91-97% of women with a successful 
bilateral placement are able to rely on the hysteroscopic sterilization procedure. For 
Ovabloc and Essure the percentages are 96% and 97% respectively. We question 
the need for confirmation three months post-Essure. 
In our opinion the reliability after an uncomplicated procedure is sufficient to 
rely on. For selective cases, where there is doubt about successful placement, or 
presence of substantial risk factors for failure, clinicians should still consider an 
three months confirmationtest. When confirmation tests are still indicated for 
every woman receiving hysteroscopic sterilization, a new, less invasive diagnostic 
test like 3D ultrasound has to be evaluated to confirm proper placement. Results 
from earlier studies (32,33,43,44-45) are promising. If tubal occlusion still has to 
be confirmed new non-radiation techniques like Contrast Infusion Sonography or 
Hysterosalpingo Contrast Sonography (HyCoSy) as suggested by Connor in 2008 
(34) or the newer Hysterosalpingo Foaminfusion Sonography (HyFoSy) could be 
considered to be evaluated as confirmation test for tubal occlusion (46-48). 
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Identified articles based on search 
strategy: 429
Not relevant to the topic based 
on title or abstract: 
363
Case reports and series: 7 
Non-consecutive cohort: 4
No follow–up or missing data: 5
Overlapping cohort: 4
Review: 1
Retrieved to read full text article: 66
 Articles included: 45
Adiana: 2
Essure: 37
Ovabloc: 6
Figure 1. Flow diagram
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Figure 2
Table 1
Reference Number of 
participants
Successful 
bilateral 
procedure first 
attempt
Satisfactory 
outcome at  
3 months  
confirmation
Number of 
patients rely on 
after successful 
bilateral  
placement*
Cumulative 
 number of 
 pregnancies
after satisfactory 
confirmation
Vancaillie 2008
Anderson 2011
645 611 551/604 570/611 12 months: 6/ 547 
24 months: 9/ 523 
36 months: 9/ 505
Feasibility and safety of Adiana *Including seven patients with successful second attempt.
Table 2
Successful bilateral 
placement 1st 
attempt (A)
Satisfactory 
 confirmation 
after total bilateral 
 placements (B)
Satisfactory 
 confirmation 
after successful 
 placement 1st 
attempt (A x B)
Pregnancies
Ovabloc 0.80 0.96 0.77 12 / 1212
Essure 0.92 0.97 0.89 08 / 7706
Adiana 0.95 0.91 0.86 09 / 570
Feasibility and efficacy of three methods of hysteroscopic sterilization.
Appropiate eligibility criteria
Adequate measurement of bilateral placement
Adequate measurement of confirmation test
Adequate measurement of pregnancy
Selective reporting (reporting bias)
0% 25% 50% 75% 100%
Risk of bias graph: review authors' judgements about each risk of bias item presented across all included Ovabloc studies.
Low risk of bias Unclear risk of bias High risk of bias
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Houck (1983)
Blok de (1992)
Loffer (1992)
Leij vdr (1996)
Ligt -Veneman(1999)
Fixed effect model
Random effects model
0.80
0.70
0.84
0.78
0.83
0.80
0.80
[0.78; 0.82]
[0.76; 0.83]
[0.76; 0.84]
[0.60; 0.78]
[0.79; 0.88]
[0.73; 0.82]
[0.79; 0.87]
25.7%
9.6%
14.5%
28.2%
21.9%
100%
--
22.1%
15.7%
18.6%
22.5%
21.2%
--
100%
Figure 3
Figure 4  OVABLOC First attemp bilateral
Appropiate eligibility criteria
Adequate measurement of bilateral placement
Adequate measurement of confirmation test
Adequate measurement of pregnancy
Selective reporting (reporting bias)
0% 25% 50% 75% 100%
Risk of bias graph: review authors’ judgements about each risk of bias item presented across all included Essure studies.
Probability of successful placement at first attempt for included Ovabloc studies. Probabilities are shown with 95%  
confidence intervals.
Low risk of bias Unclear risk of bias High risk of bias
0.65 0.7 0.75 0.8 0.85
334
80
224
319
325
415
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411
392
1601
Heterogeneity: I-squared=70%, tau-squared=0.0475, p=0.0098
Study Events
Proportion
95%-CI
W(Fixed)
W(Random)Total
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Probability of confirmed correct placement after bilateral placement for included Ovabloc studies. Probabilities are shown 
with 95% confidence intervals.
Number of pregnancies for included Ovabloc studies. Probabilities are shown with 95% confidence intervals.
Houck (1983)
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Fixed effect model
Random effects model
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Figure 5  OVABLOC confirmed bilateral placement
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Figure 6  OVABLOC pregnancies
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Figure 7  ESSURE first attemp bilateral
Fixed effect model
Random effects model
Heterogeneity: I-squared=82.9%, tau-squared=0.6656, p=0.0001
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Figure 7. Probability of successful bilateral placement at first attempt for included Essure studies. Probabilities are shown 
with 95% confidence intervals.
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Figure 8  ESSURE confirmed bilateral placement
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Figure 8. Probability of confirmed correct placement after bilateral placement for included Essure studies. Probabilities are 
shown with 95% confidence intervals.
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Figure 9  ESSURE pregnancies
Heterogeneity: I-squared=0%, tau-squared=0, p=0.6186
Number of pregnancies for included Essure studies. Probabilities are shown with 95% confidence intervals.
Study Events
Proportion
95%-CI
W(Fixed)
W(Random)Total
0 0.02 0.04 0.06 0.08 0.1
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Appendix 1
SEARCH:
((((Hysteroscopy[mesh] OR hysteroscop*[tiab] OR uteroscop*[tiab] OR 
transcervical[tiab])) AND ((sterilization , tubal[mesh]) OR ((sterilization , 
reproductive[MeSH] OR sterilization *[tiab] OR sterilization *[tiab]) AND 
(Fallopian tubes[MeSH] OR tube[tiab] OR tubes[tiab] OR tubal[tiab] OR 
intratubal[tiab]))))) OR (ovabloc[tiab] OR essure[tiab] OR microinserts[tiab])
429 hits. JANUARY 2013
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Appendix 2
Characteristics of included Ovabloc studies
de Blok 1992
Methods -  Retrospective, single center, Jan 1990 - Aug 1991, Onze Lieve Vrouwe Gasthuis, Amsterdam, 
Netherlands
- Comparison: single flow versus continuous flow
Participants - Participants: 115
- Age: not reported
- Mean age: not mentioned
- Parity: not specified
-  Exclusion: non patent tubes, pregnancy, active infection, major intrauterine pathology, allergic 
to local anaesthetics or distension medium
- Setting: out-patient
Interventions - Ovabloc intra tubal device
- Experience: not reported
- Premedication: NSAID 12 hours and 2 hours before, atropine i.m. 30 min before procedure
- Anesthesia: PB
- Timing in cycle: proliferative phase of cycle or use of oral contraceptive
- Distension medium; 1990 SF CO2 - Hyskon : 1991 CF Sorbitol
Outcomes - Successful bilateral instillation
- Satisfactory X-ray < 24 hrs
- Satisfactory X-ray after 3 months
- Complications
Funding source - Not reported
Notes
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Houck 1983
Methods - Prospective, since January 1981, Phoenix Baptist Hospital and Medical Center.
-  Comparison of categories with 1) successful procedure, satisfactory X-rays, 2) one  
unsatisfactory X-ray, 3) two unsatisfactory X-rays, 4) unsatisfactory procedure.
Participants - Participants: 415
- Mean age: 28.6 years
- Median parity: 1
- Exclusion/ inclusion criteria: Candidates were qualified under a FDA protocol
- Setting: in-office
Interventions - Ovabloc ITD
- Experience: not reported
- Premedication: not reported
- Anesthesia: PB
- Timing: not specified
- Distension medium: Hyskon
Outcomes - Successful bilateral instillation
- Satisfactory X-ray < 24 hrs
- Satisfactory X-ray after 3 months
- Pregnancy
Funding source - Not reported
Notes
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Ligt- Veneman 1999
Methods - Retrospective, multicenter (3), 1992 -1996, Dutch Hospitals, Netherlands
Participants - Participants: 392
- Mean age: 35.7 years (range 26-50; SD:4.6)
- Mean parity; 2.6
- Exclusion criteria: not reported
- Setting: out-patient
Interventions - Ovabloc ITD
- Experience: not reported
- Premedication: not reported
- Anesthesia: PB
- Timing not specified
- Distension medium: not reported
Outcomes - Successful bilateral instillation
- Satisfactory X-ray < 24 hrs
- Satisfactory X-ray after 3 months
- Satisfactory X-ray 1 year after the procedure
- Pregnancy
Funding source - Not reported
Notes
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Loffer 1992
Methods - Retrospective, unclear number of centers, 1978 -1991, Phoenix, USA
Participants - Participants: 265
- Mean age: 30 years (range: 18 - 45)
- Parity: 51 women were nulliparous
-  Exclusion criteria: retroflexed uterus, within 6 months of a delivery or 3 months termination of 
first trimester pregnancy, known tubal pathology
- Setting: in-office
Interventions - Ovabloc ITD
- Experience: not reported
- Premedication: not reported
- Timing: proliferative phase of cycle
- Anesthesia: PB
- Distension medium: not reported
Outcomes - Successful bilateral instillation
- Satisfactory X-ray < 24 hrs
- Satisfactory X-ray after 3 months
- Satisfactory X-ray 1 year after the procedure
Funding source - Not reported
Notes - Part of multicenter study of 1389 patients
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Reed 1984
Methods -  Retrospective, study period unclear: probably 1978 - 1984, Lankenau Hospital, Philadelphia, 
USA
Participants - Participants: 438
- Mean age: not mentioned
- Parity: not reported
-  Exclusion: anatomical abnormality, < after 6 months pregnancy, fixed retroversion of  
the uterus, myoma uteri, abnormal fallopian tubes, insufficient relapse of time postpartum
- Setting: out-patient
Interventions - Ovabloc ITD
- Experience: during technical learning phase of investigators
- Premedication: not reported
- Timing: not reported
- Anesthesia: PB
- Distension medium: not mentioned
Outcomes - Successful bilateral instillation
- Satisfactory X-ray < 24 hours
- Satisfactory X-ray after 3 months
- Satisfactory X-ray after 2 years
- Risk factors for failed instillation
- Pregnancy
Funding source - Not reported
Notes
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van der Leij 1996
Methods -  Prospective, April 1990 - April 1994, Number of centers unclear: probably single center, 
Schieland Hospital, Schiedam, Netherlands
Participants -  Participants: 411, 361 were supposed to be suitable (had tubal patency for both tubes  
evaluated by the methylene blue perfusion test.
- Mean age: 34.7 (22 -47)
- Parity range: 0- 8
- Exclusion: absence of one tube, not within 3 months after delivery
- Setting: out-patient
Interventions - Ovabloc ITD
- Experience: not reported
- Premedication: not mentioned
- Timing: not reported
- Anesthesia; PB
- Distension medium: not reported, continuous flow
Outcomes - Successful bilateral instillation
- Satisfactory X-ray < 24 hrs
- Satisfactory X-ray after 3 months
- Pregnancy/ terminations of use
Funding source - Not reported
Notes
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Appendix 3
Characteristics of included Essure studies
Abad 2003
Methods -  Prospective cohort study, 2003, duration 6 months, Hospital Arnau de Vilanova.  
Valencia, Spain
Participants - Number of participants: 24
- Setting: unclear, anaesthetist present as well
- Mean age: 35 (28 - 41)
- Median parity: not reported, all were multipara
-  Exclusion criteria: not specified. In result section: no previous caesareans, no uterine  
interventions. In discussion section contraindications are described, unclear whether these 
were applicated
Interventions - Essure pbc
- Experience of surgeon: first procedures
- Concomitant procedures: unclear
- Analgesics: PB, IVS
- Oral contraception until two months after the procedure
Outcomes - Patient tolerance, method unclear
- Successful bilateral placement in first attempt
Length of follow up - 6 months
Confirmation test - Transvaginal US + abdominal X-ray 1,3 and 6 months after the procedure
Funding source - Not reported
Notes
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Andersson 2009
Methods - Prospective, Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden
Participants - Number of participants: 58
- Setting: office setting
- Mean age: 39.6 (30 - 46)
- Median parity: 2.4 (1 - 5)
- Exclusion criteria: not specified
Interventions - Essure microinsert
- Experience of surgeon: unclear
- Concomitant procedures: unclear
- Analgesics: PB
-  Premedication: One hour prior to surgery, patients were given cetaminophen 1 g,  
50 mg sodium diclofenac and oxycodone hydrochloride 10 mg
- Timing: CD 3-10
- Pregnancy test before procedure
Outcomes - Successful bilateral placement in first attempt
- Successful bilateral placement in second attempt
- Procedure complications
-  Post operative adverse events, clear definition, at day of procedure, in recovery room,  
one week and three months post-procedure
- Patient satisfaction
- Pregnancy
Length of follow up - 23 months (range: 7 - 67) 81,9%
Confirmation test - X-ray (38), US (20)
Funding source -  grants from the Swedish Medical Research Council, the Karolinska Institutet Foundation, 
Stockholm.
-  consulting fee for hands-on teaching in Essure procedure
Notes - 60 % had a potential contra-indication for laparoscopy
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Arjona 2008
Methods - Prospective, Jan 2003 - June 2006, Reina Sofia University Hospital, Cordoba, Spain
Participants - Number of participants: 1630
- Setting:
- Mean age: 36.6 (± 5.7) (range: 32 - 41)
- Median parity: 2.4 (± 1.2)
- Exclusion criteria: not specified
Interventions - Essure
- Experience of surgeon: unclear
- Concomitant procedures: unclear
- Pretreatment: Continuous oral contraceptives at least 1 month before the procedure
- Analgesics: 1 hour before ibuprofen 600 mg and benzodiazepine 10 mg
Outcomes - Patient satisfaction (verbal rating scale and VAS) day 1 and 90
- Patient discomfort (Likert style scale in recovery room)
- Patient tolerance (Likert style scale, in recovery room)
- Successful bilateral placement in first attempt.
- Post operative adverse events, post-procedure.
- Pregnancy
Length of follow up - 1419 > 18 months; 1615 > 15 months after procedure
Confirmation test - X-ray; US or HSG on indication
Funding source - Andalusia Health Service for the acquisition of the microinserts
Notes - Study for satisfaction and tolerance
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Chapa 2011
Methods - Prospective, single center, March 2007 - Dec 2009, Dallas, US
Participants - Number of participants: 163
- Setting: in-office
- Mean age: not reported
- Median parity: not reported
-  Exclusion criteria: prior tubal surgery, state allergy, < 6 wks post partum for Nickel or contrast, 
bleeding day of procedure
Interventions - Essure pbc
- Experience of surgeon: unclear
- Essure 305
- Concomitant procedures: unclear
- Pre-treatment: 10 days medroxyprogesteronacetate
- Urinary pregnancy test day of procedure
-  Analgesics: PB 1% Mepivacaine without epinephrine, one hour before: Toradol,  
acetaminophen/hydrocodone
Outcomes - Successful bilateral placement in first attempt.
- Late complications
- Pregnancy
Length of follow up - Unclear
Confirmation test - US after 10 - 12 weeks + HSG 1 - 2 weeks later
Funding source - Not reported
Notes
61Chapter 2  Systematic review hysteroscopic sterilisation
2
Chern 2005
Methods - Retrospective, June 2001 - Dec 2002; Women’s and Children’s Hospital, Singapore
Participants - Number of participants: 80
- Setting: day surgery
- Mean age: 37.6 (28-45)
- Median parity: 2.9 (0-8), 90% > 2
- Exclusion criteria: abnormal bleeding, pregnancy
Interventions - Essure
- Experience of surgeon: unclear
- Concomitant procedures: unclear
- Urinary pregnacy test
- Analgesics: Buscopan i.m., Voltaren, PB
Outcomes - Patient satisfaction (verbal rating scale) days 7 and 90
- Patient discomfort (Likert style scale, during procedure and in recovery room)
- Patient tolerance (Likert style scale, in recovery room)
- Successful bilateral placement in first attempt
-  Post operative adverse events, at day of procedure, in recovery room, one week and three 
months post-procedure
- Pregnancy
Length of follow up - 3 months
Confirmation test - HSG
Funding source - Not reported
Notes
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Cooper 2003
Methods -  prospective phase III study, international multicenter. May 2000 - Febr 2001, 13 clinical sites 
located in the United States, Australia, Spain, the United Kingdom and Belgium
Participants - Number of participants: 507
- Setting:
- Mean age: 31,9 (SD: 4.6)
- Median parity: 2.3 (SD: 1.0)
-  Selection: 21-40 yrs, 90 300 lb body weight, regular menses 2 months before, at least 1 live 
birth
-  Exclusion criteria: chronic pelvic pain, severe dysmenorrhea, severe dyspareunia, or any 
chronic pain in the previous 12 months. tubal, ovarian, or endometrial pathology and women 
with a prior history of infertility treatment
-  Screening: Neisseria gonorrhoeae and Chlamydia trachomatis infection, urinary pregnancy 
test
Interventions - insert: STOP
- timing: CD 7 - 14
-  Experience of surgeon: infrequent, diagnostic hysteroscopy to routine, operative  
hysteroscopy. Of the 20 investigators, 14 had no prior experience with the microinsert
- Concomitant procedures: unclear
- pre-operative : NSAID 30 min before
- Analgesics: PB, IVS if neccessary , GA (1)
Outcomes - Successful bilateral placement in first attempt.
- Successful bilateral placement at second attempt.
- Pain 
- Occurrence of any bleeding or other symptoms, perceptions and satisfaction
- Recovery
- Adverse events
Length of follow up - 15 months after procedure, patient experience an satisfaction
- additional 4 years to obtain safety , effectiveness and reliability
Confirmation test - X-ray 24 hrs after procedure, HSG after 3 months
Funding source - Conceptus Inc
Notes -  Cooper and Kerin (2003) were funded by Conceptus, Inc., San Carlos, California, USA. John 
F.Kerin, Thomas Price, Charles S.Carignan and Jay M.Cooper are stockholders in Conceptus, 
Inc., the manufacturer of the Essure microinsert. Charles S.Carignan is an employee of Con-
ceptus, Inc. John F.Kerin, Jay M.Cooper and Thomas Price are consultants to Conceptus, Inc.
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Dewulf 2004
Methods - Single center, study period: December 2003 - April 2004, Dunkerque hospital, France
Participants - Number of participants: 24.
- Setting: Dunkerque hospital.
- Mean age: 37.5 (SD: 3.7) (range: 31 - 47)
- Median parity: 2.3 (SD:2.0)
-  Exclusion criteria: pregnancy, recent childbirth, abnormalities of uterine cavity, tubal abnormal-
ities rendering the procedure impossible, contrast allergy, regular use of corticoids, presence 
of gynecological infection, gynecological malignancies, heavy menstrual bleeding
Interventions - Essure
- Experience of surgeon: unclear
- Concomitant procedures: unclear
- Premedication: benzodiazepine
- Analgesics: GA (14) or “sub-type”analgesics.
- Post procedure: paracetamol, tramadol (7)
Outcomes - Successful bilateral placement first attempt and second attempt
Length of follow up - Unclear
Confirmation test - 3 months, X-ray or HSG
Funding source - Not reported
Notes - Language: French, overlap with Grosdemouge 2009
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Duffy 2005
Methods - Prospective, multicenter (3), “cohort controlled”, study period: unclear, UK
- Comparison: Essure versus laparoscopic sterilization 
Participants - Number of participants: 59 in Essure group
- Setting: out-patient unit of three large UK hospitals
- Mean age: 35.1 years
- Median parity: 2.3.
- Exclusion criteria: not specified
Interventions - Essure microinsert.
- Experience of surgeon: three of the four investigators in this study were inexperienced
- Concomitant procedures: unclear
- Analgesics: NA (70%) PB (30%)
Outcomes - Patient satisfaction (verbal rating scale) days 7 and 90
- Patient discomfort (Likert style scale, during procedure and in recovery room)
- Patient tolerance (Likert style scale, in recovery room)
- Successful bilateral placement in first attempt.
-  Post operative adverse events, at day of procedure, in recovery room, one week and three 
months post-procedure.
- Pregnancy
Length of follow up - 3 months
Confirmation test - HSG
Funding source - Not reported
Notes
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Grosdemouge 2009
Methods -  Partly retrospective, partly prospective, multicenter (7), study period: January 2004 -  
June 2006, France
Participants -  Number of participants: 1054 attempts, 10 were excluded because the attempt failed  
(problems with cercival catheterization (2), myoma (3), synecchia (1), perforation with  
hysteroscope (1), bilateral tube obstruction (3)
- Setting: hospitalization and installation were left to discretion of each center.
- Mean age: 41.4 (SD: 1.1) (range 28 - 50)
- Median parity: 2.5 (SD: 1.1)
- Exclusion criteria: not specified
Interventions - Essure
- 15 surgeons, senior surgeon present.
-  Concomitant procedures (89): endometriectomy (44), polypectomy (29), curettage (6),  
synechiolysis (4), IUD removal (6)
-  Analgesics: premedication: 87% received NSAID. GA/PB/ IVS/ spinal/NA depending on 
surgeon and patient preferences
Outcomes - pain during procedure, VAS scale, timing not specified
- patient satisfaction (1 - 5 score)
-  Procedure was judged successful when on X-ray showed correct position of the device or 
when HSG showed occluded tubes
- Pregnancy
Length of follow up - Unclear
Confirmation test - After successful placement (bilateral of unilateral when only one open tube was present: X-ray.
-  When bi- or unilateral placement had failed-> HSG. If HSG showed occluded tubes,  
the procedure was considered successful
Funding source - Reported conflict of interest with Conceptus. “supported by Conceptus”
Notes - French language
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Howard 2012
Methods -  Retrospective chart review, January 1 2005 - Dec 31 2010, Truman Medical Center,  
Kansas City, Missouri, 
Participants - Participants: 136 two groups (noncompliance and compliance)
- Age: 28.8 and 30.6
- parity: < 3 25.8% and 50%; > 3 74.2% and 50%
-  Exclusion criteria: not reported: one patient was excluded because it concerned an  
Adiana procedure.
- Only patients with confirmationtest included
Interventions - Successful placement rate first attempt
Outcomes - Successful placement rate at second attempt
- Successful single placement
- HSG Compliance
Length of follow up - Unclear
Confirmation test - HSG
Funding source - “no disclosure to report”
Notes
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Kerin 2003
Methods -  Prospective International mulicenter phase II study, 5 centers. Reproductive Medicine Unit, 
University of Adelaide, Ashford Hospital, Adelaide, South Australia, Australia, Women’s Health 
Research, Phoenix, Arizona, USA, Reproductive Endocrinology, Greenville, South Carolina, USA, 
Jan Palfjin General Hospital, Merksem, Belgium, Department of Obstetrics and Gynecology, 
Institut Universitari Parc Taulf. Hospital de Sabadell, Spain, Exponent, Palo Alto, California, 
USA Conceptus Inc., San Carlos, California, USA
Participants - Number of participants: 227
- Setting:
- Timing both follicular and luteal phase
- Mean age: 35 (23-45)
- Median parity: 2.2 (SD: 0.9)
-  selection: 21-40 yrs, 90 300 lb body weight, regular menses 2 months before,  
at least 1 live birth
-  Exclusion criteria: chronic pelvic pain, severe dysmenorrhea, severe dyspareunia, or any 
chronic pain in the previous 12 months. tubal, ovarian, or endometrial pathology and women 
with a prior history of infertility treatment, allergy for contrast.
- Screening: Neisseria gonorrhoeae and Chlamydia trachomatis infection, urinary pregnancytest
Interventions - insert: STOP
- timing: follicular and luteal phase
- Experience of surgeon: not reported
- Concomitant procedures: not reported
- pre -operative: NSAID 30 min before
- Analgesics: PB, IVS if necessary , GA (1)
Outcomes - Successful bilateral placement in first attempt.
- Successful bilateral placement at second attempt
- Tolerance and recovery from procedure (questionnaire 1 week)
- Safety (6 months diaries)
- Patient tolerance
- Effectiveness. 3,6,12,18,24,36 months after procedure
- Patients experience for 3 years
Length of follow up - 36 months
Confirmation test - HSG after 3 months
Funding source - Conceptus Inc.
Notes -  Cooper and Kerin (2003) were funded by Conceptus, Inc., San Carlos, California, USA. John 
F.Kerin, Thomas Price, Charles S.Carignan and Jay M.Cooper are stockholders in Conceptus, 
Inc., the manufacturer of the Essure microinsert. Charles S.Carignan is an employee of Con-
ceptus, Inc. John F.Kerin, Jay M.Cooper and Thomas Price are consultants to Conceptus, Inc.
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Legendre 2010
Methods - Prospective, single center, March 2008 -Oct 2008, Clamart, France
Participants - Participants: 40
- Setting: OR and office
- Age, mean: 41.13
- Exclusion criteria: not reported
Interventions - Essure 305
- Surgeon experience: unclear
- Concomitant procedures: in 25% of the patients
- Anesthesia: unclear: not systematically general anesthesia
Outcomes - Successful placement rate bilateral
- Successful single placement rate
- 3D US Classification
Length of follow up - no follow up
Confirmation test - 3 D US and HSG after 3 months
Funding source - Last author is a consultant for Conceptus
Notes
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Legendre 2011
Methods - Retrospective single center, October 2002 - October 2008, Clamart, France
Participants - Number of participants: 311
- Setting: OR or office
- Mean age: 41.7 (27-57)
- Median parity: 2.3 (0-7)
- Exclusion criteria: not reported
Interventions - ESS 205 (from October 2002 to Sept 2007) and the ESS 305 (after Oct 2007)
-  Experience of surgeon: The reading of both these radiography examinations was 
 retrospectively verified by two gynecologists with extensive experience with Essure
- Concomitant procedures: in 24.4% of the patients
- Analgesics: NSAID one hour before
Outcomes - Successful bilateral placement
- Successful single placement
- Diagnostic characteristics of confirmation test: SE SP NPV PPV
- Pregnancy
Length of follow up - Unclear
Confirmation test - X-ray and 3D US, HSG only after single placement
Funding source - Not reported
Notes
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Lett 2009
Methods - Retrospective chart review, 1 Dec 2005 - 31 Dec 2006, Regina General Hospital, Canada
Participants - Number of participants: 84 for first procedure
- Setting: ambulatory outpatient
- Mean age: 37.1 (23-53)
- Median parity: 2.0 (0-5)
- Exclusion criteria: second attempt and single tube
Interventions - Essure microinsert.
- Experience of surgeon: unclear
- Concomitant procedures: not reported
-  Analgesics: indomethacin 100 mg per rectum 1 h before the procedure and are administered 
either intravenous conscious sedation with fentanyl and diazepam 2.5 or oral analgesia with 
oxycodone 10 mg.
- Timing: phase A (day 0-10); phase B (day 11- 20); phase C ( > day 20)
Outcomes - Successful bilateral placement in first attempt.
- menstrual timing and hormonal suppression of endometrium
Length of follow up - 1419 > 18 months; 1615 > 15 months after procedure
Confirmation test - 3D contrast US and HSG
Funding source - Not reported
Notes - Study menstrual phase timing and hormonal endometrial suppression
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Levie 2006
Methods - Prospective, single center, study period: unclear, Montefiore Medical Center, New York, USA
Participants - Number of participants: 102
- Setting: office-based 
- Mean age (range): 35 (22 - 44)
-  Mean parity (range, SD): 3 (0 - 8, 1.28), Average BMI (range, SD): 30.3 (18,6 - 51, 6.9),  
Most patients of Hispanic origin.
- Exclusion criteria: none defined
- Screening: urine pregnancy test, cultures for gonorrhoea and chlamydia.
- Timing: unclear
Interventions - Essure
-  Approximately half of the procedures were done by residents, fellows or attending physycians 
learning the procedure. Under supervision of the primary investigator, senior member with 
expertise in hysteroscopy.
- Concomitant procedures: in 6 patients, mainly polypectomies.
- Pre-treatment: unclear
- Analgesics: IVS + PB
Outcomes - Successful bilateral placement in first attempt.
- Successful bilateral placement after more than one attempt.
- Intra-procedural or post-procedural complications
- Pregnancy
Length of follow up - At least 12 weeks after the procedure
Confirmation test - HSG at least 12 weeks after the procedure
Funding source - Not reported
Notes
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Levie 2011
Methods - Prospective, multi center (76 sites). Aug 2007 - March 2009. USA
Participants - Number of participants: 625
- Setting: divers
- Mean age: 35.3 (± 6.4)
- Median parity: 2.4 (± 1.3)
- Exclusion criteria: according IFU
Interventions - Essure, ESS 305
- Experience of surgeon: 40 experienced; > 25 ESS 205, 40 newly trained (3-5 proctored 305)
- Concomitant procedures: not reported
- Analgesics: GA (79;13.7%), Local/oral 86.3% (499)
Outcomes - Successful bilateral placement in first attempt
- Procedure time
- Risk factors for failure
-  Adverse events, at day of procedure, in recovery room, one week and three months  
post-procedure.
- Pregnancy
Length of follow up - No long term follow-up
Confirmation test - Not included
Funding source - Conceptus US
Notes
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Leyser-Whalen 2012
Methods -  Retrospective review of medical records, August 2005 - April 2011, University of Texas 
 Medical Branch, USA
Participants - Number of participants: 310
- Setting:
- Age: 34.0 (30.0 - 38.0)
- Parity: 3.0 (2.0 - 3.0)
- Exclusion criteria: old device before third generation (10), failed non-tubal procedure (14)
Interventions - Essure ESS305.
- Surgeon experience: unclear
- Concomitant procedures: not reported
- Premedication: 1/3 medroxyprogesteron i.m. one month before
-  Analgesics: (Toradol 60 ml. and Ibuprofen 800 mg) and an anxiolytic (Valium 10 mg) 1 hour 
before the procedure
Outcomes - Successful bilateral placement in first attempt.
- Successful bilateral placement after more than one attempt.
-  Risk markers associated with the inability to deploy- Successful bilateral placement  
in first attempt.
- Successful bilateral placement after more than one attempt.
- Risk markers associated with the inability to deploy
Length of follow up - No follow-up
Confirmation test - No data about confirmation
Funding source - Not reported
Notes -  The association between tubal factor failure with demographic variables of age, race/ 
ethnicity, and parity. Moreover, a history of sexually transmitted infection (STI) was of special 
interest because of its link to pelvic inflammatory disease (PID) that causes tubal scarring
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Litta 2005
Methods -  Prospective, June 2003 to July 2004 in the Department of Gynecological Science and Human 
Reproduction of the University of Padua, Italy
Participants - Number of participants: 36
- Setting:
- Mean age: 39.1 (± 3.4)
- Median parity: 3 nulli, 34: 1 or more
-  Exclusion criteria: a positive pregnancy test, uterine, cervical or adnexal pathologies, uterine 
or cervical neoplasia, abnormal uterine bleeding, chronic pelvic pain, pelvic infiammatory 
disease, previous tubal surgery, and monolateral tubal occlusion.
- Inclusion: normal US en hysteroscopy
Interventions - Essure
- Experience of surgeon: unclear
- Concomitant procedures: unclear
- pre-treatment: 0.6 ml of atropine and 0.6 ml of diazepam intramuscularly 15 min before 
- Timing: proliferative phase
- Analgesics:
- Sec. hysteroscopy after three months
Outcomes - Operation time
- Patient satisfaction (verbal rating scale) days 7 and 90
- Patient discomfort during procedure (VAS) and in recovery room)
- Pregnancy
Length of follow up - Unclear
Confirmation test - HSG after 3 months
Funding source - Not reported
Notes
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Lopes 2008
Methods - Prospective, February 2002 - May 2005, Nantes University Hospital center, France
Participants - Number of participants: 140
- Setting: outpatient setting
- Mean age: 41.1 (± 3.2)
- Median parity: 2.6 (± 0.8)
-  Exclusion criteria: medical and physical contraindications to the sterilization procedure  
or the decision not to use the Essure system.
Interventions - Essure
- Experience of surgeon: one operator all procedures
- Concomitant procedures: unclear
- Timing: first half of cycle
- Premedication: Boprofenid 150 mgr, two hrs before
- Analgesics: 70 PB, 70 nothing
Outcomes - Patient satisfaction (verbal rating scale) days 7 and 90
- Patient discomfort during procedure, 70 verbal communication, 70 VAS.
- Patient tolerance additional need for anesthesia
- Successful bilateral placement in first attempt.
- Complications
- Pregnancy
Length of follow up - 30 months
Confirmation test - X- ray after 3 months
Funding source - Not reported
Notes
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Mino 2007
Methods - Prospective, Jan 2003 - Jan 2005, Reina Sofia University Hospital, Cordoba, Spain
Participants - Number of participants: 857
- Setting: outpatient unit of three large UK hospitals
- Mean age: 36.0 years (22-49)
- Median parity: (0 - >4)
- Exclusion criteria: not specified.
- Inclusion: normal examination and US
Interventions - Essure
- Experience of surgeon: 2 gynecologists
- Concomitant procedures: not reported
- Pre-procedure: one month OC
-  Analgesics: ibuprofen 600 mg and diazepam 10 mg an hour prior to the procedure, previous 
PB (50.5%): mepivacaine cloridrate 3%, 7.2 ml
Outcomes - Patient satisfaction (verbal rating scale) days 7 and 90
- Patient discomfort (Likert style scale, during procedure and in recovery room)
- Patient tolerance (Likert style scale, in recovery room)
- Successful bilateral placement in first attempt.
-  Post operative adverse events, clear definition, at day of procedure, in recovery room,  
one week and three months post-procedure.
- Pregnancy
Length of follow up - Unclear
Confirmation test - X-ray, HSG (8,9%) on indication or US (later)
Funding source - General Manager of hospital
Notes - Second device after incorrect position (7) in all but one case
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Nichols 2006
Methods - Prospective, multicenter, study period: unclear.
- Comparison: in-office versus operating room placement
Participants - Number of participants: 320
- Setting: placement in operating room 252, placement in-office 68)
- Mean age (SD): OR: 37 (± 35.5) In-Office: 35 (±5.78)
- Gravidity/ parity: unclear
-  Exclusion criteria: all conditions considered contra indications (in Instructions for Use)  
and concomitant procedures.
- A pregnancy test was performed within 24 hours before the procedure
Interventions - Essure microinsert
-  31 physicians located throughout the United States, no previous experience in Essure 
 microinsert placement. Completed perceptive portion of training procedure.
- Pre-treatment: hormonal contraception 28%
- Analgesics: OR: PB + IVS In-office: PB + OS
Outcomes - Successful bilateral placement in first attempt.
- Pregnancy: in discussion “no pregnancies .... to date”
Length of follow up - Undefined
Confirmation test - Not studied
Funding source -  Study is subset of post-approval study by conceptus. Funded by an honorarium from conceptus
Notes
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Panel 2010
Methods - Prospective, multicenter (7), Jan 2006 - June 2006, France
Participants - Number of participants: 495
-  Setting: different settings: traditional hospitalization, day hospitalization, outpatient 
 hospitalization, in the operating room, or in a hysteroscopy room
- Mean age: 42 (28-54)
- Median parity: 2.45 (4% nulli)
- Exclusion criteria: not defined
Interventions - Essure microinserts
- Concomitant procedures: intrauterine (40; 8,1%) and extrauterine
- Experience of surgeon: unclear
- Timing: first half of cycle
- Analgesics: none, PB, IVS
Outcomes - Time of procedure
- Patient discomfort, pain (VAS)
- Successful bilateral placement in first attempt
Length of follow up - No follow-up after CT
Confirmation test - HSG after 3 months
Funding source -  First author is consultant for Conceptus France, providing medical coordination  
on observational studies of Essure
Notes - Combined (concomitant) with other hysteroscopic surgery (8.1%). High mean age
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Panel 2011
Methods -  Prospective case control study, single center, Jan 2004 - March 2009, France
-  Comparison: patients undergoing Essure only versus women undergoing concomitant  
uterine procedures
Participants - Essure
- Number of participants: 381 (B 341, A 41 concomitant bipolar surgery)
- Setting: general hospital.
- Mean age: A: 43 (39-49); B:42 (34-49)
- Median parity: A: 2.3 (1-5); B2.5 (06)
- Exclusion criteria: not defined
Interventions - Essure 
- Experience of surgeon: unclear
- Concomitant procedures: yes.
- Analgesics: unclear
Outcomes - Successful placement first attempt
- Complications
Length of follow up - Unclear
Confirmation test - X-ray at 3 months, HSG on indication
Funding source - “All authors nothing to disclose”
Notes - Case control study
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Paredes 2010
Methods -  Retrospective electronic database review, March 2007 - September 2009, Hospital  
Universitario Virgen de las Nieves, Granada
Participants - Number of participants: 400
- Setting:
- Mean age: 36.6
- Median parity: 2.4
- Exclusion criteria: not specified
Interventions - Essure
- Experience of surgeon: unclear
- Concomitant procedures: unclear
- Analgesics: Diazepam 5 mgr and ibuprfen 600 mgr one hour before
Outcomes - Patient discomfort (Likert style scale, during procedure and in recovery room)
- Successful bilateral placement in first attempt.
- Successful bilateral placement at second attempt.
- Patient satisfaction (verbal rating scale) days 7 and 90
- Complications
- Post operative adverse events
- Pregnancy
Length of follow up - Unclear, LOF for confirmation
Confirmation test - X-ray
Funding source - Not reported
Notes - Spanish language
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Povedano 2012
Methods - Retrospective, single center, March 2003 - June 2010, Córdoba, Spain
Participants - Number of participants: 4306
- Setting: office hysteroscopic unit in a teaching hospital
- Mean age: 36 (range: 19 - 49 years)
- Parity: not reported.
-  Exclusion criteria: abnormal uterine bleeding, active pelvic inflammatory disease or uncertainty 
about their desire to end fertility
Interventions - Essure microinserts.
-  Experience of surgeon: all procedures carried out or supervised by four gynecologists  
experienced in the Essure technique.
- Concomitant procedures: not reported
-  Timing: follicular phase of menstrual cycle unless taking oral contraceptives (continuously  
at least a month prior to procedure)
- Premedication: oral ibuprofen and 10 mg diazepam 1 hour before procedure
- Analgesics: PB (472)
Outcomes - Placement rate
- Successful bilateral tubal occlusion
- Perioperative adverse events
-  Early postoperative complications (during the first 3 months of follow-up, at 3 months planned 
gynecological check-up)
-  Late complications (after the initial 3 months of follow-up, patients and general practitioners 
were advised to report and refer)
- Pain (questionnaire after insertion)
Length of follow up -  “Majority of women had a follow-up beyond one year”. This follow-up is without contact/ 
appointment
Confirmation test - X-ray at least 3 months after procedure, when not conclusive a TVU with recourse to HSG.
- HSG when placement was not satisfactory
Funding source -  Authors have received expenses from conceptus to attend scientific meetings and  
congresses. “no funding”
Notes - Concomitant surgery not reported, parity unclear
82 Hysteroscopic Sterilization
2
Rosen 2004
Methods -  Prospective, Jan 2001 - March 2003, multicenter (3) Sydney Women s Endosurgery Center, 
St George Hospital, Kogarah and Royal Hospital for Women, Randwick, New South Wales, 
Australia
Participants - Number of participants: 80 (first)
- Setting: office setting
- Mean age: 37 (range: 25 - 45)
- Median parity: 2.2 (range 0 - 5)
- Exclusion criteria: Nickel allergy
Interventions - Essure
- Experience of surgeon: 1 surgeon with experience in hysteroscopy
- Concomitant procedures: not reported
- Analgesics: Diclofenac 100 mg per rectum 1 h prior, PB, IVS, GA (3)
- Urinary pregnancy test before procedure
Outcomes - Timing in cycle
- Successful bilateral placement in first attempt.
- Successful bilateral placement in second attempt.
- Learning curve
- Procedure complications
- Adverse events
Length of follow up - Unclear
Confirmation test - Unclear
Funding source -  Dr Rosen provided services to Conceptus Inc. from 2000 to 2002 as a contributor to the 
STOP 2000 trial, and later as a preceptor teaching Fellow gynecologists and Trainees the 
technique of hysteroscopic sterilization. He received payment for these services
Notes
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Savage 2009
Methods -  Retrospective (review of medical electronic records), multicenter, January 2004 to  
December 2006, Northern California, USA 
-  Comparison: analysis of risk factors for failed placement vs successful placement  
and bilateral occlusion vs no bilateral occlusion
Participants - Number of participants: 884
- Setting: inpatient and outpatient, integrated health care delivery system.
- Mean age: 36,4 (SD: 5.5)
-  Parity: only reported that there were no significant differences in nulliparity between  
successful vs failed placement and bilateral versus no bilateral occlusion
- Exclusion criteria: not reported
Interventions - Essure
-  Experience of surgeon: 118 physicians, 30 facilities, attending physicians: first procedures  
and increasing experience during this investigation, no fellows/ residents
- Concomitant procedures: not reported
- Timing: follicular phase or hormonal contraception
- Premedication: not reported
- Analgesics: not reported
Outcomes - Device placement (successful uni- or bilateral placement)
- Tubal occlusion rates (HSG)
- Risk factors for failure
Length of follow up - Follow up was assessed through December 2008 (>2 years). Self-reporting
Confirmation test - HSG performed per local facility protocol
Funding source - No financial disclosure. Supported by Kaiser Permanente Northern California
Notes
84 Hysteroscopic Sterilization
2
Shavel 2009
Methods - Retrospective chart review, single center, January 2003 to June 2007, Detroit, USA
- Comparison: analysis of risk factors for failed placement versus successful placement
Participants - Number of participants: 316
- Setting: urban non-study population at a university medical center, 2 hospitals..
- Mean age: 33.4 years (SD: 6.2)
- Mean parity: 2.9 (SD: 1.5)
- Exclusion criteria: not reported
Interventions - Essure, ESS205
- Experience of surgeon: 24 attending physicians. Majority had performed < 20 procedures
- Concomitant procedures: not reported
- Timing: not specified
- Premedication: not reported
- Analgesics: GA (172), “sedation” (132), RA (12), PB (166)
Outcomes - Factors associated with failure
- Intraoperative complications
- Device placement failure
- Post procedure pregnancies and their outcome
Length of follow up - No follow up
Confirmation test - HSG, but results not reported
Funding source -  One of the authors is a stockholder in Conceptus. Another has received research support 
from conceptus for a topic unrelated to this article
Notes
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Sinha 2007
Methods -  Prospective, August 2002 and June 2006; Birmingham Women’s Hospital
Participants - Number participants: 112
- Two experienced surgeons
- Mean age 36 (23 - 48)
- Parity: not reported
- Setting: outpatient
- Exclusion criteria: desire to preserve fertility, unable to consent, positive urinary pregnancy 
 tests, suspected lower genital tract infection
Interventions - Essure microinsert
- Concomitant procedures: not reported.
- Analgesics: PB till March 2006, than NA
Outcomes - Successful bilateral placement
- Patient satisfaction, questionnaire 3 months after procedure
- Technical feasibility, predictive factors for technical success (operator, body mass index,  
 uterine size, axis, menstrual phase and cervical stenosis)
- Complications
Length of follow up - No follow-up after CT
Confirmation test - The first 16 women had an X-ray, the remainder had a HSG
Funding source - Not reported
Notes
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Thiel 2005
Methods - Prospective, single center, June 2003 and May 2004, Saskatchewan, Canada
Participants - Participants: 50
- Setting: tertiary care hospital.
- Mean age: 36 (± 5.8) (range: 24 - 44)
- Mean Parity: 2.2 ((range 26-50; SD:4.6) 1.1)
- No exclusion criteria
Interventions - Essure microinsert
- Surgeons experience:
- Concomitant procedures: not reported.
- Pre-procedure: indomethacin 100 mg per rectum 1 hour before
- Anesthesia: IV conscious sedation with fentanyl and diazepam 2.5 mg
Outcomes - Successful placement first procedure
- Successful placement second procedure
Length of follow up - Follow up after CT?
Confirmation test - 2D US, 3D US, X-ray and HSG on indication
Funding source - Not reported
Notes
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Ubeda 2004
Methods -  Prospective, July 2002 to July 2003, observational study.  
Institut Universitari Dexeus, Barcelona, Spain
Participants - Participants: 85
- Setting daycare unit
- Age: 38 (26 - 46)
- Parity: 0 (11%) - 4
- Exclusion criteria: not reported
Interventions - Essure
- Surgeon experience:
- Concomitant procedures: not reported
- Pre medication: diazepam and Naprosyn
- No anaesthetics
Outcomes - Successful placement in first attempt
- Successful placement in second attempt
- Successful single placement
- Patient satisfaction
- Bleeding, pain, fever
- Pregnancy
Length of follow up - Unclear
Confirmation test - X- ray after 3 months, HSG on indication
Funding source -  “Supported by the Department of Obstetrics and Gynecology of  
the Institut Universitari Dexeus”
Notes
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Varo 2006
Methods - Prospective, 2007-2009 in the University Hospital La Fe in Valencia, Spain
Participants - Number of participants: 119
- Setting: out-patient
- Mean age: 37.2 ± 4.04 (27 - 46)
- Median parity: 2.9 ± 1.56 (0 - 5)
- Exclusion criteria: not reported
Interventions - Essure
- Experience of surgeon: unclear
- Concomitant procedures: not reported
- Analgesics: Diazepam 10 mgr and ibuprfen 600 mgr one hour before. PB
Outcomes - Successful bilateral placement in first attempt
- Successful bilateral placement at second attempt
- Patient tolerance (Pain: VAS 0-10)
- Complications
- Adverse events
- Pregnancy
Length of follow up - Unclear
Confirmation test - X-ray
Funding source - Not reported
Notes - Spanish language
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Veersema 2005
Methods -  Prospective, August 2002 - August 2004; 2 centers:  
St.Antonius Hospital, Nieuwegein; Rivierenland Hospital, Tiel, The Netherlands
Participants - Number of participants: 182
- Setting: office setting
- Mean age: no data
- Median parity: no data
- Exclusion criteria: not specified
Interventions - Essure
- Experience of surgeon: 2 experienced hysteroscopists
- Concomitant procedures: not reported
- Analgesics: NSAID one hour before
Outcomes - Successful bilateral placement in first attempt.
- Diagnostic characteristic of US and X-ray
Length of follow up - None
Confirmation test - US + X-ray + HSG in all cases
Funding source - None, 2 consultants of Conceptus
Notes
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Veersema 2011
Methods - Prospective multicenter (5), study period: March 2005 to January 2008, the Netherlands
Participants - Number of participants: 1145
- Setting: outpatient departments of 4 teaching hospitals
- Mean age: 39.2 (SD: 4.7)
- Mean parity: 89.9% multiparae
- Exclusion criteria: not reported
Interventions - Essure
-  Experience of surgeon: 9 trained gynecologists (experience in-office hysteroscopy and partici-
pated in training course of Essure)
-  Timing: in proliferative phase of cycle of shortly after withdrawal bleeding when using oral 
contraceptives. Continued alternative contraception until the 3 month follow-up visit.
-  Concomitant procedures: Thirty-five intrauterine devices (IUD’s) were left in situ during  
the procedure.
- Premedication: NSAID evening before the procedure + 1 hour before procedure
- Analgesics: NA
Outcomes - Successful bilateral placement.
- Successful unilateral placement.
- Correct placement confirmed with TVU.
- Mean procedural time
Length of follow up -  3 months for HSG confirmation, thereafter instructed to contact the hospital in  
case of complication or pregnancy
Confirmation test - Transvaginal ultrasound examination 12 weeks after uncomplicated procedure
-  Transvaginal ultrasound examination 4 weeks and HSG 3 months when any difficulties  
occurred during or after procedure.
-  HSG if TVU was inconclusive and after successful placement in a unilateral tube
Funding source - “no possible conflict of interest”
Notes
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Vellayan 2006
Methods - Prospective, single center, Nov 2002 - Nov 2005, Sheffield, USA
Participants - Participants: 100
- Age: unclear
- Exclusion criteria: not reported
Interventions - Essure ESS 105 (37) and ESS 205 (63)
- Setting: out-patient, teaching hospital
- Three experienced hysteroscopists
- Concomitant procedures: not reported.
- Screening PAP, microbiological test
- Timing: first half cycle or OC, instructed to start with OC for 2 months.
- Premedication: Diclofenac and Paracetamol or Codeine phosphate
- Anesthesia: PB , later NA
Outcomes - Successful placement first attempt
- Successful placement second attempt
- Patients satisfaction, tolerance and complications after 48 hrs
- Complications
Length of follow up - No follow-up after CT
Confirmation test - X-ray, HSG on indication
Funding source - Not reported
Notes
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Vleugels 2005
Methods -  Prospective, single center, August 2002 - August 2004; Rivierenland Hospital, Tiel,  
The Netherlands
Participants - Number of participants: 175
- Setting: office setting
- Mean age: 37.4 (25 - 47)
- Exclusion criteria: not specified
Interventions - Essure.
- Experience of surgeon: experienced hysteroscopists
- Concomitant procedures: not reported
- Analgesics: NSAID one hour before
Outcomes - Successful bilateral placement in first attempt
- Successful bilateral placement at second attempt
- Patient satisfaction
- Pregnancy
Length of follow up - None
Confirmation test - US + X-ray + HSG in all cases
Funding source - None, 2 consultants of Conceptus
Notes
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Weston 2005
Methods - Prospective, single center, 2002 - June 2004, Mildura, Australia
Participants - Participants: 99
- Setting: general gynecology practice
- Age: 35.5 (21 - 48)
- Parity: unclear
- Exclusion criteria: not reported
Interventions - Essure pbc
- Experience: 1 Gyn or fellow supervised by same gynecologist
- Concomitant procedures: not reported.
- Anesthesia: light IVS + PB GA (3)
Outcomes - Successful placement first procedure
- Successful placement second procedure
Length of follow up - No follow-up after CT
Confirmation test - US , an X-ray on indication
Funding source - Not reported
Notes
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Abstract
Objective To evaluate the reliability of pelvic X-ray and transvaginal ultrasound to localize Essure 
microinserts (Conceptus, San Carlos, California) after successful placement in both fallopian tubes 
3 months after placement. 
Design  Prospective, observational study.
Setting Gynecology departments at two teaching hospitals.
Patient(s) One hundred eighty-two patients who underwent hysteroscopic sterilization by 
placement of Essure microinserts between August 2002 and August 2004.
Intervention(s) Transvaginal ultrasound, pelvic X-ray, and hysterosalpingography (HSG) 3 months 
after sterilization with Essure.
Main Outcome Measure(s) Transvaginal ultrasound confirmation of correct localization of 
microinserts after a 3-month follow-up.
Result(s) In 150 of 182 patients, confirmation of successful bilateral placement of two microinserts 
(300 devices) was possible. In 9 patients it was not possible to identify both devices with 
ultrasound, or there was doubt about the extension of the device through the uterotubal junction. 
The other 291 devices were identified as being in a good position.
Conclusion(s) Hysterosalpingography at the 3-month follow-up after successful placement of 
Essure microinserts can be replaced by transvaginal ultrasonography. A 3-month follow-up with 
HSG after the Essure procedure is only required after unsatisfactory placements. In those patients 
in whom transvaginal ultrasonography cannot confirm satisfactory localization, a complementary 
pelvic X-ray should be performed.
Key Words Essure, hysteroscopic sterilization , hysterosalpingography, pelvic X-ray,  
transvaginal ultrasound
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Introduction
Essure is a new device for hysteroscopic tubal sterilization. The Essure System 
(Conceptus, San Carlos, CA) was approved by the European Health Office in 
 November 2001 and by the U.S. Food and Drug Administration in November 
2002. It is an expanding spring device made of a nickel–titanium outer coil and a 
flexible stainless steel inner coil with Dacron fibers. This microinsert is placed in 
the proximal section of the fallopian tube under hysteroscopic visualization. The 
Dacron fibers cause localized tissue ingrowth from the surrounding tube, thereby 
achieving mechanical occlusion of the tube. The tissue response is the result of a 
chronic inflammatory and fibrotic response to the fibers. Over a 3-month period 
this ingrowth completely occludes the tubal lumen.
The effectiveness of the Essure microinsert in preventing pregnancy is believed 
to be due to a combination of the space-filling design of the device and this local, 
occlusive, benign tissue response to the fibers. This tissue ingrowth in the devices, 
caused by the fibers, results in both device retention and pregnancy prevention (1).
Initially all patients were scheduled for hysterosalpingography (HSG) 3 months 
after an Essure microinsert placement procedure (2,3). The HSG was performed 
to evaluate microinsert location and fallopian tube occlusion. Until the Essure 
sterilization was completed after 3 months and confirmed by HSG, all patients 
were advised to use alternative contraception.
Because of the potential risks, higher cost, inconvenience, and discomfort of 
the required HSG, clinical data of 700 patients included in a phase II trial were 
reviewed (4). This included a review of HSGs, radiographs, and videotapes of all 
the procedures in which the HSG detected a potential problem. On the basis of this 
review, criteria were developed for identifying the small proportion of patients who 
might benefit from an HSG evaluation, on the basis of their 3-month pelvic X-ray 
results. The current recommendation is to check the position and alignment of 
the microinserts with pelvic X-ray 3 months after a satisfactory bilateral placement. 
Satisfactory placement involves good visualization of the tubal ostia and microinsert 
location across the uterotubal junction, with 3–10 visible expanded coils trailing 
into the uterus. Hysterosalpingography is only requested in cases of no placement, 
unilateral placement, or incorrect placement (>10 device loops outside the tubal 
lumen) (4,5). In cases of satisfactory bilateral one-step placement, X-ray showed 
100% correct position of both devices (5). In another report (4), only one patient 
had abnormal X-ray findings (too much distance between the two devices) after 
satisfactory bilateral placement. Hysterosalpingography revealed tubal occlusion. 
Therefore, in cases of optimal placement, 100% bilateral occlusion was detected 
with X-ray only (5).
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Although X-ray seems to be a sensitive test in detecting the microinserts, limited 
information is gained about the soft tissue structures that envelope it. Ultrasound 
seems to be well suited for microinsert localization. It has many advantages over 
X-ray. Ultrasound has the ability to locate the device and visualize its relationship 
with the surrounding tissue. The position of the device within the uterotubal 
junction can be displayed on ultrasound, whereas it can be merely inferred on plain 
X-ray films. Ultrasound provides real-time and dynamic imaging information to 
aid with device location, whereas X-ray provides a single, static image. Importantly, 
ultrasound is a nonionizing method of imaging that potentially can be performed in 
the doctor’s office without the need for an extra visit to a radiology department, thus 
shifting and reducing follow-up expenses. An early post-insertion ultrasound can 
even be used to ensure correct positioning of the device or its eventual malposition. 
In an earlier study, 5 patients were examined by ultrasound within 4 weeks after 
insertion. Fourteen pairs of devices were seen. One device was malpositioned, and 
in 1 patient a device was missing (6).
In this study, we assessed the test characteristics of transvaginal ultrasono-
graphic localization of the microinserts, compared with pelvic X-ray and HSG.
Figure 1 
Transvaginal ultrasound at 3 months. (A) Microinsert crossing the cornua of the uterus,  
with the proximal end in the uterine wall. (B) Transverse section of the uterus demonstrating  
both microinserts.
A
B
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Materials and methods
Between August 2002 and August 2004, 182 consecutive patients were included 
in the clinical evaluation of the Dutch Essure trial in two clinics in the Netherlands 
(St. Antonius Hospital Nieuwegein and the Rivierenland Hospital Tiel). In both 
clinics the investigators followed the same study protocol and obtained approval 
from the clinical and ethics committees. All women gave their written, informed 
consent in the knowledge that this new method of sterilization is irreversible, 
and data of a long-term follow-up are not yet available. In 150 women (82.4%), a 
successful bilateral Essure placement in a one-step procedure was achieved. These 
patients were advised to continue alternative contraception for the next 3 months 
and were scheduled for transvaginal ultrasound after 3 months. Transvaginal 
ultrasound was followed by HSG in that same session. Hysterosalpingography was 
started with a blank abdominal X-ray. Ultrasound was performed with an Aloka 
SSD 550 (Biomedic Nederland BV, Almere) or a Toshiba Eccobee (Toshiba Medical 
Systems Nederland BV, Zoetermeer).
After the microinserts were localized by ultrasound, the position of the reflections 
of the microinsert in relation to the outer line of the uterus was described. The 
position of the devices was “satisfactory” when the reflections of the microinsert 
crossed the outer line of the uterine wall and the proximal ends of both devices were 
visualized inside the outer line or in the region of the endometrial cavity (Fig. 1). 
The physician was asked to predict the occlusion of each fallopian tube, which 
was confirmed by HSG. The criteria used to evaluate the HSG for “satisfactory” 
placement were [1] both microinserts visible with ≤50% of the length of the inner 
coil trailing into the cavity, [2] the proximal ends of the inner coils appear to be <30 
mm into the tube from where contrast fills the uterine cornua, and [3] no contrast 
visible in the tubes beyond the microinserts or in the peritoneal cavity (7).
The pelvic X-ray was “satisfactory” when the microinserts appeared to be in the 
tubal lumen, spanning the uterotubal junction, and relatively symmetrical.
All data were collected with commercial statistical software (SPSS, Chicago, IL). 
Sensitivity, specificity, positive predictive value, and negative predictive value for 
transvaginal ultrasound and X-ray were calculated. Hysterosalpingography was 
considered the “gold standard”.
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Results
In 150 patients with successful bilateral placement, 2 microinserts (300 devices) 
could be examined by transvaginal ultrasound. In 9 patients it was not possible 
to identify both devices with ultrasound, or there was doubt as to the extension of 
the device through the uterotubal junction. The other 291 devices were identified 
and in a good position. In 1 of the 9 patients with unsatisfactory ultrasound results 
only 1 microinsert was present on pelvic X-ray; this patient seemed to have had an 
expulsion (Fig. 2). In 149 patients the pelvic X-ray was determined to be satisfactory 
with both microinserts. One of these 149 women was found to have some evidence 
of dye passage (patency) past the microinsert into the distal tubal lumen upon HSG 
(Fig. 3). This patient refused to continue the use of alternative contraception and 
insisted on sterilization. Forty-nine weeks later she underwent a repeat HSG, and 
bilateral tubal occlusion was achieved at this time. This patient did not become 
pregnant despite unprotected sexual intercourse. One hundred forty-eight patients 
were instructed to discontinue alternative contraception because of bilateral tubal 
occlusion 3 months after the procedure. In the patient with the expulsion a second 
microinsert was placed in a new attempt. The patient continued with alternative 
contraception for 3 more months, and HSG was repeated.
The results of transvaginal ultrasound as compared with the results of HSG as 
the “reference test” show a sensitivity of 50% and a specificity of 95%. Compared 
with pelvic X-ray as the reference test these values are 100% and 95%, respectively. 
The predictive value of a satisfactory transvaginal ultrasound result is 99% and the 
predictive value of an unsatisfactory result is 11%.
 
Figure 2
Pelvic X-ray at 3 months, demonstrating expulsion of the 
left microinsert; only the right microinsert is present.
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Discussion
The 3-month follow-up period after hysteroscopic sterilization with Essure is 
based on the time it takes the tissue ingrowth to completely occlude the tubal lumen 
(1). Because the initial recommendation of an HSG has been changed to pelvic X-ray 
3 months after successful bilateral placement, exclusion of tubal patency is no longer 
a requirement (4). After satisfactory pelvic X-ray results, the patient can rely on the 
microinserts for sterilization (7). In the present study, ultrasound detection of both 
devices was satisfactory in 141 of the 150 patients with successful bilateral placement. 
One patient with an expulsion of a microinsert was recognized with ultrasound 
as well as with pelvic X-ray. A second patient with tubal patency on HSG had a 
satisfactory pelvic X-ray, and both devices were in a good position on transvaginal 
ultrasound. It has been postulated that the absence of absolute physical occlusion of 
the tubes does not necessarily equate with failure of sterilization. In only 8 patients 
with satisfactory pelvic X-ray results was it not possible to confirm the satisfactory 
position of the devices with transvaginal ultrasound. Transvaginal ultrasound has 
great advantages over pelvic X-ray because it is a non-ionizing method of imaging. 
It can be done on an outpatient basis in departments of gynecology by the patient’s 
own physician and can be repeated at any time without any risk to the patient.
We conclude that HSG at the 3-month follow-up of hysteroscopic sterilization 
with Essure can be replaced by transvaginal ultrasound. In those patients for whom 
transvaginal ultrasound cannot confirm satisfactory localization, a complementary 
pelvic X-ray should be performed. 
Figure 2
Hysterosalpingogram at 3 months: note correct placement 
of both devices and patency of the right fallopian tube.
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Hysterosalpingography is only required after unsatisfactory placements. The 
number of HSGs and pelvic X-rays can be minimized, thus reducing costs, 
inconvenience, and discomfort. In cases of technical difficulties during the procedure 
or for patients with abnormal bleeding after the insertion, a transvaginal ultrasound 
can be scheduled 4 weeks after the procedure. This will prevent unnecessary 
anxiety in these women and offers the possibility of preventing a potential delay in 
diagnosing expulsion or misplacement of a microinsert.
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Abstract
Objective To estimate the diagnostic accuracy and the interobserver reproducibility of pelvic X-rays 
in the diagnosis of successful bilateral sterilization with Essure after a 3-month follow-up period.
Design Interobserver study.
Setting  Outpatient department of obstetrics and gynecology in a Dutch teaching hospital.
Patient(s)  Patients with successful bilateral Essure placement.
Intervention(s) Hysteroscopic sterilization with Essure and pelvic X-ray and hysterosalpingography 
after a 3-month follow-up period.
Main Outcome Measure(s): Six observers evaluations of 47 pelvic X-rays from 47 patients 3 months 
after a technical successful bilateral placement of microinserts to estimate the reliability of the 
sterilization. Diagnostic accuracy of pelvic X-ray per observer in detecting incorrectly positioned 
microinserts was expressed in terms of sensitivity and specificity, with hysterosalpingography as the 
reference strategy. Reproducibility of the interpretation of the pelvic X-ray was expressed as κ-values.
Result(s) The sensitivity and specificity for X-rays read by gynecologists was 0.67 (95% confidence 
interval [CI], 0.29-0.96) and 0.79 (95% CI: 0.58-1.00) and for radiologists 1.0 and 0.5 (95% 
CI: 0.36-0.64). The interobserver agreement in reliability of pelvic X-ray of hysteroscopic sterilization 
assessment with Essure ranged from slight (k-value 0.09) for gynecologists to moderate (κ-value = 
0.52) for radiologists.
Conclusion(s) Test characteristics of pelvic X-ray as the imaging technique to assess the position 
of the Essure microinserts and tubal patency were poor, as was the reproducibility, particularly 
if gynecologists performed the evaluation. We do not recommend the use of pelvic X-ray for 
the assessment of the positioning of microinserts after hysteroscopic sterilization. (Fertil Steril 
2010;94:1202–7)
Key Words Essure, hysteroscopic sterilization , confirmation test, X-ray, interobserver 
reproducibility
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Introduction 
The Essure Permanent Birth Control System (Conceptus Inc, Mountain View, CA) is 
a new method of proximal tubal occlusion by hysteroscopic placement of a microinsert 
in the uterotubal junction (1–3). The procedure is gaining popularity because it can 
be performed under local or no anesthesia in the office. During hysteroscopy, the 
introduction device is inserted in the fallopian tube, after which the device can expand 
and the Essure microinsert remains in position. The Essure microinsert consists 
of a stainless steel inner coil, a nickel titanium alloy outer coil, and polyethylene 
terephthalate (PET) fibers covering the inner coil. The PET fibers induce a tissue 
response, which causes fibrous tissue in growth with tubal occlusion (4).
The position of the devices has to be confirmed 3 months after the procedure 
before the patient can rely on this permanent contraception and cease her alternative 
contraception. Different imaging techniques are used to document localization of 
the microinserts and tubal occlusion 3 months after placement. The traditional 
hysterosalpingography (HSG) is the only imaging method currently approved by 
the U.S. Food and Drug Administration (FDA). The current recommendation in 
countries outside the United States is to check the position and the alignment of the 
devices with pelvic X-ray (5). The limitations of pelvic X-ray are the risk of ionizing 
radiation and lack of soft tissue and tubal patency information.
Adverse events after the Essure sterilization , such as subsequent pregnancy, 
expulsion of the microinsert, or perforation, have been described in previous 
studies and are associated with incorrect placement procedures (1,3).
Earlier phase II and pivotal multicenter trials were started in 1998 and strongly 
advised patients to use alternative contraception for 3 months after the procedure 
until tubal occlusion was confirmed by HSG (1,3). Satisfactory bilateral insertion 
was achieved in 664 of 734 patients (90%). Satisfactory placement implied good 
visibility of the tubal ostia in hysteroscopy and microinserts location across the 
uterotubal junction, with three to eight visible expanded coils trailing into the 
uterine cavity. The 100% bilateral tubal occlusion after an initial satisfactory bilateral 
placement was confirmed by HSG. To exclude unexpected failures, a less invasive 
diagnostic test may be sufficient.
Two earlier reports on the results of clinical trials in Spain with hysteroscopic 
sterilization with Essure and the use of pelvic X-ray 3 months after a satisfactory 
bilateral placement (6,7) are available.
A recent analysis of 1630 women who underwent an office hysteroscopic tubal 
sterilization with Essure between January 2003 and June 2006 showed a successful 
insertion rate of 99% (8). Women were advised to use an alternative contraceptive 
method until a simple X-ray examination was performed at least 3 months after 
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the insertion. Hysterosalpingography or ultrasonography was performed when 
the placement was not satisfactory (more than eight or fewer than three coils 
remaining visible by hysteroscopy, insertion in only one tube, unclear radiologic 
results). None of these patients have become pregnant after confirmation at the 
3-month follow-up evaluation. These results indicate that pelvic X-ray may be useful 
to confirm successful bilateral placement in an uncomplicated procedure. However, 
no data are available about the diagnostic accuracy and the reproducibility of the 
pelvic X-ray as a confirmation test for Essure sterilization. In cases of poor test 
characteristics or reproducibility, routine use of pelvic X-ray may be misguided, 
adding no useful additional information and wasting health-care resources.
Our study was designed to test the accuracy of pelvic X-ray compared with the 
standard HSG as reference test among radiologists and gynecologists for the 
diagnosis of successful bilateral sterilization with Essure after a 3-month follow-up 
period and to estimate the interobserver agreement.
Materials and methods
The study was conducted in the Department of Obstetrics and Gynecology of the St. 
Antonius Hospital, a teaching hospital in Nieuwegein, the Netherlands. The approval 
of the institutional review board was not considered necessary as patients were not 
in any way involved in the study and patient data were anonymous. Moreover, the 
study is part of large cohort study of 100 consecutive patients (9) that was approved 
by the institutional review board. All women gave their written informed consent to 
being part of the cohort, and to knowing that the Essure technique of sterilization 
is irreversible and that data of a long-term follow-up study were not yet available. 
Patients were eligible for this study if an adequate plain pelvic X-ray as well as a HSG 
were digitally available. As the quality of the X-rays was suboptimal in many cases, 
only 47 cases were included as having digital X-rays of optimal quality.
Hysteroscopic sterilization using the Essure system inserted by use of the 
standard technique was performed in an outpatient setting. Three months after 
the procedure, a pelvic X-ray was performed with the patient in supine position, 
followed by a HSG with a water-soluble contrast medium (Telebrix-Polyvidone; 
Guerbet SA, Villepinte, France). The contrast medium was instilled into the uterine 
cavity after the pelvic X-ray was made, using a silicone balloon HSG catheter (Cook 
Ireland Ltd., Limerick, Ireland). All images were digitally recorded to enable digital 
demonstration afterward (5). The captured images were evaluated by a radiologist 
and gynecologist using the algorithm from the HSG protocol in the manufacturer’s 
physician training manual (5). If there was a satisfactory position of both devices 
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and bilateral tubal occlusion, the sterilization was considered successful, and the 
patient was advised to cease alternative contraception.
In 2005, all X-rays were evaluated simultaneously by an international panel 
formed by six observers. The observers were not informed about the clinical data of 
the hysteroscopic sterilization procedures. The only clinical information available 
at the time of evaluation was that a bilateral hysteroscopic sterilization had been 
successfully performed 3 months before the X-ray. The participants were three 
gynecologist, all specialists in hysteroscopic sterilization with good experience in 
reading X-rays after Essure sterilization (Gyn 1-3), two radiologists, with good and 
moderate experience (Rad 1 and 2), and a registrar in radiology with experience in 
reading HSGs after Essure sterilization (Rad R).
The observers were blinded for the results of the HSG. They were not allowed to 
discuss the results. The Essure X-ray protocol from the manufacturer’s physician 
training manual (5) was used while evaluating of the pelvic X-rays.
According to the manufacturer’s protocol, the observers evaluated the pelvic 
X-rays with regard to the position of the microinserts, the symmetrical appearance 
of the devices, and the distance between the two devices. In addition, they had to 
judge the X-ray as satisfactory, uncertain, or unsatisfactory and determine whether 
the patient could rely on the sterilization (Table 1).
Table 1
Observer assessment items for 3-month evaluations of Essure placement X-rays.
Evaluation items Options
Ability to assess Good Acceptable Nondiagnostic (ND) 
Position right device Correct Incorrect ND
Position left device Correct Incorrect ND 
Symmetrical appearance Yes No ND 
Distance <4 cm 4-5 cm >5 cm
Conclusion Satisfactory Suspicious Unsatisfactory
Rely on Essure? Yes No ND
Notes: The observers evaluated the pelvic X-rays on ability to assess the position of the microinserts, symmetrical ap-
pearance of the devices, and the distance between the two devices. They also had to grade the X-ray as satisfactory, 
uncertain, or unsatisfactory and determine whether the patient could rely on the sterilization .
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Statistical Analysis
Reproducibility was expressed using Fleiss’s κ-statistics (10). Fleiss’s kappa (κ) 
works for any number of raters giving categorical ratings to a fixed number of 
items. It can be interpreted as expressing the extent to which the observed amount 
of agreement among raters exceeds what would be expected if all raters made their 
ratings completely randomly. A κ-value of 0 indicates no agreement beyond chance, 
a κ-value of 1 indicates perfect agreement between observers. The reproducibility 
in the case of κ-values between 0 and was regarded as slight, between 0.2 and 0.4 
as fair, between 0.4 and 0.6 as moderate, between 0.6 and 0.8 as substantial, and 
between 0.8 and 1.0 as almost perfect.
The κ-values were calculated for the six observers together and for the three 
gynecologists and three radiologists separately.
In the assessment of diagnostic accuracy of the X-ray, HSG was considered to be 
the reference test.
Diagnostic accuracy was calculated for each observer and expressed in terms of 
sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV). An unsatisfactory or uncertain evaluation of an X-ray as of the position 
of the microinserts was regarded as a positive test result, whereas a satisfactory 
evaluation was regarded as a negative test result (successful sterilization).
Results
Between December 2003 and July 2004, 47 patients with technically successful 
bilateral placement of Essure were included in the study. All patients were evaluated 
by HSG and pelvic X-ray after a 3-month follow-up period. In 44 cases, the HSG 
confirmed correct position of both implants and bilateral occlusion of the fallopian 
tubes. There were three cases of an abnormal position of one of the microinserts 
and a patent tube on HSG: one complete expulsion, one expulsion to the uterine 
cavity (Fig. 1), and one perforation with the device in the abdominal cavity (Fig. 2).
The diagnostic accuracy for each observer is expressed in terms of sensitivity 
and specificity. The pooled sensitivity and specificity of both gynecologists and 
radiologists was 15 out of 18 (83%) and the specificity 170 out of 264 (64%). 
According to medical specialty, the sensitivity for the three radiologists was 
100%, and the specificity was 66 out of 132 (50%). For 27 cases, at least one of 
the radiologists advised additional HSG to confirm a reliable sterilization (false 
positive). The sensitivity for the X-ray evaluated by the gynecologists was 6 out of 9 
(67%), and the specificity was 79%. Two gynecologists accepted the X-ray from the 
case with the perforation as satisfactory, and one gynecologist did not recognize the 
expulsion into the cavity (false negative) (Table 2).
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The overall interobserver agreement with regard to reliability of the hysteroscopic 
sterilization with Essure ranged from slight (κ=0.09) for gynecologists to moderate 
(κ=0.52) for radiologists (Table 3). 
There was agreement between all observers that the sterilization was satisfactory 
in 11 cases, with advice to the patients that they could rely on the sterilization. Only 
for the case with one patent microinsert (due to expulsion of the other) was there 
agreement between all six observers that the sterilization was unsatisfactory. The 
agreement between the observers on the visibility of both devices was perfect, 
while the agreement on the position of the devices (0.28 to 0.30), the symmetrical 
appearance of both devices (0.37), and the distance between the two devices (0.27) 
was fair. The agreement on the final conclusion of the X-ray was slight (0.17) (Table 3).
The patient with the perforation underwent a laparoscopic sterilization with 
Filshie Clips (Femcare-Nikomed Limited, Hampshire, UK.). During the same 
procedure, the microinsert was released from the omentum. The two other 
patients with incorrect position of the microinsert underwent a second successful 
hysteroscopic sterilization confirmed by HSG after 3 months. None of the patients 
has become pregnant.
Table 2 
Diagnostic performance of X-ray as diagnostic tool for the assessment of reliability of hysteroscopic sterilization with 
Essure for each observer (gynecologists and radiologists) expressed as sensitivity, specificity, positive predictive 
value, and negative predictive value.
Observer Sensitivity% Specificity% PPV% NPV%
Gyn 1 33 100 100 96
Gyn 2 67 70 13 97
Gyn 3 100 66 17 00
Mean (±95% CI) 67 (±38) 79 (±21) 43 (±56) 98 (±3)
Rad 1 100 64 16 100
Rad 2 100 48 12 100
Rad R 100 39 10 100
Mean (±95% CI) 100 50 (±3) 12 (±0.03) 100
Note: Rad R = Radiology Registrar.
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Discussion
In this study, six observers evaluated 47 X-rays, including three cases of incorrect 
position of a device. The test characteristics of the X-rays were better in the hands 
of radiologists (sensitivity 100%, specificity 50%) than in the hands of gynecologists 
(sensitivity 67%, specificity 79%). The interobserver agreement (κ) in visualizing 
the microinsert was 100% in both radiologists and gynecologists; however, 
in scoring reliability of the Essure sterilization there was a large difference in the 
agreement between radiologists (52%) and gynecologists (9%).
In the United States, hysterosalpingography (HSG) is the only imaging method 
currently approved by the FDA for the diagnosis of tubal occlusion after the Essure 
sterilization procedure. In other countries, other diagnostic tools are used for 
confirmation. In Europe, pelvic X-ray is recommended by CE Mark guidelines.
 
Table 3 
Interobserver agreement kappa values.
All 
κ 95% CI
Radiologist
κ 95% CI
Gynecologists
κ 95% CI
Right device Visible 1.0 1.0 1.0
Optimal position 0.28 0.25–0.31 0.45* 0.30–0.59 0.15 0.3–0.28
Left device Visible 1.0 1.0 1.0
Optimal position 0.30* 0.27–0.33 0.54* 0.39–0.69 0.08* -0.05–0.21
Accessibility 0.14* 0.11–0.18 1.0 0.27 0.12–0.42
Symmetrical 0.37* 0.34–0.41 0.77* 0.61–0.94 0.05 -0.10–0.19
Distance 0.27* 0.24–0.30 0.44* 0.32–0.58 0.07 -0.05–0.19
Conclusion 0.17* 0.14–0.20 0.25* 0.13–0.37 0.14 0.01–0.27
Rely on 0.24* 0.21–0.28 0.52* 0.35–0.68 0..9 -0.05–0.25
Notes: Agreement between the three radiologists and three gynecologists about visibility, optimal position of the device, 
accessibility of the X-ray, symmetrical appearance, and distance between the two devices, the final conclusion for the 
X-ray, and the reliability of the sterilization. The reproducibility in the case of κ-values between 0 and 0.2 was regarded as 
slight, between 0.2 and 0.4 as fair, between 0.4 and 0.6 as moderate, between 0.6 and 0.8 as substantial, and between 
0.8 and 1.0 as almost perfect. (*P< .0001.)
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To the best of our knowledge, ours is the first report on the diagnostic accuracy of 
pelvic X-ray in the assessment of the correct placement of the Essure microinserts 
using HSG as a reference test. Hysterosalpingography is the best available diagnostic 
test to assess the efficacy of the Essure sterilization in terms of position of the 
microinserts and blockage of the tubes. However, the combination of position and 
patency is crucial, as blocked tubes alone do not guarantee an effective sterilization.
As to the different performance of gynecologists and radiologists in favor of the latter, 
any explanation is speculative. The pelvis X-rays as evaluated by the gynecologists 
gave a low sensitivity and evaluated by the radiologists gave insufficient specificity. 
Figure 2 
Pelvic X-ray and hysterosalpingography of patient with perforation 
of the left device to the abdominal cavity.
Figure 1
Pelvic X-ray and hysterosalpingography of patient with partial expulsion 
of right device into the uterine cavity.
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In other words, not one radiologist confirmed an adequate sterilization for the three 
patients with a failure, but they advised additional HSGs to perform, whereas the 
gynecologists accepted more X-rays as reliable sterilization s, but two gynecologists 
did not recognize the perforation, and one of them did not recognize the expulsion 
to the uterine cavity.
Radiologists are used to evaluating images with little or no clinical data, and they are 
aware of the clinical consequences if they miss an important abnormality. As imaging 
specialists, they may be more inclined to adhere to given instructions on diagnostic 
criteria than doctors in other specialties. All the observers were instructed on the 
criteria of failed position of the microinserts according to the protocol (see Table 1). 
Unfortunately, the alignment of the fourth marker, which is considered to be an 
important criterion nowadays, was not included in the criterion list. As the frequency 
of failed insertion of the Essure device is low, so is the experience of the observers.
In our case series, in three out of 47 X-rays the displacement of the microinsert 
was reported. This low frequency is in line with former publications (1,3,8,11). In the 
phase II study (1) of 226 patients evaluated with HSG after a three-month follow-up 
period, six perforations of the uterine wall or tubal lumen and one expulsion were 
reported. In the published European series with X-ray as the confirmation test, there 
was a 100% success rate after bilateral placement, with no unsatisfactory device 
locations (12, 13). In the most recent study by Arjona et al. (8), three pregnancies 
occurred during the first 3 months after 1650 procedures.
The issue of better instruction and training of the X-ray reviewers was also 
addressed by van der Leij et al. (12), who reported in 1997 on the interobserver and 
intraobserver agreement in the evaluation of radiographic images after hysteroscopic 
sterilization with Ovabloc (formed-in-place intratubal silicone devices; European 
Medical Contract Manufacturing B.V., CH Nijmegen, the Netherlands). A group of 
eight gynecologists had only poor interobserver agreement on the reliability of the 
sterilization. The investigators concluded that this underlined the need for training 
in standardized interpretation of X-rays concerning the reliability of sterilization (12).
Another reason for the poor diagnostic performance and agreement among 
gynecologists in particular may be the lack of clinical data, such as information 
on any difficulties during experienced the Essure insertion procedure. In daily 
practice, these data may alert the X-ray observer that there may be cause for an 
underestimation of the accuracy of the X-rays.
In a recent study in the United Kingdom to determine patient satisfaction of 
outpatient female sterilization , the majority of women (96%; 95% CI: 88-99%) 
reported satisfaction with their overall experience of the Essure hysteroscopic 
sterilization procedure and follow-up evaluations. Two patients declined to have their 
scheduled HSG, and only 72% of the patients reported the HSG as an ‘‘acceptable test.’’ 
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The use of pelvic X-ray, which is less invasive and causes less inconvenience, 
demonstrates intra-abdominal localization of the microinserts. Because of the lack of 
soft tissue detail and no filling of the uterine cavity with contrast dye, no information 
is available regarding the relationship of the microinsert to the uterine cornua.
Our study shows that a correct position of the microinserts in the fallopian tube 
is difficult to assess by plain X-ray alone. Pelvic X-ray was a perfect diagnostic tool 
to confirm a complete expulsion of a microinsert, but it missed discrete dislocation 
where the dislocated microinsert was still attached to the uterine wall. The lack of 
additional clinical information and history of the patient, and possibly the insufficient 
training of the observers may be associated with the poor test characteristics and 
reproducibility of pelvic X-rays after Essure sterilization. The results of our study do 
not justify the routine use of this radiographic tool in clinical practice.
Recently, it was shown (13-17) that transvaginal ultrasound assessment may 
be as reliable as HSG for uterotubal localization of the microinserts. The use of 
ultrasound obviates the need for ionizing radiation in the majority of patients. 
Future studies on other imaging techniques such as ultrasound are necessary to 
optimize imaging after Essure placement.
Acknowledgments: The authors thank L. Koobs, A. Ubeda-Hernandez, Professor 
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Abstract
Objective T o describe incorrect positions of Essure microinserts detected at 3 months’ follow-up.
Design Case series report.
Setting  Outpatient department of obstetrics and gynecology in a Dutch teaching hospital.
Patient(s) Initial series of 100 patients who underwent hysteroscopic sterilization using Essure 
between December 2003 and June 2004.
Intervention(s) Hysteroscopic placement of the Essure System, follow-up at 3 months with 
transvaginal ultrasound (TVU), and hysterosalpingograp (HSG).
Main Outcome Measure(s) Bilateral placement rate, tubal obstruction, and detection of incorrect 
Essure microinsert localization at follow-up after apparent successful bilateral placement.
  
Result(s) Bilateral placement of Essure microinserts in one session was successful in 93 women 
(93%). In 90 of these women (96.8%), tubal obstruction was proven at follow-up 3 months later. 
Three incorrect positions of an Essure insert were seen: two expulsions and one perforation into the 
abdominal cavity.
Conclusion(s) Incorrect position of Essure microinserts was seen only when the initial placement 
procedure was difficult. When a placement procedure was difficult or other suboptimal conditions 
are present during the procedure, we advise performing a TVU or pelvic X-ray in these women 
4 weeks after the procedure or after the first vaginal bleeding, instead of waiting for follow-up after 
3 months. 
Key Words Essure, Hysteroscopic sterilization , Transcervical sterilization ,  
Perforation, Expulsion
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Introduction
Transcervical sterilization using the Essure System (Conceptus, Mountain View, 
CA) is becoming increasingly popular as a means of permanent birth control. 
Worldwide, more than 100,000 women have been sterilized with this method. It is 
a patient-friendly procedure that does not require general anesthesia and surgical 
incisions (1,2).
During office hysteroscopy the uterine cavity is inspected and the tubal 
openings identified. The introduction device is inserted in the fallopian tube, 
after which the device can be deployed and the Essure microinsert remains in 
position (2). After insertion and deployment, ideally 3-8 coils of the insert are 
visible outside the tubal opening (2).
An Essure microinsert consists of a stainless steel inner coil, a nickel titanium 
alloy outer coil, and polyethylene terephthalate (PET) fibres covering the 
inner coil (1,3). The PET fibres induce a tissue response, which causes fibrous 
tissue ingrowth and thus tubal occlusion (3, 4). Patients have to use additional 
contraception until at 3 months’ follow-up correct placement of the inserts and/
or tubal obstruction is proven.
Transvaginal ultrasound (TVU) examination has proved to be an adequate 
method to confirm the microinsert position at follow-up (5-8). When ultrasound 
examination is inconclusive or an undesirable position of an insert is suspected, a 
hysterosalpingography (HSG) can be performed (8).
Bilateral placement rate in one session ranges from 86% to 91.3% (2,6,11,12). 
Perforation, expulsion, and inability to place the inserts bilaterally are known 
undesirable events of the Essure placement procedure. Most of these events 
described in earlier studies have been detected during the procedure itself and were 
attributed either to a design problem of the material that was subsequently improved 
or to incorrect placement procedures (3,4). Malformations or abnormalities of the 
uterine cavity and the fallopian tubes are associated with placement failure (1,2, 
9,10). Other factors, such as tubal spasms, are also suspected to have a negative 
influence on Essure placement procedures (1,10,12). More recently, a case has been 
described in which there was no tissue ingrowth with a correctly positioned device 
3 months postpartum (13).
Between December 2003 and June 2004 an initial series of one hundred women 
were sterilized with the Essure System in our teaching hospital. At three months 
follow-up three patients were diagnosed with an incorrect position of one of the 
inserts; we report those cases here.
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Materials and methods
This was a prospective cohort study set in a university-affiliated teaching hospital 
with outpatient hysteroscopy facilities, where 500 outpatient hysteroscopic 
procedures are performed annually. Institutional Review Board approval was not 
necessary for this study. Placement of Essure devices started in December 2003, 
and the first 100 procedures were recorded. One gynecologist (S.V.) specialized in 
hysteroscopy performed all the procedures. The procedure was scheduled in the 
proliferative phase of the cycle or shortly after a withdrawal bleeding if patients 
were using oral contraceptives. Women were advised to take a non-steroidal 
anti-inflammatory drug (NSAID) the evening before and 1 h before the placement 
of the Essure microinserts.
The procedure was performed using a 5.5-mm continuous flow rigid hysteroscope 
with a 30° lens (Olympus; Winter and Ibe, Hamburg, Germany) and a 5-French 
working channel. Uterine distension was obtained using pumped saline solution with 
a pressure of 100 mm Hg. The hysteroscope was introduced using a vaginoscopic 
approach without speculum, tenaculum, or local anaesthetics. If bilateral placement 
was unsuccessful in the first session, a second attempt was offered.
Patients’ characteristics and procedure characteristics were recorded in a database. 
All procedures were recorded on VHS video.
After surgery, patients were instructed about possible complications and when 
they should contact the hospital. They were scheduled for a 3-month follow-up, 
which included TVU and HSG. After proven correct position of microinserts at 
follow-up, patients were given the advice to stop other methods of contraception.
Outcome was defined as successful bilateral placement and tubal obstruction. 
Incorrect localizations detected at 3 months’ follow-up were analyzed. Findings at 
TVU and HSG were also recorded in the database.
Results
From December 2003 to June 2004, 100 women underwent an Essure procedure. 
Mean operating time was 10 min (range 4-34 min). Patients were 29-47 years old 
with a mean age of 38 years, and parity ranged from zero to six with a median of two 
births (Table 1). Before the procedure, most women (47%) used oral contraception. 
All of the patients left the hospital within 2 h after the procedure and were able to 
return to normal activity within 24 hours.
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Table 1
Patients’ characteristics.
Mean Median Range
Age (yrs) 38 38 29 – 47
Parity 2 2 0 – 6
Operating time (min) 10 8 4 – 34
Bilateral microinsert placement in one session was successfully performed in 
93 patients (93%); in seven patients (7%) the procedure failed. A second attempt 
was performed in three of these seven patients, and in all three cases the second 
procedure was also unsuccessful.
At 3 months’ follow-up, correct cornual localization of both devices was confirmed 
by ultrasound in 84 (90.3%) of the 93 cases with successful bilateral placement. 
In 90 patients (96.8%), HSG showed bilateral occlusion of the fallopian tubes. 
In three patients an incorrect localization of one of the microinserts with patency 
of the ipsilateral fallopian tube was seen on HSG: one perforation, an expulsion 
into the uterine cavity, and one complete expulsion. The latter two patients were 
successfully sterilized in a second Essure placement procedure. We present here 
the three cases with failure of the Essure system detected at follow-up.
Case Descriptions
Patient A was a 42-year-old multiparous woman. No abnormalities were seen 
during hysteroscopy. During insertion of the microinsert in the left fallopian tube, 
a resistance occurred and was eventually over won. This was thought to be a tubal 
spasm. When bilateral placement was completed, three coils were visible on the 
right side and six coils on the left side. Procedure time was 10 min.
At TVU follow-up after 3 months, both inserts were not clearly visible. On pelvic 
X-ray an abnormal configuration of the left microinsert was seen. In evaluating 
microinsert position with X-ray or HSG, it is very important to note the ‘‘markers’’ 
for the proximal and distal ends of the inner and outer coil.
The inner coil can be recognized very easily as a thin line structure with two 
landmarks: the distal end, most lateral (first marker), and the proximal end (third 
marker). The distal end of the outer coil (second marker) is next to the first marker, 
and the platinum band at the proximal end of the outer coil is visible as the fourth 
marker. In a normal configuration, the fourth marker is in line with the other three 
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markers. In this case, the fourth marker was not in line with the other three markers 
and too close to the second marker. The HSG showed patency of the left tube (Fig. 1).
Retrospectively, the patient had experienced abdominal pain for several weeks after 
placement of the Essure System. Perforation of the left device into the abdominal 
cavity was suspected, and a laparoscopy was performed. The Essure microinsert 
was detected in the omentum. No signs of inflammation or adhesions were seen. 
During laparoscopy, the insert was removed, and tubal ligation of the left tube was 
performed using a Filshie Clip.
Patient B was a 42-year-old multiparous woman. During hysteroscopy, a normal 
uterine cavity was seen with some small endometrial polyps. Insertion of both 
Essure microinserts was difficult. After insertion, one coil extended from the 
right tubal ostium. The number of coils extending from the left tubal opening was 
not clearly visible. At the time of the procedure, it was speculated that this was 
attributable to thickened endometrium. Procedure time was 17 min.
The TVU 3 months later detected only the right microinsert in a cornual position; 
no insert was seen on the left side. Pelvic X-ray showed one device present in the 
pelvis. On HSG, the right microinsert was seen with tubal occlusion, whereas the 
left tube was patent (Fig. 2). The patient had not noticed an expulsion. In a second 
procedure, another microinsert was placed in the left fallopian tube. After another 
3 months, obstruction of both fallopian tubes was proved by HSG.
Patient C was a 43-year-old multiparous woman with a history of two caesarean 
sections. During the procedure, a levonorgestrel intrauterine device was removed. 
Figure 1 
The microinsert on the right side shows a normal configuration of the four markers. The left-side insert 
has an abnormal configuration and an abnormal position in the pelvis; on HSG the left tube is patent.
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Intrauterine adhesions were seen in the left tubal corner. Insertion of the left 
device was very difficult but successful, although it took longer than usual. 
Owing to the formation of edema caused by the extended procedure time, the 
placement on the right side became unexpectedly difficult, too. Three coils were 
visible on the left side and two coils on the right side; total procedure time was 31 min.
On follow-up TVU, the left insert was visible in a correct position, but the insert 
on the right side could not be made clearly visible. On pelvic X-ray, the right device 
was seen in an abnormal position, proximal of the right tube. The HSG showed a 
patent right fallopian tube (Fig. 3). During hysteroscopy, the right microinsert was 
floating in the uterine cavity. After removal, another Essure microinsert was placed 
in the right tube with three coils visible. Control HSG after 3 months showed tubal 
obstruction on both sides.
Discussion
Perforation rate in our initial series of 100 patients was 1%, which is in accordance 
with the literature. Through the years, the perforation rate has decreased from 3-7% 
(2,4) to 1-2,6% (1,9). In 2% of our patients, we observed an expulsion after an 
initially apparent successful placement procedure. Expulsion from the fallopian 
tube is reported in 1.3-3.6% and is due to incorrect insertion of the microinsert, 
mostly concerning placement too proximal in the tube (1,2).
Figure 2 
Only the right insert is visible, and the left tube is patent for contrast fluid.
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Every procedure has its period of training, and the learning curve for this 
particular intervention has been shown in other studies to be short, about five 
completed procedures (1,2). When accustomed to performing a hysteroscopy, 
physicians rate the Essure placement procedure as simple or moderately simple 
(1). It is unlikely that the learning curve contributes much to misplacement rates. 
However, even in the hands of experts, placement procedures can result in an 
incorrect position of microinserts.
When we review our own cases, we see that in case A, in which the left insert 
perforated into the abdominal cavity, a resistance thought to be a tubal spasm was 
over won. In retrospect, this was probably the moment of perforation. The insert 
migrated to the abdominal cavity in the weeks after the procedure, causing the 
patient abdominal pain. Why the patient did not contact the hospital with this 
complaint is unknown. Patient education and staff education are very important 
to recognize symptoms associated with complications. Tubal spasms can occur 
during a hysteroscopic procedure, but perforation and thus making a false route 
with the Essure placement device can mimic a tubal spasm, as we have seen here. 
Tubal spasms have been reported to have an adverse effect on the Essure placement 
(1,10,12). A spasmolytic such as butylscopolamine can be administered before the 
procedure to prevent tubal spasms (12). Use of NSAIDs before the procedure is also 
associated with better placement rates (1).
Figure 3 
The right device has an abnormal position in the pelvis on X-ray,  
and on HSG the right tube is not obstructed.
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In case B, the complete expulsion, the uterine cavity contained some endometrial 
polyps, which could have blurred vision. The insertion was also more difficult 
than normal and procedure time was longer than usual. When the procedure was 
completed, the left insert, which would later be expelled, was not clearly visible. In 
this case, there were multiple suboptimal conditions that could have caused the 
insert misplacement. Failure to place the Essure microinserts bilaterally is more 
often seen in the presence of abnormalities of the uterine cavity or openings of the 
fallopian tubes (1,2,9,10).
In the case of expulsion into the uterine cavity, case C, the procedure time was 
significantly longer than average. This was due to removal of the intrauterine device 
in the beginning of the procedure and to the placement procedure that turned out 
to be difficult on both sides. The first device was placed on the side with adhesions, 
which was thought to be the most difficult side to place, but because of the prolonged 
procedure time, the other side turned out to be difficult to place as well. This last 
microinsert was later expelled into the uterine cavity. After placement, both sides 
showed a normal number of coils extending from the uterotubal corner. We think the 
prolonged procedure time caused a fluid collection to form under the endometrium 
and thus complicated the placement of the second insert. The second insert was 
probably placed under a layer of endometrium instead of in the opening of the tube, 
and a shedding of endometrium, such as in a menstrual bleeding, released the insert.
In conclusion, perforation into the abdominal cavity and expulsion from the 
fallopian tube can occur with or after placement of Essure microinserts, even in the 
hands of experienced physicians. It is important that patients are seen at follow-up 
with at least TVU to make sure that microinserts are in the correct position. Only 
after normal findings at followup examination should patients get the advice to stop 
contraception.
Complications can be detected during the procedure itself or at follow-up. When, 
during the procedure, there is doubt about the position of a microinsert, a TVU can be 
performed at that time. But one should realize that in case of perforation and expulsion, 
most incorrectly placed microinserts will migrate in the period after the procedure. 
A majority of cases will not be detected during or directly after the procedure.
We advise screening patients with apparent successful bilateral placement but with 
difficult placement procedures, other suboptimal conditions during the procedure, or 
abdominal pain earlier than 3 months after the procedure. Initially this can be done with 
TVU after the patient’s first period or withdrawal bleeding (approximately 4 weeks), 
and when in doubt, a pelvic X-ray can be performed. Perforation and expulsion do not 
seem to cause serious adverse events in patients. These women will have to undergo a 
laparoscopy to trace and remove the missing insert in case of perforation, and undergo 
a new Essure insertion procedure or choose a different form of birth control.
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Abstract
Objective To analyze the data of cases of unintended pregnancies after Essure sterilization.
Design Retrospective case series analysis.
Setting National multicenter.
Patient(s) Ten cases of unintended pregnancies after Essure sterilization in the Netherlands were 
reported from August 2002 through May 2008.
Intervention(s) Data on the hysteroscopic Essure sterilization procedures and post-procedure 
confirmation tests of the reported cases were reviewed and analyzed by two authors. The causes of 
the unintended pregnancies were determined in agreement with the physicians who performed the 
sterilizations.
Main Outcome Measure(s) Most pregnancies occurred in patients with only one device placement 
and bilateral occlusion on hysterosalpingography (HSG). Other cases included misinterpretation 
of HSG, undetected abnormal device position by ultrasound, one undetected pre-procedure 
pregnancy, and two patient failures to follow up with the physician advice.
Conclusion(s) The risk of pregnancy after hysteroscopic sterilization may be reduced by strictly 
following the follow-up protocol, performing a urinary pregnancy test on the day of the procedure, 
and instructing the patient to return for the follow-up visit. A procedure with only a single device 
placement in a patient without a history of salpingectomy of the heterolateral tube should be 
considered unsuccessful.
Key Words  Essure sterilization, Confirmation test, Unintended pregnancy, 
Hysterosalpingography, Ultrasound
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Introduction
Transcervical sterilization using the Essure System (Conceptus, Mountain View, CA) 
is becoming increasingly popular as a means of permanent birth control. Worldwide, 
more than 200,000 women have been sterilized with this method. In combination 
with the vaginoscopic no-touch technique of hysteroscopy, it is a patient-friendly 
procedure that does not require general or regional anesthesia or surgical incisions 
(1,2). In the Netherlands, around 9,000 women are sterilized each year (3). In May 
2008, Essure sterilization was first offered to patients who requested permanent 
contraception in 45 out of 100 Dutch hospitals. Since its introduction in 2002, more 
than 6000 procedures have been performed. All gynecologists performing the Essure 
method are appropriately trained gynecologists with experience in office hysteroscopy 
who have been trained by a precept in the procedure. During office hysteroscopy, the 
uterine cavity is inspected and the tubal openings are identified. The introduction 
device is inserted into the fallopian tube, after which the device is allowed to expand 
while the Essure microinsert remains in position. After insertion and expansion of 
the microinsert,ideally three to eight coils of the insert are visible outside the tubal 
opening (2). The Essure microinsert consists of a stainless steel inner coil, a nickel 
titanium alloy outer coil, and polyethylene terephterate (PET) fibres covering the 
inner coil (1,4). The PET fibres induce a tissue response, which causes fibrous tissue 
to grow and hence tubal occlusion (4,5). Patients have to use additional contraception 
until correct placement of the inserts and/or tubal obstruction is proven at 3-month 
follow-up. Transvaginal ultrasound examination has proven to be an adequate 
method to confirm the microinsert position at follow-up (6-9). When ultrasound 
examination is inconclusive or an abnormal location of a microinsert is suspected, a 
hysterosalpingography (HSG) is indicated.
The inability to place the inserts bilaterally, perforation, and/or expulsion are 
known undesirable events of the Essure placement procedure. Most of these events 
described in previous studies have been detected during the procedure itself and 
were either attributed to a design problem of the material that was subsequently 
improved or to incorrect placement procedures (4,5). Malformations or abnormalities 
of the uterine cavity and the fallopian tubes are associated with placement failure 
(1,2,10,11). Other factors, such as tubal spasms, are also suspected to have a negative 
influence on Essure placement procedures (1,11,12). 
Because hysteroscopic sterilization is a rather new method, it is important that 
all pregnancies are reported and that the cases are reviewed to determine the 
cause of the unintended pregnancy. Some of the causes might be preventable. 
Understanding these causes can be helpful to improve the follow-up protocols and 
reduce the number of failures in the future.
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Materials and methods
This study is a retrospective multicenter case series in the Netherlands. An 
estimated 6,000 hysteroscopic sterilizationswere performed in 45 hospitals in 
the Netherlands from August 2002 to May 2008 as estimated from the data from 
the Dutch distributor. All procedures were performed by appropriately trained 
gynecologists with experience in office hysteroscopy who participated in a training 
course for hysteroscopic sterilization with Essure. The procedures were scheduled 
in the proliferative phase of the cycle or shortly after a withdrawal bleeding if 
patients were using oral contraceptives. Women were advised to take a non-steroidal 
anti-inflammatory drug on the evening before and 1 hour before placement of the 
Essure microinserts. The majority of procedures were performed by a vaginoscopic 
approach hysteroscopy, using a 4.2 to 5.5 mm continuous-flow rigid hysteroscope 
without the use of local or general anesthesia. Uterine distension was obtained using 
saline that was introduced through a fluid management system or by gravity. From 
the beginning, all patients underwent a HSG after 3 months of follow-up. Since the 
introduction of the Dutch protocol for the follow-up of Essure sterilization in 2005, 
vaginal ultrasound has been used for confirmation of tubal-cornual location of the 
Table 1 
Overview of 10 cases of unintended pregnancies after Essure sterilization .
Case Age Parity Year Confirmation 
test
Intervala, 
months
Cause of failure Conclusion B
A 36 0 2004 US, HSG 8 Perforation Misread
B 31 4 2005 US 3 Expulsion NC
C 41 2 2005 HSG 24 Unilateral placement NA
D 38 3 2006 US 10 Expulsion Misread?
E 36 1 2006 US 11 Unknown Unknown
F 40 2 2006 US 7 Perforation NA
G 39 5 2007 — 6 Partial expulsion NC
H 41 2 2007 HSG 6 Unilateral placement NA
I 41 1 2007 HSG 4 Unilateral placement NA
J 24 3 2007 — 0 Luteal pregnancy NA & NC
a Interval between Essure placement and pregnancy. US = ultrasound.
b NA = nonadherence to protocol; NC = patient noncompliance.
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microinserts after an uncomplicated successful bilateral placement. In all other 
cases, an HSG is still indicated (6). Patients were instructed to continue alternative 
contraception until the follow-up visit at 3 months.
The reported cases were reviewed by one of two authors who participated in 
the faculty of the physician training courses and who supervised as preceptors all 
first three to five procedures of beginning gynecologists of Essure sterilization in 
The Netherlands.
Results
As of May 2008, 10 pregnancies were reported to the authors. Table 1 provides the 
causes of the pregnancies as determined by the reporting physicians in collaboration 
with the reviewers. In case A, there was a misinterpretation of the HSG at follow-up. 
The right device was in an unsatisfactory position (perforation), with patency of the 
right tube. This patient was also examined with ultrasound before the HSG, and 
an abnormal location of the microinsert or even perforation was not recognized. 
In two cases, the reported pregnancy was associated with a noncompliance of the 
patient. In case B, the physician suspected an abnormal location of one microinsert 
on ultrasound at the 3-month follow-up, but the patient did not return for HSG. 
One patient, patient G, failed to return for the 3-month follow-up. After delivery of 
a healthy child, ultrasound examination showed both devices to be in an apparently 
normal position, while on HSG there was an unsatisfactory device location, with 
kinking of the left device and patency of the left tube.
One patient, patient D, showed a complete expulsion of one device on X-ray after 
the delivery of a child. In this case, the ultrasound examination at her 3-month 
follow-up had probably been misinterpreted. A second patient, patient F, who had 
a misinterpretation of the ultrasound at 3 months of follow-up, had a complicated 
placement, with placement of a third device after a spontaneous expulsion of the 
first device. During laparoscopic sterilization after termination of pregnancy, one 
device was located intramurally under the serosa because of partial perforation, 
while the other one was in a proper position in the other tube (13).
One pregnancy occurred before the device placement was done (patient J). 
Taking the probable date of conception into account, it must have been a luteal-
phase pregnancy due to a failure of contraception before the procedure. A urinary 
pregnancy test on the day of the procedure was not performed.
In three patients (C, H, and I) there was a unsuccessful attempt of device 
placement on one side, and only one device was placed. On HSG, the heterolateral 
tube seemed to be occluded.
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One patient, patient E, delivered a healthy child by caesarean section. Tubal 
sterilization was performed during the procedure, but no information was obtained 
about the location of the device and patency of the tubes during surgery. At the 
3-month follow-up after the initial uneventful procedure, both microinserts were in 
normal position on ultrasound.
Discussion
The Essure device has become an increasingly popular alternative for laparoscopic 
sterilization in the Netherlands and other Western countries because of its 
minimally invasive and well-tolerated placement without the need for general or 
local anesthesia. Since its introduction in the Netherlands in 2002, 10 unintended 
pregnancies have been reported. The majority of these pregnancies (cases B, C, F, 
G, H, I, and J) are associated with patient noncompliance or non-adherence to the 
Dutch follow-up protocol introduced in 2005.
It is apparent that Essure sterilization will not prevent pregnancy in all cases. It 
is impossible to prevent pregnancy in all cases with any contraceptive technique 
other than bilateral oophorectomy. There will always be product failures and human 
errors that result in pregnancy.
Until now, no pregnancies have been reported in patients from the phase II or 
pivotal trial, but recently Levy et al. reported about 64 pregnancies after Essure 
sterilization that were reported to the device company from countries all over 
the world up until December 2005 (14). The most important cause of reported 
pregnancies was patient or physician non-adherence to protocol (47%). The most 
common manifestation of non-adherence was the patient failure to return to the 
follow-up visit. The second most common finding was misinterpretation of X-ray 
films or HSG at the follow-up visit. Improperly read or interpreted results accounted 
for 18 (28%) of the reported unintended pregnancies. Contraceptive failure before 
device placement occurred in eight (12.5%) of the reported pregnancies; seven of 
these pregnancies were luteal-phase pregnancies.
Two more cases of pregnancy were reported (15). One patient cancelled the HSG 
due to financial concerns and was lost to follow-up. The second patient underwent 
a followup evaluation appropriately at 3 months. Her HSG appeared to indicate 
proper placement of the microinserts with subsequent bilateral tubal occlusion. 
Upon removal of the uterus by vaginal hysterectomy 6 months after termination of 
pregnancy, a microinsert was noted protruding through the upper myometrium at 
the left cornu of the uterus.
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In this series of 10 cases of unintended pregnancies in the Netherlands, there 
were only two cases (B and G) of non-compliance of the patient (20%) Only one 
patient failed to return for the 3-month follow-up visit.
In three cases (A, D, and F), an abnormal position of one device was not 
recognized by the confirmation test (A: HSG + ultrasound; D and F: ultrasound) 
at the follow-up. The ultrasound images are not useful for reviewing because the 
final decision and results of the ultrasound examination are made by the physician 
performing a real-time ultrasound scan. The real-time images of ultrasound 
examination are not recorded and therefore not available for reviewing. This is 
one of the main disadvantages of ultrasound used as a diagnostic tool to confirm 
satisfactory device localization after Essure sterilization. Saved three-dimensional 
(3D) ultrasound volume data may serve that purpose in the future. Patient A, with 
the misinterpretation of the HSG (perforation of left device), was also examined 
by ultrasound during the 3-month follow-up visit. An abnormal position of one 
of the devices was not suspected. The procedure of case F was complicated by a 
spontaneous expulsion of the first device and placement of a third device. Only an 
ultrasound examination was done to confirm bilateral localization. According to the 
Dutch follow-up protocol, in this case an HSG was indicated. In addition, one patient 
who was lost to follow-up had a normal ultrasound after termination of pregnancy, 
while on HSG there was an abnormal positioning of one device with tubal patency. 
The explanation for these contradictions in the results of these different diagnostic 
tests could be that it is difficult to visualize the entire device on a single image plane. 
The full distal (tubal) extent of the device cannot always be followed. 
The radio opaque markers at the ends of the coils are not visible on ultrasound 
images. The outer coil is always visible as two interrupted echogenic lines. The 
inner coil can be incidentally seen as a central linear echogenic line (16). In case 
of a partial perforation with the outer coil located intramurally or near the cornual-
isthmic junction, the location of the microinsert could resemble a normal position 
on ultrasound. This means that if there is any suspicion of tubal or myometrial 
perforation (i.e., a sudden drop in resistance or difficult sounding of the tube) an 
HSG should be performed. It may be that 3D ultrasound with or without contrast 
infusion improves the diagnostic characteristic of two-dimensional imaging (8,17). 
Another pitfall of ultrasound could be that one device is recognized twice by turning 
the ultrasound probe from one site to the other. The same device will be seen at 
the opposite site of the uterus after turning the probe 180 degrees. According to 
the instructions to the physicians in the training courses, both devices have to be 
recognized at the same time in one single plane during ultrasound examination 
to be sure that two devices are examined. A print or recording of this view is 
recommended. Training should be initiated to guarantee the specific ultrasound 
143Chapter 6  Unintended pregnancies
6
skills needed to recognize adequate placement of the microinserts in the patients 
undergoing Essure sterilization.
In the three patients with failed attempts on one side (C, H, and I), the delivery 
system could not be advanced to the ostia, and only one device was placed in a proper 
position. Subsequent HSGs showed occlusion of both tubes, which was thought to 
be caused by fibrosis of the tube. In an earlier report, such cases were omitted from 
the failures and considered to be successful (11). We advise that in case of a unilateral 
placement and an unsuccessful placement at the opposite site, without a history of 
tubectomy for this site, the procedure is considered to be unsuccessful and no HSG 
or other technique for evaluation should be performed. Even in instances in which the 
follow-up HSG shows occlusion of the tube, the occlusion could be caused by factors 
other than the device. Therefore, to rely on the device for contraception, it must be in a 
proper position and show occlusion on HSG.
Probably not all cases of pregnancy have been reported to the authors, although 
the estimated number of unreported cases is low. The number of pregnancies, 10 
in 6,000, is similar to the number published earlier for global data, 64 in 50,000. 
The pregnancy rate is low, and it seems that the majority of the cases appear to be 
preventable. Misinterpretation of radiological as well as ultrasound imaging does occur.
The use of ultrasound imaging diminishes the need for radiological assessment, 
although the printed images are not useful for retrospective evaluation of abnormal 
localization of devices and other complications after microinsert placement. 
Procedures have to be performed by a gynecologist who has been properly trained 
in the technique as well as in the diagnostic tests during the follow-up visit. Patients 
have to be informed about the complication risks of hysteroscopic sterilization and 
the need for adequate contraception before the procedure and until the 3-month 
confirmation test has shown a satisfactory position of both devices.
 
Conclusion
This study illustrates that hysteroscopic sterilization with Essure is a popular 
and reliable alternative for laparoscopic sterilization in the Netherlands. The risk 
of pregnancy with hysteroscopic sterilization may be reduced by strictly following 
the protocol for follow-up, performing a urinary pregnancy test on the day of the 
procedure, and instructing the patient to return for the follow-up visit. A procedure 
with only a single device placement in a patient without a history of tubectomy of 
the heterolateral tube should be considered as unsuccessful.
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Abstract
Objective To evaluate the protocol for confirmation of satisfactory Essure placement using 
transvaginal ultrasound.
Design Prospective multicenter cohort study (Canadian Task Force classification II-2).
Setting Outpatient departments of 4 teaching hospitals in the Netherlands.
Patient(s) Eleven hundred forty-five women who underwent hysteroscopic sterilization using the 
Essure device between March 2005 and December 2007.
Intervention Transvaginal ultrasound examination 12 weeks after uncomplicated successful bilateral 
placement or as indicated according to the transvaginal ultrasound protocol after 4 weeks, and 
hysterosalpingography (HSG) at 12 weeks to confirm correct placement of the device after 3 months.
Measurements & Main results The rate of successful placement was 88.4% initially. In 164 women 
(15%), successful placement was confirmed at HSG according the protocol. In 9 patients (0.84%), 
incorrect position of the device was observed at HSG. The cumulative pregnancy rate after 18 months 
was 3.85 per thousand women.
Conclusion(s) Transvaginal ultrasound should be the first diagnostic test used to confirm the adequacy 
of hysteroscopic Essure sterilization because it is minimally invasive, averts ionizing radiation, and 
does not decrease the effectiveness of the Essure procedure.
Key Words Essure, Confirmation test, Transvaginal ultrasound, HSG, Placement rate,  
Cumulative pregnancy rate
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Introduction
 
Transcervical sterilization with Essure (Conceptus Inc., Mountain View, CA) 
is becoming increasingly popular in the Netherlands. In combination with the 
vaginoscopic procedure of hysteroscopy, it is a patient friendly procedure that does 
not require general or regional anesthesia (1,2). It is highly effective, with a 5-year 
effectiveness rate of 99.8% (3). Consequently, hysteroscopic sterilization is rapidly 
replacing interval laparoscopic sterilization. More than 9,000 women have been 
sterilised in 60 Dutch clinics using this method since its introduction in 2002 
(Sigma Medical BV, Apeldoorn, the Netherlands).
The European Health Office approved the Essure method in 2001, and the US 
Food and Drug Administration (FDA) approved the method in 2002. Because the 
microinserts are highly effective when placed in the proper site and configuration, 
the European Health Office requires radiographic examination to confirm adequate 
position and configuration (4), and the FDA requires hysterosalpingography (HSG) 
at 3 months after placement of the device.
Transvaginal ultrasound (TVU) has proved to be an adequate alternative method 
for confirmation of the microinsert placement at follow-up (5-8).
It has great advantages over radiographic examination and HSG because it is 
a nonionizing method of imaging. It has the ability to locate the device within 
the enveloping tissue, and additional information is gained about surrounding 
soft-tissue structures. It can be performed on an outpatient basis in departments of 
gynecology by the patient’s own physician, and can be repeated at any time without 
risk to the patient. However, systematic use of TVU as a first-line confirmation test 
has not been studied in detail.
Since the introduction of Essure in the Netherlands in 2002, HSG is scheduled 
at 3 months after an Essure procedure according the recommendations of the 
FDA. The first scout film of the HSG, without constrast medium, was regarded 
as the X pelvis requested by the European Health Organization. In January 
2005, a revised protocol for follow-up after Essure sterilization was introduced 
in the Netherlands (Fig. 1) to reduce the need for radiologic confirmation (X-ray 
examination and HSG), without compromising the effectiveness of Essure (5). 
In January 2005, a revised protocol for follow-up of Essure sterilization was 
introduced in the Netherlands (Fig. 1) to reduce the number of HSGs without 
compromising the effectiveness of Essure. 
With this new Dutch protocol, TVU is used for the 3-month confirmation of 
tubocornual location of the microinserts after an uncomplicated successful 
bilateral placement. 
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The criteria for a normal successful bilateral procedure include procedure time of 
15 minutes or less, microinsert visible after placement, fewer than 9 coils protruding 
into the uterine cavity, and no unusual events during the procedure. In all other 
cases, HSG is still indicated (5). A procedure with only a single device placement 
in a patient without a history of tubectomy of the heterolateral tube should be 
considered unsuccessful, and HSG should be abandonded, because of a high risk 
of false positive confirmation of occlusion of the heterolateral tube. When findings 
at ultrasound examination are inconclusive or abnormal location of a microinsert 
is suspected, HSG is indicated.
The objectives of the present study was to evaluate the revised protocol based 
on first-line confirmation using TVU at 3 months after uncomplicated successful 
Essure sterilization and to analyze the rate of success of placement and effectiveness 
of the method.
Hysteroscopic 
sterilization with 
Essure
Bilateral normal 
procedure?
Microinsert visible 
Number of coils ≤8 
Procedure time ≤15 min
After 3 months, TVU
Satisfactory
Successful 
sterilization 
Successful 
sterilization 
Successful 
sterilization 
Satisfactory
Bilateral occlusion?
Expulsion?
Perforation?
Second fallopian tube 
removed
Satisfactory
After 3 months,
hysterosalpingographya
After 3 months,
hysterosalpingographyb
After 4 weeks, pelvic 
radiography or TVU
ATTENTION!
Pelvic radiography
Microinserts
Distance
Location
Symmetric
Position fourth marker
Alignment
Placement of 
2 microinserts?
Placement of 
1 microinsert?
Unsuccessful 
sterilization 
Unsuccessful 
sterilization 
Unsuccessful 
sterilization 
Consider surgical 
intervention
yes yes
no
?
no
nonono
no
nono
no
yes yes yes
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Time Schedule
T0  = Essure procedure 
T4  = T0 + 4 weeks
T12 = T0 + 12 week
Figure 1
Flow chart of follow-up protocol after Essure sterilization. a. Begin hysterosalpingography with plain 
scan (without contrast medium). b. If patient uses non-steroidal anti-inflammatory drugs, corticoids, 
or cytostatic agents, perform hysterosalpingography after 6 months.
T0 
T0 T4 
T4 
T0 
T12 T12
T12
150 Hysteroscopic Sterilization
7
Materials and Methods
All 1145 patients who underwent hysteroscopic sterilization using Essure at 5 
clinics from March 2005 up to, but not including, January 2008 were enrolled in 
the study. The procedures were performed by 9 appropriately trained gynecologists 
with experience in office hysteroscopy and who participated in a training course 
for hysteroscopic sterilization using Essure. The procedures were scheduled in 
the proliferative phase of the cycle or shortly after withdrawal bleeding if patients 
were using oral contraceptives. Women were advised to take a non-steroidal 
anti-inflammatory drug on the evening before the procedure and 1 hour before 
placement of the Essure microinserts. Procedures were performed via vaginoscopic 
hysteroscopy using a 4.2 to 5.5mm continuous-flow rigid hysteroscope, without the 
use of local or general anesthesia. Uterine distension was obtained using saline 
solution via a fluid management system used in the hospital setting or via gravity.
Table 1
Patient demographic characteristics
Variable Value
No. of patients 1145
Age, mean (SD; 95% CI), y 39.2 6 4.7 (38.9–39.5)
Body mass index, mean (SD; 95% CI) 25.1 6 5.1 (24.8–26.0)
Parity, No. (%)
0 116 (10.1)
1 159 (14.0)
2 543 (47.4)
3 225 (19.7)
0,3 92 (8.0)
Contraception, No. (%)
Condom 301 (26.3)
Oral contraceptive/vaginal ring 512/6 (45.2)
LNG IUD/MLCu-375 70/27 (8.5)
Other/none 262 (22.9)
LNG IUD = levonorgestrel intrauterine device; MLCu-375 = multiload copper contraceptive device.
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Three months after successful uncomplicated bilateral placement as defined by 
the protocol, TVU was planned according to the Dutch protocol to confirm correct 
intramural position of the device at the tubocornual junction of the uterus. In case 
of difficult placement, procedure time longer than 15 minutes, incorrect number 
of coils (none or more than 10), or prolonged pain after the procedure, patients 
were scheduled to undergo an additional TVU examination at 4 weeks after the 
procedure, followed by HSG at 3 months after the procedure.
If the ultrasound examination after 3 months was inconclusive because the 
microinserts were not visible or seemed to be in a location other than the tubocornual 
junction, HSG was indicated. In cases of successful placement in a patient with a 
history of salpingectomy on the other side, HSG was also required according the 
protocol (Fig. 1).
Patients were instructed to continue alternative contraception until the 3-month 
follow-up visit. After correct positioning of the microinserts was proved at follow-up, 
patients were advised to discontinue other methods of contraception. They were 
instructed to contact the hospital in case of any complication or unintended pregnancy.
Written informed consent was obtained from all patients. Patient characteristics, 
procedure features, and results of TVU and HSG were recorded in a database. 
Institutional review board approval was not necessary for this study.
Results
Patient demographic data are given in Table 1. Of 1145 hysteroscopic sterilization 
procedures, bilateral placement was successful in 1,034 (90.3%), unilateral placement 
was successful in 13 patients (1.1%), and bilateral placement was successful after the 
second attempt in 25 patients (2.2%) (Fig. 2). The overall successful placement rate 
was 93.6% (1,072 of 1,145 intentions to treat). Thirty-five intrauterine devices (IUDs) 
were left in situ during the procedure, and were removed at the 3-month follow-up 
visit. Mean procedure time (scope in to scope out) of all procedures was 7.2 minutes 
(95% CI: 7.0-7.4). Mean procedure time for successful bilateral placement was 6.73 
minutes (95% CI: 6.52-6.94), while for unsuccessful placement was 11.84 minutes 
(95% CI: 10.26-12.70). Mean procedure time for successful single placement in 
patients with only 1 tube was 5.82 minutes (95% CI: 3.76-7.88).
In 69 of 1,145 patients with intention to treat (6.0%), Essure sterilization was 
successfully completed; however, the procedure was not considered straightforward. 
According to the Dutch protocol, TVU was scheduled at 4 weeks after the procedure, 
and HSG at 3 months. In 52 cases (4.5%), the ‘‘standard‘‘ 3-month TVU was 
inconclusive; thus, HSG was scheduled as outlined in the protocol. 
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In 50 of these 52 patients, HSG confirmed bilateral occlusion with normal position 
of the devices. Only in 2 of these patients was there abnormal positioning of 1 device: 
expulsion and perforation, respectively. Including patients with a successful second 
attempt and successful single placement, in 159 patients HSG was indicated at 3 
months. In 1 patient who refused HSG, pelvic radiographic examination confirmed 
adequate localization and configuration of the devices (Fig. 3).
Another 5 women underwent HSG outside of the agreed protocol despite 
uncomplicated Essure procedures (Fig. 4). Thus, 14.3% of patients (164 of 1145) 
with intention to treat underwent HSG. In 7 patients (4.3%), HSG demonstrated 
patency of 1 or both tubes, with normal positioning of the devices. 
In 2 of these 7 patients, the second HSG at 6 months after the procedure still 
showed patency of 1 tube. Three patients decided not to undergo a second HSG, and 
relied on operative sterilization while there was still patency as demonstrated at HSG. 
Subjects to Hystero-
scopic sterilization 
1,145
Successful Bilateral 
Placement
1,034
Placement Failure
98
Successful Bilateral 
placement after 2nd 
Attempt 
25
Loss of Follow-Up or 
Incomplete File
21
TVU at 12 weeks
Satisfactory 
887
Rely on sterilization 
1,037
Tubal Patency
5
Perforation
7
Expulsion
2
Bilateral Confirmation 
by TVU + HSG
5
TVU at 12 weeks
Satisfactory 
52
HSG Confirmation
164
HSG at 12 weeks Un-
straightful procedure
69
Failure
73
Successful Unilateral 
Placement
13
Figure 2
Flow diagram of enrolled patients.
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In 9 patients, HSG showed evidence of an abnormal position of 1 or 2 devices 
(2 expulsions and 7 perforations), and these patients were instructed not to rely on 
the sterilization procedure.
At 3-months, 21 patients were lost to follow-up. Moreover, because of missing data 
in the files, only 1037 patients were instructed to rely on the sterilization.
The 24-month pregnancy rate was 3.86 per 1,000 (4 of 1,037 patients). In 
1 patient, radiographic examination demonstrated complete expulsion of 1 device 
after delivery of a healthy child. It is probable that findings at TVU examination 
at 3-month follow-up were misinterpreted or that expulsion occurred after the 
3-month visit. In the second patient, placement was complicated, and a third device 
was placed after spontaneous expulsion of the first device. Violation of the control 
Figure 3
X-ray film shows a levonorgestrel intrauterine device and Essure microinserts.
Figure 4
Transvaginal ultrasound image of both Essure microinserts.
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protocol occurred in that only TVU was performed instead of HSG at 3 months. 
At this TVU, the position of the devices was misinterpreted. During laparoscopic 
sterilization after termination of pregnancy, 1 device was located intramural under 
the serosa due to partial perforation, and 1 was in the proper position in the 
contralateral tube. In the third patient, device placement was unsuccessful on 1 side, 
and only 1 device was placed. At HSG, the contralateral tube seemed to be occluded, 
and the patient was instructed incorrectly to cease alternative contraception. This 
was also a violation of the Dutch protocol. In the fourth patient, placement was 
complicated, with a levonorgestrel IUD in situ. After placement of the first device, 
the IUD was removed; however, the other ostium could not be observed. During the 
second attempt with the patient under general anesthesia in the operating room, 
this ostium was opened with a grasping forceps, and a second device was placed 
easily. The TVU at 4 weeks after the second procedure showed both devices in 
a normal tubocornual position. The HSG after 3 months showed bilateral tubal 
occlusion. During laparoscopic examination after termination of pregnancy, 1 
device was intramural under the serosa due to partial perforation, and the other 
was in a proper position in the contralateral tube. During laparoscopy, tubal patency 
could be evoked using methylene blue pertubation with high pressure.
Discussion
With the introduction of the revised protocol for confirmation of Essure sterilization, 
the number of radiologic diagnostic HSGs for verification of hysteroscopic sterilization 
has been reduced dramatically, from 100% to 14.3% of all successful placements, 
without compromising the reliability of the sterilization. With this new protocol, it is 
possible to identify a large subgroup of patients who can rely on Essure sterilization 
without the standard 3-month HSG confirmation. In a multicenter cohort study, the 
rate of successful placement was 93.6%. Patient compliance with the 3-months control 
with TVU as the confirmation test was 98%. The 24-month cumulative pregnancy 
rate was 3.86 per 1000, which is lower than the cumulative pregnancy rate with 
laparoscopic sterilization methods (e.g., 5 to 19 per 1000 with the Filshie Clip) (9). 
None of the 4 pregnancies was related to failure of the sterilization method when the 
device was properly placed; in 1, the device was absent or incorrectly positioned, and 
in 3, there was noncompliance with the protocol. This illustrates that strict follow-up 
of the protocol may reduce the failure rate.
In the United States, the FDA requires HSG after hysteroscopic sterilization. 
However, in an urban clinic population in Michigan, compliance to a protocol 
including HSG was revealed to be only 12.7% (10). In Europe, pelvic radiographic 
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examination is recommended. The diagnostic characteristics of a plain abdominal 
radiographic examination to confirm satisfactory localization of Essure microinserts 
are equal to those of ultrasound for confirmation of satisfactory placement. The 
results of TVU compared with HSG, the ‘‘reference test,’’ showed sensitivity of 50% 
and specificity of 95%. The predictive positive value of a satisfactory TVU result was 
99% (5).
Analysis of data from 169 unintended pregnancies after Essure sterilization 
worldwide revealed that in 30%, the HSG or radiographic examination was 
misinterpreted (4). In 37% of cases, there was patient noncompliance, primarily 
with the HSG confirmation test.
In the present study, 3 patients decided to rely on Essure sterilization when the 
HSG demonstrated that there was still patency, and none of them became pregnant. 
It has been postulated that the absence of absolute physical occlusion of the tubes 
does not necessarily equate with failure of sterilisation. There is a well-documented 
discrepancy between histologic and functional occlusion of the fallopian tubes (3).
In 9 of 164 patients (5%), failed sterilization was due to incorrect positioning of 
1 of the devices (i.e., 2 expulsions and 7 perforations). This relatively high number 
enforces the need for strict compliance with the criteria for indications of HSG 
after Essure sterilization in our protocol. Two patients in the present study became 
pregnant after HSG confirmation of occluded tubes. It should be remembered that 
HSG was developed as a diagnostic test for the fertility workup to diagnose tubal 
disease. Limiting technical factors include excessive or insufficient pressure during 
dye instillation, and false-positive or false-negative results because of tubal spasm 
or intravasation (6).
The revised protocol for confirmation of hysteroscopic sterilization with Essure 
confirmed the theory that correct placement of the microinserts correlates well with 
tubal occlusion. No higher failure rate seems to occur when the microinserts were 
identified at TVU and HSG was substituted after uncomplicated procedures. Two 
of 4 pregnancies demonstrated violation of the protocol.
Conclusion
Transvaginal ultrasound has great advantages over radiographic examination 
or HSG because it causes less inconvenience to the patient. It is a nonionizing 
method of imaging, and can be performed on an outpatient basis by the patient’s 
own physician and can be repeated at any time without risk to the patient.
In patients in whom placement is unsatisfactory or TVU cannot confirm 
satisfactory placement, a complementary HSG is required. The Dutch protocol for 
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confirmation of Essure sterilization reduced the number of HSGs, thus reducing 
costs, inconvenience, and discomfort without influencing the effectiveness of 
the sterilization. Compared with the FDA protocol, the Dutch control protocol is 
associated with high patient compliance.
In cases of difficult placement, the extra TVU confirmation at 4 weeks did not 
reduce the number of HSGs. Thus, the need for routine TVU after a difficult 
hysteroscopic procedure should be abandoned, with sole reliance on the 3-month 
HSG as a confirmatory test.
References
1.  Cooper JM, Carignan ChS, Cher D, Kerin JF. 
Microinsert nonincisional hysteroscopic steri-
lization. Obstet Gynecol. 2003;102:59-67.
2.  Kerin JF, Cooper JM, Price T, et al. Hystero-
scopic sterilization using a microinsert device: 
results of a multicenter phase II study. Hum 
Reprod. 2003;18:1223-1230.
3.  Connor V. Essure: a review six years later. 
J Minim Invasive Gynecol.2009;16:282-290.
4.  Heredia F, Cos R, Moros S, Torrabadella L, 
Cayuela E. Radiological control of Essure 
placements. Gynecol Surg. 2004;1:201-203.
5.  Veersema S, Vleugels MP, Timmermans A, 
Brolmann HAM. Follow-up of successful bilat-
eral placement of Essure microinserts with 
ultrasound. Fertil Steril. 2005;84:1733-1736.
6.  Teoh M, Meagher S, Kovacs G. Ultrasound 
detection of the Essure permanent birth con-
trol device: a case series. Aust NZ J Gynecol. 
2003; 43:378-380.
7.  Thiel JA, Suchet IB, Lortie K. Confirmation of 
Essure microinsert tubal coil placement with 
conventional and volume-contrast imaging 
three-dimensional ultrasound. Fertil Steril. 
2005;84:504-508.
8.  Kerin JF, Levy BS. Ultrasound: an effective 
method for localization of the echogenic 
Essure sterilization microinsert: correlation 
with radiologic evaluations. J Minim Invasive 
Gynecol. 2005;12:50-54.
9.  Peterson HB, Xia Z, Hughes JM, et al. The risk 
of pregnancy after tubal sterilization: findings 
from the US Collaborative Review of Sterili-
zation. Am J Obstet Gynecol. 1996;174:1161-
1170.
10.  Shavel VI, Abdallah ME, Diamond MP, Ber-
man JM. Placement of a birth control device 
at a university medical center. J Reprod Med. 
2009;54:218-222.

Essure hysteroscopic
tubal occlusion device
for the treatment of
hydrosalpinx prior to in
vitro fertilization-embryo
transfer in patients with
a contraindication for
laparoscopy.
8
V. Mijatovic
S. Veersema
M.H. Emanuel
R. Schats
P.G. Hompes
Fertil Steril. 2010;93:1338-42. 
159Chapter 8  Pre-IVF closure of hydrosalpinges
8
Abstract
Objective To investigate the success rate of proximal tubal occlusion with Essure devices in subfertile 
women with hydrosalpinges, and to observe the results of subsequent treatment with IVF.
Design Prospective, single arm, clinical study.
Setting University hospital and teaching hospital.
Patient(s) Ten women with uni- or bilateral hydrosalpinges prior to IVF. In all patients laparoscopy 
was contraindicated.
Intervention(s)  Hysteroscopic placement of Essure devices in an office setting.
Main Outcome Measure(s) Placement rate, successful proximal tubal occlusion, and pregnancy 
rate after IVF. Result(s): All patients had successful placement of the Essure devices without any 
complications. Proximal tubal occlusion was confirmed by hysterosalpingography in 9 out of 10 
patients. A 40% ongoing pregnancy rate was achieved with 20% life births after one IVF cycle and/
or frozen embryo transfer. 
Conclusion(s)Proximal occlusion of hydrosalpinges with Essure devices before IVF is a successful 
treatment for patients with a contraindication for salpingectomy.
Key Words  Essure hysteroscopic tubal occlusion, Hydrosalpinges, IVF-ET
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Introduction
The tubal factor accounts for up to 35% of female infertility, and is the most 
obvious indication for in vitro fertilization-embryo transfer (IVF-ET). Distal tubal 
occlusion may lead to formation of hydrosalpinges, which are found in 10% to 30% 
of all patients undergoing IVF-ET (1).
Patients with hydrosalpinges have been identified as a subgroup with 
significantly poorer outcomes of IVF-ET compared to tubal factor patients without 
hydrosalpinges. This has been demonstrated in two meta-analysis of retrospective 
studies concluding that hydrosalpinges were associated with a reduced chance of 
implantation and a increased risk of miscarriage (2,3). Especially patients with 
hydrosalpinges large enough to be visible on ultrasound are associated with the 
poorest IVF-ET prognosis (4,5).
The theories explaining the harmful effect of hydrosalpinges on IVF outcomes 
are multiple, and include the following: [1] a mechanical washout of the transferred 
embryos through tubouterine reflux of hydrosalpinx fluid, [2] a direct embryotoxic 
effect even when a low concentration of hydrosalpinx fluid is present in the uterine 
cavity, [3] a lower endometrial receptivity as an effect of disturbed expression of the 
cytokine and integrin system by the presence of a hydrosalpinx, thus impairing the 
implantation potential.
Laparoscopic salpingectomy before IVF-ET has been shown to restore IVF-ET 
outcomes in patients with hydrosalpinges (6-10). However, this procedure is 
associated with an increased risk for complications in patients with severe pelvic 
adhesions. Proximal occlusion of a hydrosalpinx by hysteroscopic placement of an 
Essure device may offer an alternative to laparoscopic surgery in these patients. 
Therefore, we conducted a prospective, single-arm, clinical study aiming to 
investigate the success rates of proximal tubal occlusion with Essure devices in 
subfertile women presenting with hydrosalpinges in which laparoscopy was felt to 
be contraindicated, as well as to observe the results of subsequent treatment with 
IVF-ET or frozen embryo transfers with follow-up including pregnancy and delivery.
Materials and methods
Ten patients with uni- or bilateral hydrosalpinx undergoing IVF-ET or frozen 
embryo transfers were included in this clinical study. A hydrosalpinx was defined 
as a distally occluded fallopian tube that was pathologically dilated or became 
pathologically dilated when patency was tested by hysterosalpingography (HSG). 
We included patients in this study after confirming the presence of hydrosalpinges 
with transvaginal ultrasound (midcyclic) and when laparoscopic surgery was 
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considered to be contraindicated because of extensive pelvic adhesions. Patients 
were excluded if their age was over 40 years and if they were not suitable for IVF 
treatment. Approval of the institutional review board was obtained.
The Essure device was approved by the U.S. Food and Drug Administration in 
2002, and indicated for hysteroscopic tubal sterilization. Essure (Conceptus Inc., 
San Carlos, CA) is an expanding spring device (diameter: 2 mm; length: 40 mm) 
made of Nitinol and stainless steel, which contains Dacron fibres that induce a local 
inflammatory response and subsequent fibrosis of the proximal part of the tube. 
Nitinol consists of nearly equal atomic nickel–titanium (NiTi) alloy. The presence 
of nickel is a cause of concern related to embryologic development, but the NiTi 
alloy showed no cytotoxic, allergic, or genotoxic activity in animal studies, and was 
similar to the clinical reference material, 316 stainless steel (11). The hysteroscopic 
placement of the Essure devices was done under antibiotic prophylaxis (Doxycyclin: 
200 mg, 5 days) in the second week of the patient’s menstrual cycle. The Essure 
devices were placed with up to four coils visible in the uterine cavity under direct 
hysteroscopic view using a special delivery system. Three months postprocedure 
an HSG was performed to evaluate proximal tubal occlusion. Thereafter, all 
patients underwent IVF-ET and/or frozen embryo transfer. Patients with severe 
endometriosis were pretreated with long-term (≤3 months) GnRH-agonists before 
IVF-ET according to Sallam et al. (12).
Results
Ten women (mean age: 33.5 years; range: 28-38 years) with unilateral (N=7) or 
bilateral hydrosalpinges (N=3), because of undergoing IVF, were included (Table 1). 
Laparoscopy was felt to be contraindicated because of previous extensive pelvic 
surgery because of endometriosis (N=7) and Crohn’s disease (N=1) or frozen pelvis 
as a result of pelvic inflammatory disease (N=2). Before the placement of the Essure 
devices six patients underwent unsuccessful IVF treatment.
All Essure procedures were performed in an office setting. No anaesthetics 
were administered, except for two cases where a paracervical block was needed. 
Successful placement was achieved in all patients. A mean number of three coils 
(range: 1-4 coils) of the device spring were left protruding into the uterine cavity. No 
intraoperative or postoperative complications occurred. The procedure times ranged 
between 5 and 8 minutes. An HSG was performed after 3 months, demonstrating 
tubal occlusion in 9 patients.
IVF was started after a mean duration of 4.5 months following the Essure 
procedure (Table 2). The first two patients (cases A and B) became pregnant on their 
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Table 1
Demographics and Essure data.
Case Age 
(years)
Duration 
subfertility 
(years)
IVF-ET
prior to 
Essure
Pathology Hydrosalpinx 
(uni/bilateral)
Essure 
coils in 
uterine 
cavity (N)
Tubal 
patency 
postprocedurea
A 32 2 Yes Endometriosis Unilateral 1 No
B 30 5 Yes Endometriosis Bilateral 3 + 3 No
C 32 3 Yes Endometriosis Unilateral 4 No
D 38 9 Yes Endometriosis Bilateral 2 + 3 Yes 
(Left side)
E 34 8 No Endometriosis Bilateral 4 + 4 No
F 36 3 No Endometriosis Unilateral 3 No
G 28 4 No Endometriosis Unilateral 3 No
H 30 2 Yes Frozen pelvis 
(post-PID)
Unilateral 4 No
 I 37 4 Yes Morbus Crohn Bilateral 4 + 3 No
J 38 3 No Frozen pelvis 
(post-PID)
Unilateral 2 No
Note: PID = pelvic inflammatory disease; IVF-ET = in vitro fertilization-embryo transfer.
aDetermined with hysterosalpingography 3 months after Essure placement.
first IVF treatment cycle. The course of these pregnancies was normal, and both 
patients had a spontaneous term vaginal delivery of healthy infants. Postpartum 
hysteroscopy showed in both cases complete tissue encapsulation of the Essure 
devices (Fig. 1).
In case C, the patient experienced a miscarriage nearly 7 weeks after oocyte retrieval 
in her first IVF cycle. Frozen embryo transfer is now pending for this patient.
Case D involved a patient in which two Essure devices were placed bilaterally. 
One of them (the left side) showed tubal patency at the HSG (Fig. 2). A repeat HSG 
has not been performed and she became pregnant after a frozen embryo transfer 
performed 5 months postprocedure. (The patency rate in earlier studies with HSG 
3 months after hysteroscopic sterilization with Essure was 3-4%, and in all cases a 
repeat HSG after 6-7 months showed bilateral occlusion) (13). 
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Unfortunately, she delivered at 24 weeks of gestation and her child died shortly 
after birth. Two weeks earlier she was admitted to an obstetric ward with complaints 
of discomfort in the lower abdomen and back in combination with sonographic 
observations of shortening cervical length. During the admission she developed 
a chorioamnionitis with subsequent rupture of membranes, which made the 
placement of an emergency cerclage impossible. Hysteroscopic evaluation after the 
delivery demonstrated in this case total tissue encapsulation of the left sided Essure 
device. On the right side only the tip of the device was visible. Six months after 
the delivery a frozen embryo transfer was performed, which was unsuccessful. A 
second frozen embryo transfer resulted in a ongoing pregnancy.
One patient, case E, did not achieve pregnancy after three IVF cycles and one 
frozen embryo transfer despite goodquality embryos. Two patients (cases F and G) 
ceased their IVF treatment after their first cycle because of partner separation. The 
last three patients (cases H, I, and J) from our study underwent all one unsuccessful 
IVF treatment cycle. One of them is currently undecided as whether to proceed with 
further treatment.
Figure 1
Hysteroscopic view 3 months after vaginal delivery (patient B): complete tissue 
 encapsulation of the Essure device. The arrow is pointing at the tissue overgrowth  
at the ostium tubae.
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Discussion
 
In line with the pathophysiologic concepts of hydrosalpinges, any surgical 
intervention interrupting the communication between hydrosalpinx and uterine 
cavity would stop the leakage of hydrosalpinx fluid and would improve the endometrial 
environment for implantation. Laparoscopic salpingectomy before IVF in patients 
with hydrosalpinges restores IVF-ET outcomes but carries also all the risks (visceral 
injury, vascular damage, and unintended laparotomy) associated with laparoscopic 
intervention and general anesthesia (14). Our study shows that a hysteroscopic 
approach to proximal occlusion of hydrosalpinges with Essure devices is safe, highly 
effective, and feasible in an ambulatory setting. In the 10 patients that were treated 
no intraoperative or postoperative complications occurred. Successful placement was 
achieved in all patients using local anaesthetics only in 20% of the cases. The Essure 
devices induced complete proximal occlusion in 9 out of 10 patients. 
Only in one patient (case D) was one-sided patency observed during HSG. On 
the other hand, hysteroscopy after her immature delivery showed total tissue 
encapsulation of this device, suggesting that the induced fibrosis by the Dacron fibres 
may take >3 months to establish complete occlusion of the proximal tubal lumen.
In the last 3 years four reports (15-18) on the use of Essure devices for the 
treatment of hydrosalpinx before IVF have been published. As far as we know, our 
study is the largest case-series on this topic. A similar study, but slightly smaller 
with respect to the number of patients (N=7), was presented at the annual meeting 
Figure 2
Hysterosalpingogram 3 months after Essure placement (patient D).  
Two devices are visible with contrast medium in the left hydrosalpinx.
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Table 2
Artificial reproductive treatments and their subsequent outcomes after hysteroscopic placement  
of Essure devices.
Case ART 1 Outcome ART 2 Outcome ART 3 Outcome ART 4 Outcome
A IVF Life birth — — — — — —
B IVF Life birth — — — — — —
C IVF Miscarrage Frozen ET No 
pregnancy
— — — —
D Frozen 
ET
Immature 
delivery
Frozen ET No 
pregnancy
Frozen ET Ongoing 
pregnancy
— —
E IVF No 
pregnancy
IVF No 
pregnancy
IVF No 
pregnancy
Frozen ET No 
pregnancy
F IVF No 
pregnancy
— — — — — —
G IVF No 
pregnancy
— — — — — —
H IVF No 
pregnancy
— — — — — —
I IVF No 
pregnancy
— — — — — —
J IVF No 
pregnancy
— — — — — —
Note: ART = artificial reproductive treatment; IVF = in vitro fertilization; ET = embryo transfer. 2009.
of the ASRM in 2007 (17). Both case-series show good pregnancy rates with IVF-ET 
following Essure placement, which are in line with those found after laparoscopic 
salpingectomy (10).
In our study five pregnancies occurred, including two term vaginal deliveries of 
healthy infants, a miscarriage, and a immature delivery. In case D, the immature 
delivery appears primary to be related to cervical insufficiency (although risk factors 
for cervical insufficiency are lacking), leading to a chorioamnionitis and subsequent 
rupture of the membranes. However, it remains difficult to rule out any influence 
of the visible Essure tip (seen on the right side at postpartum hysteroscopy) on this 
chain of events in this case.
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A significant concern in using Essure devices for the treatment of hydrosalpinx in 
women wishing to conceive is the trailing of Essure coils into the uterine cavity and 
its possible effects on implantation as well as on pregnancy. Therefore, we decided, 
in line with other investigators (16-18), to limit the number of coils remaining in 
the cavity to three. Our experience is that this is usually feasible. The second-look 
hysteroscopies performed after delivery in our study confirmed earlier observations 
that deep placement of the Essure devices usually leads to total encapsulation of the 
device with exclusion from the uterine cavity, which is reassuring (19).
In conclusion, our study confirms earlier reports on the effectivity of Essure 
devices in inducing proximal tubal occlusion in infertile patients with ultrasound 
visible hydrosalpinges. Up to now, our study is the largest prospective case-series 
on this subject including second-look hysteroscopies after childbirth. Our data 
show successful placement in all cases without intraoperative or postoperative 
complications. A 40% ongoing pregnancy rate was achieved with 20% life births 
after one IVF-ET cycle and/or frozen embryo transfer (in this same time frame 
an overall live birth rate of 26% was achieved in women without hydrosalpinx (or 
Essure placement) treated at our IVF center). In our opinion, these results warrant 
a randomized comparison between laparoscopic salpingectomy and hysteroscopic 
placement of Essure devices for ultrasound visible hydrosalpinges in patients 
before IVF-ET.
Acknowledgments: We thank Mandy Griffioen, Nathalie Field, and Alie Hemmes 
for their excellent logistic assistance in this study.
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Abstract
This was a retrospective review of all pregnancies reported after Essure in situ in the Netherlands. 
Pregnancies included those that were unintentional (resulting from lack of protocol adherence and/
or misread confirmation tests) and those that were intentional (resulting from off-label use of Essure 
microinserts for hydrosalpinx closure before in vitro fertilization/intracytoplasmic sperm injection 
with embryo transfer or in vitro fertilization with embryo transfer after regret of sterilization). 
The outcomes of 50 pregnancies in women with 1 or 2 microinserts in situ were evaluated. Eight 
unintended pregnancies and 18 intended pregnancies resulted in birth of a full-term healthy baby. 
Seven infants were delivered via Caesarean Section. Two women delivered prematurely by C-section, 
(singleton after 34 weeks 1 day, twins after 35 weeks 3 days). All babies are healthy and without any 
congenital anomalies. There were 2 stillbirths after 20 weeks; however, it is unlikely that this was 
related to the presence of the microinserts. In conclusion, it is unlikely that the presence of intratubal 
microinserts interferes with implantation and the developing amniotic sac and fetus. 
Key Words Essure microinserts; Hysteroscopic sterilization ; Hydrosalpinges; In vitro fertilization; 
Permanent birth control; Pregnancy outcomes; Unintended pregnancies
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Introduction
The Essure hysteroscopic sterilization method has been in use worldwide for 
>10 years. From 2001 through 2010, almost 500,000 Essure kits were distributed 
worldwide. During that time, 748 pregnancies were reported, or 15% of the 
estimated user population of distributed kits. Of these, most were due to patient 
or physician noncompliance or misinterpreted confirmation test results (n=476). 
Luteal phase pregnancies or pregnancy at the time of the procedure resulted in 32 
reported pregnancies. The remaining 240 reports of pregnancy lacked sufficient 
information to evaluate causality (1).
Patients who regret sterilization after Essure placement and desire to become 
pregnant must rely on in vitro fertilization and embryo transfer (IVF/ET). Although 
not an approved use, successful pregnancy outcomes with the use of IVF after Essure 
sterilization has been documented (2). Several studies have reported successful 
pregnancies with IVF after proximal occlusion of hydrosalpinges via hysteroscopic 
placement of Essure microinserts (2-7).
A theoretical concern for all women who want to become pregnant or who 
have an unintended pregnancy after Essure placement is the trailing microinsert 
coils in the uterine cavity and their possible effects on pregnancy. In theory, 
the microinserts could cause similar tissue effects as with an intrauterine 
device, and consequent myometrial contractions or rupture of membranes 
could be considered a possible cause of premature birth; the literature reports 
an increased risk of preterm delivery and chorioamnionitis with the use of 
intrauterine copper devices (8).
This retrospective analysis was designed to review all pregnancies reported in 
the Netherlands from 2002 to 2010, whether unintended or intended as part of 
IVF-ET, subsequent to Essure placement and to analyze the obstetric outcomes of 
the subsequent pregnancies.
Material and Methods
All 136 gynecologists in the Netherlands who perform Essure sterilization were 
asked via E-mail in December 2010 about either intended (IVF-ET) or unintended 
pregnancies in patients after the Essure procedure. After a positive reply, 
a questionnaire was sent to collect data about patient history, the Essure procedure, 
and obstetric outcomes. Data from patients with a successful IVF-ET and/or frozen 
embryo transfer (FET) after Essure who participated in a previous prospective 
clinical study were included (6,7).
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Table 1
Outcome of unintended not terminated pregnancies after failed Essure sterilization  
in the Netherlands, 2002–2011
Pat. Age, 
yrs
Parity Year of 
sterilization 
No. of coils, 
left/right
Months of 
reliance on 
sterilization 
Pregnancy, 
weeks + 
days
Outcome
1 36 0 2004 5/2 < 12 40 + 4 Vaginal delivery, healthy 
boy, 2970g
2 31 4 2005 7/4 < 12 19 + 4 Vaginal delivery, healthy 
boy, 3750g
3 36 1 2006 3/1 < 12 38 + 1 Caesarean section, 
healthy girl, 3755g
4 38 3 2006 5/3 < 12 41 + 6 Vaginal delivery, healthy 
boy, 4020g
5 37 2 2008 3/1 < 12 40 + 5 Vaginal delivery, healthy 
girl
6 31 2 2009 2/2 NA 40 + 3 Healthy girl, 3680g
7 41 2 2009 1/1 NA NA NA, healthy boy
8 35 3 2010 5/5 None 38 + 3 Vaginal delivery, healthy 
boy
9 36 1 NA NA NA 40 + 8 Vaginal delivery, healthy 
boy
NA = not available
Data sources included information retrieved from the Dutch National 
Perinatal Registry, data from a previous prospective trial (N=22), and responses 
(N=28) to E-mails sent to physicians who perform Essure procedures (N=136). 
The data on pregnancies and outcomes were collected from the national perinatal 
registry (Landelijk Verloskunde Registratie (LVR)) used by all obstetric departments 
in the Netherlands. All professional organizations have their own voluntary medical 
registry: the LVR1 registry (midwives), the LVR1 registry (general practitioners), 
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the LVR2 registry (obstetricians), and the LNR registry (paediatricians and 
neonatologists). The LVR1, LVR2, and LNR registries are linked to one combined 
PRN registry. All patient identification information was de-identified, and 
institutional review board approval was obtained to collect the data.
Results
De-identified data were collected for 50 pregnancies in 43 patients in the 
Netherlands who became pregnant with 1 or 2 Essure microinserts in situ. In 26 
patients an unintended pregnancy occurred after hysteroscopic sterilization with 
Essure. Twenty-two pregnancies occurred in 15 patients who underwent IVF-ET 
because of infertility due to unilateral (n=9) or bilateral (n=6) hydrosalpinges. In 
these women, laparoscopic salpingectomy was relatively contraindicated because 
of extensive endometriosis, a frozen pelvis, or inflammatory bowel disease with a 
history of multiple abdominal operations. Two patients experienced sterilization 
regret and subsequently achieved successful pregnancies after Essure and IVF/ET.
Of 26 unintended pregnancies after hysteroscopic sterilization with Essure 17 
(65.4%) were electively terminated, and 9 (34.6%) resulted in the birth of a baby 
(Table 1). In 7 women, pregnancies ended in spontaneous vaginal delivery after 
uncomplicated pregnancies. One patient delivered via primary caesarean section at 
38 weeks 1 day because of breech presentation. Eight healthy babies were born. No 
information was provided regarding the outcome of 1 pregnancy.
Intended Pregnancies: Pre-IVF Occlusion of Hydrosalpinges
Most of the outcomes of IVF/ET after closure of 1 or 2 hydrosalpinges via 
hysteroscopic insertion of the Essure microinserts have been published previously 
(7). In 15 patients, IVF/ET resulted in 1 biochemical pregnancy and 21 pregnancies 
confirmed via vaginal ultrasound; 6 of these were miscarried at 6 to 11 weeks (Table 2).
Two pregnancies (9.1%) ended in premature delivery, 2 (9.1%) in premature 
delivery including a twin pregnancy, and 10 (45.5%) term deliveries. Six of these 
patients delivered via caesarean section. Overall, 15 of 23 pregnancies (65%) were 
ongoing. Only 2 patients had a microinsert with 5 coils in the uterine cavity. In 1 of 
these patients, pregnancy ended in miscarriage. 
In the other patient, pregnancy ended with stillbirth. This woman became 
pregnant after a seventh IVF/ET cycle, which was the first IVF treatment after 
tubal closure of hydrosalpinges. Two Essure microinserts were placed before, 
with proximal closure of 2 hydrosalpinges. A singleton pregnancy was achieved; 
however, premature rupture of membranes resulted in stillbirth at 19 weeks 3 days. 
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Table 2
Pregnancies after ART after proximal tubal occlusion of hydrosalpinges with Essure microinserts
Patient Age, yr Parity Tubal  occlusion. 
Date
No. of
microinserts
No. of coils, 
left/right
ART cycle after
tubal  occlusion
1 32 0 12-21-05 1 0/1 IVF 1b
IVF 2a 
IVF 3a 
IVF 4a
2 30 0 12-30-05 2 3/3 FET 1b
3 32 0 08-05-06 1 5/0 IVF 2
4 38 0 11-29-06 2 3/2 FET 1b
FET 2b
5 29 0 4-5-07 1 3/0 FET 2b
FET 2
Spontaneous
6 36 1 2-7-08 2 1/1 FET 1a
7 30 1 2006 2 NA FET 1
8 33 0 3-12-08 1 2/0 IVF 2a
9 36 0 10-16-08 2 4/1 IVF 2a
FET 1a
10 32 0 3-17-09 1 2/0 IVF 2a
11 31 0 1-16-08 1 0/1 FET 2a
12 35 0 4-1-09 1 2/0 IVF 1a
13 38 0 6-19-08 1 4/0 IVF 1a
14 29 0 9-10-10 1 NA IVF 1a
15 33 0 2009
2011
2
0
0/5
NA
IVF 1
IVF 2
ART 5 assisted reproduction technology; FET 5 frozen embryo transfer; IVF 5 in vitro fertilization; NA 5 not available.
a Previous published (6).
b Previous published (6,7).
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Duration of pregnancy,  
weeks + days
Outcome
39 + 2
<12
<12
38 + 4
Vaginal delivery, healthy girl, 3040g 
Miscarriage
Miscarriage
Vaginal delivery, healthy girl, 3224g 
40 + 0 Vaginal delivery, healthy boy, 3651g
<12 Miscarriage
24
35 + 3
Vaginal delivery, normal infant
Caesarean section, breech, healthy girl, 3400g
<12
< 5
<12
Miscarriage
Biochemical 
Miscarriage
37 + 2 Vaginal delivery, premature rupture of membranes, healthy girl, 2920g
39 + 2 Caesarean section, breech, healthy girl, 3236g
42 + 2 Caesarean section, asphyxia, recovered, boy, 3880g
<12
41 + 3
Miscarriage
Caesarean section, dystocia, healthy girl, 4240g
38 + 2 Vaginal delivery, healthy boy 3310g
34 + 1 Caesarean section, healthy boy, 2060g, 1 healthy girl, 1905g
38 + 5 Caesarean section, breech, healthy girl, 2757g
<12 Miscarriage
38 + 3 Vaginal delivery, healthy girl, 3128g
19 + 3
18+3
Vaginal delivery, normal infant
Vaginal delivery, normal infant
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No fetal dysmorphias were visible. Several weeks later, hysteroscopy showed an 
encapsulated microinsert on the left side, and on the right side, 5 outer coils and the 
inner PET fibres of the microinsert were protruding into the uterine cavity. After several 
months, laparoscopic tubal coagulation was performed at the left salpinx, and Filshie 
Clip placement at the right salpinx, and both microinserts were hysteroscopically 
removed. The eighth IVF cycle resulted in a twin pregnancy. Primary cerclage was 
performed at gestational week 13, and at 17 weeks 6 days premature rupture of 
membranes occurred, and the patient delivered 4 days later despite injection of 500 
mg hydroxyprogesterone (Proluton). Histologic examination of the placentas showed 
evidence of chorioamnionitis.
Another woman, became pregnant after frozen embryo transfer at 5 months after 
bilateral Essure placement. She delivered prematurely at 24 weeks due to cervical 
insufficiency, and the baby did not survive. Eight months later the patient became 
pregnant again after a second frozen embryo transfer with the microinserts in place. 
She carried almost to term with a primary cervical cerclage and delivered a healthy 
infant at 35 weeks 3 days.
IVF Pregnancies After sterilization Regret
Each of the 2 patients with sterilization regret treated via IVF/ET conceived after the 
first single embryo transfer. One delivered a healthy baby via caesarean section (indicated 
because of fetal condition during labour) at 40 weeks 3 days, and the other delivered a 
healthy baby spontaneously at 36 weeks 6 days.
Discussion
We analyzed the obstetric outcomes of 50 pregnancies in 43 women with 1 or 2 
Essure microinserts in place and found a good outcome for ongoing pregnancies. 
The number of miscarriages in the group who underwent IVF/ET after proximal 
closure of hydrosalpinges is not unexpectedly high and reflects findings reported in 
the literature (10). The number of ongoing pregnancies in this group is encouraging 
and congruent with the literature on pre-IVF salpingectomy or tubal occlusion (9).
To achieve proper location and occlusion and to prevent movement of the device, 
the manufacturer advises 3 to 8 coils protruding into the uterine cavity for the purpose 
of permanent birth control. Authors of articles about Essure placement before IVF/
ET advise placement of ≤4 intrauterine coils. In the present study, at least 10 patients 
had microinserts with 4 coils in the uterus after placement. One of these patients 
delivered prematurely; however, this woman experienced another premature delivery 
after microinsert removal, indicating that it is unlikely that there is a relation between 
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the earlier fetal loss and the microinserts or the number of coils in the uterine cavity.
Hydrosalpinges are associated with a reduced chance of implantation and 
increased risk of miscarriage after IVF (11,12). To exclude negative effects of 
hydrosalpinges, salpingectomy or occlusion of the fallopian tubes is advised before 
assisted reproductive techniques (10,12,13). IVF/ET outcomes in a patient with 
hydrosalpinges was initially studied by Rosenfield et al (3).
Kerin and Cattanach (2) described 2 patients who underwent IVF/ET procedures 
after Essure. Both patients underwent a second-look hysteroscopy within 3 months 
after the IVF procedure. Device encapsulation by tissue ingrowth reduced the 
average number of coils trailing into the uterine cavity from 4 to 1, with no evidence 
of inflammation or other abnormality. Another study showed that coils protruding 
into the uterine cavity shortened from 5.7 mm to 2.0 mm and from 5.4 mm to 1.8 
mm after a mean of 20 months. Progressive device encapsulation was observed 
over time in 7 women who underwent hysteroscopic procedures to treat unrelated 
gynecologic conditions between 4 and 43 months after Essure placement. In these 
patients the average length of coils in the uterine cavity had decreased from 6 mm 
to mm at second-look hysteroscopy. Complete encapsulation was observed in 25% 
of cases after 13 to 43 months (14).
A later prospective 2-center clinical study of 20 women with hydrosalpinx who 
were recruited for off-label unilateral (n=8) or bilateral (n=8) placement of Essure 
before IVF/ ET resulted in 12 live births. During placement of the microinserts, the 
number of coils was limited to 2 to 4. Four obstetric complications not likely related 
to microinserts were reported including placenta previa, hypertension, maternal 
diabetes with premature rupture of membranes, and pre-eclampsia. The median 
gestational age at birth was 37 weeks (range, 33-40 weeks), with 3 pairs of full-term 
twins, 1 pre-term pair of twins at 33 weeks, 6 full-term singleton births, and 2 
preterm singleton births at 33 and 35 weeks. In 1 additional pregnancy, nonviable 
twins were lost during the first trimester. Six deliveries were via caesarean section 
because of complications including placenta previa, hypertension, preeclampsia, 
and maternal diabetes with premature rupture of membranes. Pregnancies and 
births were otherwise uncomplicated, and the infants were healthy (4).
Thébault et al (5) published successful results of IVF after Essure placement in 7 
women with hydrosalpinges. The number of coils left in the uterine cavity was ≤3 
in all cases except one with 3 and 6 coils. Four pregnancies ended in miscarriage. 
and 1 ended in fetal death at 27 weeks due to platelet allo-immunization. The same 
patient conceived again and delivered twins at 36 weeks via caesarean section. One 
woman delivered a healthy infant after 41 weeks, and 1 delivered twins via caesarean 
section at 37 weeks. There were no obstetric complications caused by premature 
contractions or infection. 
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In our series, both patients in whom pregnancy ended in stillbirth delivered a 
second time after consecutive IVF/ET. In 1 woman, cervical cerclage prevented 
premature birth, indicating cervical incompetence as a cause of earlier fetal loss 
rather than premature labour induced by the microinserts. In the other woman, 
both microinserts were removed before a following IVF/ET cycle was started. 
However, a second stillbirth occurred, indicating that the cause of both fetal losses 
was not likely related to the presence of microinserts.
Although most women remain satisfied with their decision to undergo Essure 
placement as a final contraceptive means, there will always be a small group of 
women who regret sterilization. Careful pre-sterilization counselling, thorough 
informed consent, and emphasis that sterilization is irreversible will reduce the 
risk of regret but will not completely eliminate it. There will inevitably be a small 
number of women who, due to unexpected life events, may wish to have children 
after sterilization. In the US Collaborative Review of sterilization (CREST) study, 
the percentage of women expressing regret was 20% for those aged ≤30 years at the 
time of sterilization , compared with 6% for women aged >30 years at the time of 
tubal ligation. For women aged <25 years, the rate was as high as 40%. The regret 
rate was also high for women who were not married at the time of tubal ligation or 
for those who underwent tubal ligation less than a year after delivery (15). Patients 
with sterilization regret after Essure who want to become pregnant must rely on 
IVF/ET. In the present study only 2 patients with sterilization regret were treated 
via IVF/ET. Both conceived after the first single embryo transfer and delivered a 
healthy baby.
The Essure contraindication to nickel hypersensitivity has been changed to a 
warning on the basis of data that suggest that the reported incidence of adverse 
events suspected related to nickel hypersensitivity is extremely small (1%) and is 
consistent with data from other nickel-containing devices. 
These findings are reassuring and beg the question of whether nickel reactions 
are clinically relevant in the use of nitinol-containing microinserts for hysteroscopic 
sterilization (16). Nevertheless, the presence of nickel in the microinserts is a cause 
of concern related to embryologic development, although animal studies showed 
no cytotoxic, allergic, or genotoxic activity of the nickel-titanium alloy, and reactions 
were similar to the clinical reference material, 316 stainless steel (17). In the present 
study we did not find any indication of nickel-related adverse effects.
To our knowledge, ours is the largest study published to date about the outcomes 
of pregnancies after hysteroscopic tubal occlusion using Essure microinserts. 
Limitations of the study are the nonstandardized collection of data, which were 
combined from a retrospective case series study (unintended pregnancies and 
intended IVF/ET pregnancies after sterilization regret) and an uncontrolled 
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cohort study (pre-IVF tubal occlusion), the different populations, and the lack of 
a control group. However, the potential recall bias associated with retrospective 
trials is reduced by intensive communication between the Dutch gynecologists and 
the distributor of Essure to ensure the timely and accurate reporting of all Essure-
related events, including pregnancies. Although part of the data were published 
earlier, those reports focused mainly on the cause of unintended pregnancies 
and the success rate of IVF treatment after pre-IVF closure of hydrosalpinges 
rather than evaluation of the potential risks and effects of the microinserts on the 
pregnancy. Data from the present study and literature review indicate that relevant 
to subsequent adverse obstetric and perinatal outcome, pregnancies with Essure 
microinserts in place have a good prognosis.
Larger studies are needed to confirm these findings. Nevertheless, there seems 
to be no reason to discourage patients who request IVF/ET after hysteroscopic 
sterilization or with an indication of proximal tubal occlusion of hydrosalpinges. 
This information can also be helpful for patients with unintended pregnancies who 
have to make one of the most difficult decisions of their lives as to whether to 
terminate or continue the pregnancy.
In conclusion, the results of this case series report support the conclusion of 
earlier reports (3,9,10) that it is unlikely that the presence of Essure microinserts 
interferes with implantation and the developing amniotic sac and fetus.
181Chapter 9  Outcomes of pregnancies
9
Referencs
1.  Levy BS, Munro MG, Veersema S, Vleugels 
M. Reported pregnancies after Essure hyster-
oscopic sterilization: a retrospective analysis 
of pregnancy reports worldwide: 2001-2010. 
Presented at the 40th Annual AAGL Global 
Congress of Minimally Invasive Gynecology, 
November 7–10, Hollywood, Florida.
2.  Kerin J, Cattanach S. Successful pregnancy 
outcome with the use of in vitro fertilization 
after Essure hysteroscopic sterilization. Fertil 
Steril. 2007;85:1212E1-1212E4.
3.  Rosenfield RB, Stones RE, Coates A, Mat-
teri RK, Hesla JS. Proximal occlusion of 
hydrosalpinx by hysteroscopic placement of 
microinsert before in vitro fertilization-em-
bryo transfer. Fertil Steril. 2005;83:1547-1550.
4.  Galen DI, Khan N, Richter KS. Essure mul-
ticenter off-label treatmentfor hydrosalpinx 
before in vitro fertilization. J Minim Invasive 
Gynecol. 2010;18:338-342.
5.  Th’ebault N, Broux PL, Moy L, Vialard J. 
Utilization du micro-implant Essure pour 
exclusion d’hydrosalpinx dans un contexte 
d’infertilite. J Gynecol Obstet Biol Reprod. 
2011;41:145-150.
6.  Mijatovic V, Veersema S, Emanuel MH, 
Schats R, Hompes PGA. Essure hystero-
scopic tubal occlusion device for the treat-
ment of hydrosalpinx prior to in vitro ferti-
lization-embryo transfer in patients with a 
contraindication for laparoscopy. Fertil Ster-
il. 2010;93:1338-1342.
7.  Mijatovic V, Dreyer K, Emanuel MH, Schats 
R, Hompes PG. Essure hydrosalpinx occlu-
sion prior to IVF-ET as an alternative to lapa-
roscopic salpingectomy. Eur J Obstet Gynecol 
Reprod Biol. 2012;161:42-45.
8.  Ganer H, Levy A, Ohel I, Sheiner E. Pregnancy 
outcome in women with an intrauterine 
contraceptive device. Am J Obstet Gynecol. 
2009;201: 381.e1-381.e5.
9.  Hammadieh N, Coomarasamy A, Papaioannou 
S, Afnan M, Sharif K. Ultrasound-guided 
hydrosalpinx aspiration during oocyte collec-
tion improves pregnancy outcomes in IVF: 
a randomized controlled trial. Hum Reprod. 
2008;23:1113-1117.
10.  Practice Committee of the American Society 
for Reproductive Medicine in collaboration 
with the Society of Reproductive Surgeons.
11.  Salpingectomy for hydrosalpinx prior to in 
vitro fertilization. Fertil Steril. 2008;90(Sup-
pl 3):S66-S68.
12.  Zeyneloglu HB, Arici A, Olive DL. Adverse 
effects of hydrosalpinx on pregnancy rates 
after in vitro fertilization-embryo transfer. 
Fertil Steril. 1998;70:492-499.
13.  AC, Muasher SJ. The significance of hydro-
salpinx in vitro fertilization. Fertil Steril. 
1998;69:373-384.
14.  Camus E, Poncelet C, Goffinet F, et al. Preg-
nancy rates after IVF in cases of tubal infer-
tility with and without hydrosalpinx: meta- 
analysis of published comparative studies. 
Hum Reprod. 1999;14: 1243-1249.
15.  Kerin JF. Tissue encapsulation of the Essure 
device from the uterine cavity after hystero-
scopic sterilization. J Minim Invasive Gynecol. 
2007;14:202-204.
16.  Grubb GS, Peterson HB, Layde PM, Rubin 
GL. Regret after decision to have a tubal ster-
ilization. Fertil Steril. 1985;44:248-253.
182 Hysteroscopic Sterilization
9
17.  Zurawin R, Zurawin J. Adverse events due to 
suspected nickel hyper-sensitivity in patients 
with Essure microinserts. J Minim Invasive 
Gynecol. 2011;18:475-482.
18.  Wever DJ, Veldhuizen AG, Sanser MM, 
Schakenraad JM, van Horn JR. Cytotoxic, 
allergic, and genotoxic activity of a nickel-tita-
nium alloy. Biomaterials. 1997;18:1115-1120.

General discussion
and future perspectives
10
185Chapter 10  General discussion and future perspectives
10
186 Hysteroscopic Sterilization
10
Preceding experience with hysteroscopic sterilization 
For more than 100 years, physicians have searched for a transcervical way to 
occlude the fallopian tubes at their uterotubal junction to avoid the complications 
that are associated with general anesthesia and abdominal instrumentation. Methods 
using electrocoagulation, cryocoagulation or other techniques of heating the tubal 
openings by access through the uterine cavity were unsuccessful. Many designs of 
intratubal mechanical devices (screws, plugs and formed-in-place intratubal devices) 
have been tried out over the past 60 years, with limited success (1,2).
Only three methods were released on the European Market (Ovabloc Intratubal 
Device System (1980), Essure System (2002) en Adiana Permanent Contraception 
System (2009), while the FDA only approved the Adiana (3) en Essure (4,5,6). The 
Ovabloc and the Adiana were both withdrawn from the market. The Ovabloc in 
1988 after reports of disappointing results, technical problems with the cold storage 
of the silicon and the fact that the claim to be a reversible sterilization technique 
could not be confirmed by a histological study. The Adiana was withdrawn as part 
of a deal to settle ongoing patent infringement litigation in March 2012. Currently, 
the Essure method is the only available hysteroscopic sterilization method.
Placement rates, efficacy and safety of current hysteroscopic sterilization devices.
The latest Cochrane Review of techniques for the interruption of tubal patency 
for female sterilization concluded in 2011 that data on rare and long-term outcomes 
are available from cohort studies, rather than from randomised controlled trials (8). 
Despite the different clinical settings (office or theatre; in-patient or out-patient) 
and differences in pre-medication and the use of different kind of anaesthetics 
(none, paracervical block, sedation or general anesthesia,) during the procedures 
all authors claimed high patient tolerance and satisfaction and a high effectiveness 
and safety of the methods.
Since the introduction of Essure in 2002 only gynecologists with experience in 
hysteroscopy were trained to perform this new method of sterilization , but studies 
have been shown that the learning curve for successful bilateral placement is 
steep (9). According to Levie the procedure can be recommended to be carried 
out by general obstetrician/gynecologists after an appropriate training course and 
supervision for the first several procedures. No differences were found in patient 
age, nulliparity, and BMI between successful and incorrect placement procedures 
(10,11). However, second half of menstrual cycle at the time of surgery and an 
enlarged uterus are predictors of unsuccessful placement. Difficulty to visualize 
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the tubal ostia, was significantly associated with failure. A longer procedure time 
was also associated with failure (12), likely due to procedure difficulty rather 
than as a direct cause of placement failure. In most of the published studies the 
procedures were scheduled in the proliferative phase of the menstrual cycle or oral 
contraceptives were prescribed, starting one month before the procedure to induce 
endometrial suppression. 
In chapter 2 we conducted a systematic review to examine the placement rate, 
efficacy, safety and risk factors for failure of hysteroscopic sterilization techniques. 
In total, 45 studies were included. Feasibility was expressed as successful bilateral 
placement rate in one attempt (A, table 1.). For Ovabloc, Essure and Adiana, these 
placement rates were respectively: 80% (95% CI: 76-83%), 92% (95% CI: 91- 
94%) and 94.7%. The percentages of women that could rely on successful bilateral 
placement confirmed at three months follow-up (B, table 1.) were respectively: 
0.96% (95% CI: 0.93-0.96), 0.97 (0.95%-0.98) and 0.91. Because of unspecified 
follow-up data and variation in sample size we were not able to pool the data and 
calculate cumulative pregnancy rates for Ovabloc and Adiana methods. Twelve 
pregnancies occurred in 1212 patients who relied on Ovabloc sterilization (1.2%), 
while 8 pregnancies occurred in 7,706 women after successful Essure sterilization 
(0.1%). The 36 months cumulative pregnancy rate of Adiana was 1.5%.
Complications during the hysteroscopic procedures were incidentally reported. 
During the Ovabloc procedures, perforation of the uterine wall occurred in five out of 
438 cases (13). The most important risk factors for placement failure of Ovabloc were 
bad visualization, tubal spasm or inability to obtain linear axis between obturator tip of 
the catheter and tubal ostium (14) In the Essure studies, two perforations during the 
procedure were reported (15), while 42 expulsions, 45 perforations and 9 migrations 
of devices were notified at the three-month control in a total of 10,124 cases. 
Hyponatremia (sodium 129 mEq/L) occurred in one case of sterilization with Adiana. 
Table 1: Feasibility and efficacy of three methods of hysteroscopic sterilization.
Successful 
bilateral 
placement 1st 
attempt (A)
Satisfactory 
 confirmation 
after total bilateral 
 placements (B)
Satisfactory 
 confirmation 
after successful 
 placement 1st 
attempt (A x B)
Pregnancies
after 
 confirmation 
Ovabloc 0.80 0.96 0.77 12 / 1212
Essure 92 0.97 0.89 8 / 7706
Adiana 0.95 0.91 0.86 9 /570
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Based on this systematic review it seems that the Essure method has the highest 
successful placement rate at first attempt with proper position at confirmation and 
the highest efficacy.
Confirmation of correct bilateral placement and bilateral tubal occlusion.
As the primary objective of sterilization is occlusion of both tubes, the obvious 
‘gold standard’ reference test is testing tubal patency. Other, less invasive tests such 
as transvaginal ultrasound and X-ray aim to confirm the appropriate position of the 
devices in both tubes, but are constructs for tubal patency. If tubal patency can be 
predicted accurately by the position of the devices, better tolerated confirmation tests 
may become the professional standard.
It is remarkable that in the United States of America an hysterosalpinography 
(HSG) is obligatory after successful bilateral placement, while the European 
Health Office approved the Essure method requiring only an X-ray or transvaginal 
ultrasound three months after the procedure accepting the lack of information of 
tubal occlusion. A review of the clinical data from studies by Kerin et al. and Cooper 
et al. of more than 700 patients showed that an HSG seems not always necessary 
(6,16,17). During these phase II and III multicenter clinical trials, satisfactory 
bilateral insertions were ultimately achieved in 664 of 734 patients (90%). The 
original protocol required that an HSG has to be performed three months after 
placement to confirm tubal occlusion. However, in patients in whom a satisfactory 
bilateral insertion had been achieved, a 100% bilateral occlusion rate was found (18).
A three-month confirmation test is not uncommon after hysteroscopic sterilization 
methods. Also for the Adiana Permanent Contraception System and Ovabloc 
Intratubal Device Method, a three months confirmation was indicated. In the late 
1970’s the three-month HSG was abandoned as a routine follow-up after laparoscopic 
sterilization because of discordance between tubal patency and pregnancy rates 
(19). In a pre-hysterectomy study of Valle, with the STOP microcoil device (an 
earlier type of the Essure ESS 105 with a stainless steel inner coil, an outer coil 
of nitinol and PET fibres) hysteroscopic placement was performed in women 
who required hysterectomy. Histology data of the tubes demonstrated that tissue 
in-growth reaction was predictable, occurred in all fibered specimens collected 
and was localised to the device. More than 80% occlusion was noted more often 
in specimens in which the device had been in place for more than four weeks. 
Histological confirmation of complete occlusion of the tube histologically was 
difficult, as artefacts may have been introduced during processing. Other studies have 
demonstrated that an inflammatory response peaks between two and three weeks, 
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after which the inflammatory response slowly resolves during a 10-week period 
(20). In the study of Valle (21), tubal occlusion was also evaluated by HSG just prior 
to hysterectomy. It is remarkable that occlusion was noted in all tubes, even in those 
cases with device placement less than two weeks before hysterectomy.
In chapter 3, we evaluated the diagnostic characteristics of pelvic X-ray of the 
pelvis and a transvaginal ultrasound after Essure sterilization with HSG as a 
reference test. In 9 of 150 patients with successful bilateral placement it was not 
possible to identify both devices in correct position with ultrasound. In one of these 
nine patients one microinsert was missing on pelvic X-ray; this patient seemed to 
have had an expulsion. In the other 149 patients the pelvic X-ray was determined to 
be satisfactory with both microinserts in situ. In one of these 149 women there was 
evidence of dye passage (patency) past the microinsert into the distal tubal lumen 
upon HSG. The sensitivity of transvaginal ultrasound with the HSG as reference 
test for correct position of the devices and tubal occlusion was 50% (one true 
positivea, one false negativeb), and the specificity was 94.6% (Table 2). If compared 
with X-ray as reference test sensitivity and specificity were respectively 100% (one 
true positivea) and 94.6% (table 3). 
The positive predictive value of ultrasound to diagnose a correctly positioned 
microinsert was 99 %, while the negative predictive value was only 11%. This means 
that when a microinsert is not clearly visible by ultrasound one should not conclude 
that it is an unsatisfactory sterilization but that further evaluation is indicated. In 
our second study, described in chapter 4, we analyzed the interobserver agreement 
of X-ray without contrast after Essure sterilization and concluded that interobserver 
agreement was low. Even gynecologists with extensive experience in reading 
radiographs after Essure, were not able to recognise suspicious or unsatisfactory 
X-rays of patients with abnormal positions of the devices. In scoring reliability 
of the Essure sterilization there was a large difference in the agreement between 
radiologists (moderate, κ-value: 0.52) and gynecologists (slight, κ-value: 0.09), 
Table 2: Counts of position of Essure microinsert, diagnosed by transvaginal ultrasound with HSG 
as reference test. 
HSG unsatisfactory satisfactory total
TVU
unsatisfactory 1a 8 9
satisfactory 1b 140 141
total 2 148 150
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while for a high number of cases (27/47) at least one of the radiologists advised 
additional HSG to confirm a reliable sterilization .
In chapter 5, three cases with different types of incorrect position of Essure 
microinserts at three-months follow-up and their appearance on X-ray and by 
ultrasound were discussed (one case of complete expulsion with a missing device, 
one case of perforation and one case of proximal position of a device, which was 
located in the uterine cavity). In the cases of the perforation and the proximal 
position, pelvic X-ray demonstrated an abnormal position of one microinsert and 
abnormal configuration with a deviation of the fourth marker (proximal end of outer 
coil). In chapter 6 we analyzed data collected from 10 patients with unintended 
pregnancies after Essure sterilization in the Netherlands and identified one case of 
luteal pregnancy (pregnancy already occurred before the procedure). In three cases 
single placement was followed by a three months HSG and bilateral tubal occlusion 
was concluded. In the other six cases an abnormal position of a microinsert was 
recognized after termination of pregnancy. 
Table 3: Counts of position of Essure microinsert, diagnosed by transvaginal ultrasound with X-ray as reference test
X-ray unsatisfactory satisfactory total
TVU
unsatisfactory 1a 8 9
satisfactory 0 141 141
total 1 149 150
Table 4: Counts of position of Essure microinsert, diagnosed by X-ray with HSG as reference test. 
HSG unsatisfactory satisfactory total
X-ray
unsatisfactory 1a 0 1
satisfactory 1b 148 149
total 2 148 150
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Based on our own findings, conclusion from other studies (18,22,23) and 
analysis of unintended pregnancies cases we developed a new follow-up 
protocol for Essure sterilization with transvaginal ultrasound as first-line 
investigation after an uncomplicated bilateral placement (Addendum Fig. 1): 
-  No unintended pregnancies occurred after proper demonstration of bilateral 
occlusion following device placement (24). 
-  Improper placement of devices was usually preceded by difficult or complicated 
procedures (25).
-  Procedure time of failed procedures was longer than procedure time of bilateral 
successful placements (26). 
-  Unilateral device placement in patients with bilateral tubal occlusion on HSG, 
without a history of salpingectomy was related to unintended pregnancy (24).
-  Transvaginal ultrasound (TVU) has proved to be an adequate alternative method 
for confirmation of the microinsert placement at follow-up (18,23,25,27).
This revised Dutch protocol was validated in a center study, as described in chapter 7. 
With a reduction of the number of HSG’s to less than 15%, the effectiveness of 
hysteroscopic sterilization was not reduced. The two-years cumulative pregnancy rate 
was 3.86 per 1,000, while two of four pregnancies occurred after violation of the protocol 
(VOP). In one case, placement was complicated, and a third device was placed after a 
spontaneous expulsion of the first device. Ultrasound examination was performed at 
three months instead of HSG. In the second patient, device placement was unsuccessful 
on one side, and only one device was placed. At HSG, the contralateral tube seemed 
to be occluded, and the patient was instructed to cease alternative contraception. This 
suggests that strict following of the protocol could further reduce the already low 
pregnancy rate. The extra four-weeks ultrasound examination as suggested by others (27) 
to detect perforations before the 3 months control, did not cause any deviations from the 
protocol and should be reserved for specific indications (difficult procedure with high 
risk for perforation or patient with post-procedure abdominal pain). The results of our 
study supported the submission to receive the CE mark for transvaginal ultrasound as 
first-line confirmation test after Essure sterilization , which was assigned in 2011. Others 
studies (23,28,29,30) confirmed the validity of ultrasound as first-line confirmation test. 
In 2011 a clinical trial was initiated to obtain FDA approval for transvaginal ultrasound 
confirmation in the United States.
Thiel et al. (23) and Legendre et al. (32,33) assessed the position of the microinsert 
with 3D ultrasound. The use of volume-contrast 3D imaging improved the visualization 
of the microinserts within the uterine cornua and proximal fallopian tube. A 
classification with four different positions of the microinsert (perfect, proximal, distal 
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and very distal) was proposed. 3D-US showed a sensitivity of 100% and a Specificity of 
58.2% with HSG as reference test and inadequate evaluation of 3D-US was regarded 
as a positive test result (indicative of sterilization failure), whereas a satisfactory 
evaluation was regarded as a negative test result (indicative of successful sterilization). 
The Negative Predictive Value (NPV) of 3D-US was 100% (95% CI: 100–100%) 
(i.e. proportion of patients with negative results, i.e. satisfactory position and 
successful sterilization on 3D-US, with actual negative results) and the Positive 
Predictive Value (PPV) of 3D-US was 23.3% i.e. proportion of women with at 
least an unsatisfactory position on 3D-US whose sterilization was correctly found 
to have failed (33). Advantage of the 3D ultrasound compared to 2D is that the 
volume 3D data can be preserved for a later assessment. As far as we know the 
performance of 2D and 3D ultrasound to confirm hysteroscopic sterilization has 
not yet been compared. Connor evaluated Contrast Infusion Sonography (CIS) as 
a first-line Essure confirmation test (34). The contrast solution infused consists of 
1 mL of a perflutren microsphere contrast agent (Bristol Myers-Squibb Medical 
Imaging, North Billerica, MA) mixed with 20 mL of normal saline. Preliminary 
data suggested that CIS is a feasible, safe and accurate confirmation test, which is 
well accepted by patients.
Outcome of unintended pregnancies and IVF pregnancies after regret or pre-procedure 
closure of hydrosalpinges.
Finally we started a prospective study to investigate the success rate of proximal 
tubal occlusion with Essure devices in subfertile women with hydrosalpinges and 
to observe the results of subsequent treatment with IVF. Our case series in chapter 
9,shows good pregnancy rates with IVF-ET following Essure placement, and is 
consistent with rates found after tubal obstruction with microinserts or laparoscopic 
salpingectomy (35-38).
A significant concern for women with unintended pregnancies and subfertile 
women wishing to conceive with microinserts in situ, is the trailing of Essure coils 
into the uterine cavity and its possible effects on implantation as well as on pregnancy. 
Although two out of 50 pregnancies in our case series ended with a stillbirth 
we concluded that it was unlikely that these events were induced by the presence 
of the microinsert. In a recent review on the efficacy and safety of Essure in the 
management of hydrosalpinges prior to IVF, data of 115 women in 11 studies 
were pooled. Successful placement of Essure was achieved in 96.5% (95% CI: 
91.1-98.9%) of women and tubal occlusion in 98.1% (95% CI: 93.1-99.9%). 
Subsequent IVF resulted in 38.6% pregnancy rate (95% CI: 30.9-46.8%), 
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27.9% live birth rate (95% CI: 21.1-35.8%) and 28.6% combined ongoing pregnancy 
and live birth rate (95% CI: 21.7-36.6%) per embryo transfer (39).
The strength of this thesis is the high clinical relevance. The outcomes of 
our studies were used to revise the Dutch follow-up protocol of hysteroscopic 
sterilization, which was validated in a large multicenter study. The major limitation 
of the studies is that they were not comparative and based on single-arm prospective 
cohort studies and case series. 
The effectiveness of hysteroscopic sterilization methods is based on correct 
intra-tubal position of devices confirmed by a diagnostic test after three months. 
The predictive value of a diagnostic test for recognizing an abnormal position of a 
device depends on the incidence of these improper placed devices. Because of the 
low incidence of abnormal positioned devices we found a low negative predictive 
value. However confirmation of the proper position of the devices makes effective 
sterilization very likely. To evaluate the diagnostics characteristics of a confirmation 
test, a larger cohort of patients would have been preferable. Although we studied the 
interobserver agreement for X-ray we could not study this for transvaginal ultrasound 
examination. The biggest disadvantage of using ultrasound as a diagnostic test is 
that it is a real-time examination, while capturing the diagnosis on a hardcopy. 
We did not succeed in capturing videos of all our ultrasound examinations. 3D 
ultrasound volumes that can be stored and reviewed, may solve the problem of 
retrospective analysis of diagnostic data. 
Conclusion
At this moment there is only one hysteroscopic sterilization method available. The 
Essure method can be performed in an office setting without anesthetics during the 
procedure. Patient satisfaction and tolerance are high. Hysteroscopic sterilization 
with a strict follow-up protocol with transvaginal ultrasound as first-line test for 
confirmation is highly effective and reduces the need for radiologic examination. 
The risk of complications (perforation, expulsion and pregnancy) is low. Radiologic 
confirmation is only needed for strict indications. The use of microinserts to 
obstruct hydrosalpinges in an IVF program to improve the “take home baby” rates 
is promising and related to less burden (in contrast to laparoscopic treatment, 
hysteroscopic treatment can be performed in an outpatient setting, without use 
of general anesthesia, with shorter procedure times and a quicker recovery) and 
possibly also less interventional and/or anesthesiologic risk for the patient. It is 
unlikely that the presence of Essure microinserts interferes with implantation and 
the developing amniotic sac and fetus.
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Future perspectives
The need for a confirmation test after sterilization is questionable. Because 
the contraceptive principle of hysteroscopic sterilization methods such as Essure 
System and Adiana Permanent Contraception System is based on tubal occlusion 
by tissue in-growth and not by direct tubal occlusion by the device itself, it makes 
sense to use a tubal patency test for confirmation after the procedure. On the other 
hand, persisting anatomical tubal patency does not necessarily imply sterilization 
failure and a negative dye spill post-procedure sterilization HSG does not complete 
exclude the possibility of pregnancy at a later stage (40). HSG is an ionizing 
radiation technique inconvenience for the patient and risk of anaphylactic reaction. 
In the United States it is an obligatory test although the patient-compliance is very 
low (41). A theoratical risk of flushing the fallopian tube with contrast medium and 
wash-out of scarred tissue has not been described (21).
One of the outcomes of this thesis is that the chance of an abnormal position of 
Essure microinserts after bilateral placement (one or more attempts) is less than 3%. 
Perforation or expulsion happened after complicated procedures. Pregnancies were 
described after violation of protocol or in patients who were non compliant to the 
protocol. None of the cases of pregnancy were a method failure but all were related 
to improper position of a device. Our hypothesis is that a standard confirmation 
test is not necessary and can be removed from the flow chart. It will not reduce 
the effectiveness of Essure sterilization. In case of an “abnormal” procedure, with 
a procedure time of more than 12 minutes, to deep or to proximal placement 
(more than eight coils visible) or the need for a second attempt, confirmation by 
transvaginal ultrasound or X-ray is indicated X-ray. In these scenarios X-ray and 
transvaginal ultrasound are complementary. X-ray verifies devices presence, the 
position, symmetry and distance between the microinserts and the configuration 
of the devices with its four markers, while ultrasound visualizes the relation of the 
microinserts to soft tissue, and the tubocornual junction in particular. 
If the first-line test is unsatisfactory, the complementary test has to be performed. 
If both tests have an unsatisfactory result (meaning: there is doubt in the efficacy of 
the sterilization ), additional HSG should confirm proper position of the device and 
tubal occlusion. This renewed Dutch protocol has to be validated in a prospective 
multicenter study (Addendum Fig. 2, page 215 ).
The “ideal” hysteroscopic sterilization device, with 100% effectiveness and 100% 
safety and no not need for confirmation, has not been developed yet. There is still 
a need to improve the available intratubal devices.
195Chapter 10  General discussion and future perspectives
10
Three new hysteroscopic sterilization devices will be launched in the near future. 
One is a redesigned Ovabloc Intratubal Device System. Challenges related to the 
design included the storage of material under room temperature conditions achieving 
reliable curing times and incorporating a contrast agent to facilitate visibility for 
evaluation. A study with a new model of the Essure System has recently been 
completed. The investigational device offers immediate, permanent contraception 
without a three-month confirmation test. A multicenter pivotal study for safety and 
efficacy of Altaseal will be started this year. The Altaseal (42) is a hysteroscopically 
placed mechanical occlusion implant for immediate contraception.
In case that in the future confirmation tests are still indicated after hysteroscopic 
sterilization , a new diagnostic test like 3D ultrasound has to be evaluated to confirm 
proper placement. Results from earlier studies (32,33,43-45) are promising. If tubal 
occlusion still has to be confirmed new non-radiation techniques like Contrast 
Infusion Sonography or Hysterosalpingo Contrast Sonography (HyCoSy) as 
suggested by Connor in 2008 (34) or the newer Hysterosalpingo-Foaminfusion 
Sonography (HyFoSy) could be considered to be evaluated as confirmation test for 
tubal occlusion (46-48). 
Patient Outcome Measurement Tool (POMT) is a surgical registry that has recently 
been introduced in the Netherlands for the collection, analysis and reporting of 
patient clinical data for gynecological patients undergoing surgical interventions. 
Procedures and adverse events or complications will be related to patients unique 
Citizen Service Number (BSN), independent of where the procedure was performed. 
Registration of sterilization procedures and complication, gives the opportunity for 
long-term follow-up of all methods of sterilization and life-table mathematics to 
calculate 2-year, 5-year or 10-year cumulative pregnancy rates. Therefore, we strongly 
recommend that all data of patients seeking for sterilization will be registered in 
this module. 
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Summary
Chapter 1 gives an overview and historical perspective of sterilization methods and 
describes the outline of this thesis.
In chapter 2 we conducted a systematic review to evaluate the feasibility, reliability 
and safety of modern hysteroscopic sterilization methods. All longitudinal studies 
addressing hysteroscopic tubal sterilization were considered for inclusion, both 
prospective and retrospective. Studies were included if they investigated reliability 
or safety of sterilization techniques, risk factors for failure of hysteroscopic 
sterilization. Only original studies were included with cohorts of 20 or more 
patients. Descriptive articles, case-series (non-consecutively), reviews, surveys, 
and technical reports were excluded. A total of 45 articles were included: 7 articles 
concerned Ovabloc, 36 Essure, and 2 Adiana sterilization. 
The Ovabloc Intratubal Device methode is an office procedure which can be done 
using local anesthesia. A catheter is installed into the ostium and a silicon mixture 
solidifies within 5 minutes into a soft rubber plug. The procedure is repeated on the 
contralateral side. A post-procedure X-ray is captured. If after three month a second 
X-ray shows that the position of the devices has not altered, the patient can rely on 
Ovabloc for sterilization. 
The Essure is an 4 cm expanding spring device made of a nitinol outercoil and 
stainless steel innercoil with PET fibers. The microinsert is placed in the proximal 
section of the fallopian tube. The PET fibres cause localised tissue ingrowth from 
the surrounding tube, thereby achieving mechanical occlusion of the tube and 
anchoring of the device. Different diagnostic tests (hysterosalpingography, X-ray 
and ultrasound) are described to confirm adequate position and bilateral tubal 
occlusion after three months.
The Adiana System is a combination of the 60-second application of radiofrequency 
(RF) to the mucosa of the fallopian tube, followed by deployment of a porous silicon 
3.5  mm matrix in to the thermal lesion. The procedure is than repeated on the 
other side. The matrix provides a substrate for tissue ingrowth, leading to tubal 
occlusion. A three-months hysterosalpingography is indicated to confirm bilateral 
tubal occlusion. The devices are not radiopaque.
All hysteroscopic sterilization technique offers distinct advantages over 
laparoscopic sterilization or mini-laparotomy with reduced need for anesthesia 
and decreased risk for injury to intra-abdominal organs. It can be performed in an 
office setting with local or no anesthesia. Patient tolerability and satisfaction were 
high in all studies despite the large difference in settings and pain management 
protocols used (no anesthetics, para-cervical block, intravenous sedation and 
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general anesthesia). The Ovabloc system had a higher placement failure rate, 
because of higher numbers of unsatisfactory position at the three-month control, 
due to migration or expulsion of the plugs. Also the number of unsuccessful 
procedures was higher but we have to realise that procedures were performed with 
larger (8 mm) single flow instruments, initially with Hyskon or carbon dioxide as 
distension medium.
Long-term data were spare. At least 12 patients, of a group of 1,588 patients who 
relied on Ovabloc, conceived after a satisfactory three-month X-ray. In 2009 the 
method was stopped.
The bilateral placement reliance represents the number of women who were 
ultimately instructed they could rely on the sterilization , divided by the number of 
intention to treat, and was similar for both techniques. The three-years cumulative 
pregnancy rate for Adiana was 15/1,000, while we calculated a 1/1,000 pregnancy 
rate for commercial use of Essure. Since March 2012 the Essure method is the only 
available method on the market.
Chapter 3 describes a study comparing the test characteristics of two diagnostic 
tests for Essure confirmation. Pelvic X-ray, transvaginal ultrasound and HSG 
imaging were performed in 150 women with successful bilateral placement. 
The results of transvaginal ultrasound compared with the results of HSG as the 
“reference test” showed a sensitivity of 50% and a specificity of 95%. One patient 
with correct position of the microinserts but with tubal patency on one side could 
not be identified by ultrasound or X-ray. A second patient with an expulsion of one 
microinsert was well diagnosed by both ultrasound and X-ray. When we compared 
diagnostic characteristics of the ultrasound with pelvic X-ray as the reference test 
(accepting the case with tubal patency as satisfactory) the sensitivity and specificity 
were 100% and 95%, respectively. In only eight patients with a satisfactory pelvic X-ray 
it was not possible to confirm satisfactory position of the devices with ultrasound. 
The predictive value of a satisfactory transvaginal ultrasound result is then 99% 
and the predictive value of an unsatisfactory result 11%.In this cohort of 150 women 
there was no case of perforation of a microinsert. Therefore we developed a new 
study to estimate the diagnostic accuracy and interobserver reproducibility of pelvic 
X-rays in the diagnosis of bilateral sterilization with Essure. 
In Chapter 4 six observers evaluated X-rays from 47 patients, including one case 
with a complete perforation of one device, one case of proximal position and tubal 
patency on HSG and one abnormal X-ray from the patient with complete expulsion 
of one device and tubal patency on HSG. Three gynecologists with experience 
in Essure sterilization and X-ray reading and three radiologists with specific 
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training in confirmation of Essure sterilization with X-ray were involved. After 
evaluation of the results it seemed that the test characteristics of pelvic X-ray as the 
imaging technique to assess the position of the microinserts were poor, as was the 
reproducibility. The sensitivity and specificity for X-rays read by gynecologists was 
0.67 (95% CI: 0.29-0.96%) and 0.79 (95% CI: 0.58-1.00%) and for radiologists 
1.0 and 0.5 (95% CI:  0.36-0.64%). The interobserver agreement in reliability 
(Fleiss’ κ-statistics) of pelvic X-ray of hysteroscopic sterilization assessment with 
Essure ranged from slight (κ-value: 0.09) for gynecologists to moderate (κ-value: 
0.52) for radiologists. Because of the limitations of X-ray compared to ultrasound 
and the non-superior diagnostic characteristics and poor interobserver agreement, 
we do not recommend the routine use of pelvic X-ray for the assessment of the 
positioning of microinserts after hysteroscopic sterilization. Only if expulsion or 
perforation of a device is suspected and ultrasound examination is not confirmative 
a X-ray can be helpful. 
In chapter 5 we describe three different types of incorrect position of Essure 
microinserts detected at three-month follow-up and their appearance on X-ray 
and by ultrasound. In a series of 100 patients who underwent hysteroscopic 
sterilization with Essure, three cases were identified with an abnormal position of a 
microinsert. In case A, both inserts were not clearly visible with vaginal ultrasound 
while on pelvic X-ray an abnormal configuration of one insert was seen. HSG 
showed tubal patency. The perforated microinsert was laparoscopically removed. 
Retrospectively, the patient had experienced abdominal pain for several weeks after 
the procedure. In Patient B one device was missing which was recognized with all 
confirmation tests. The patient had not noticed an expulsion. In a second attempt 
a new microinsert was placed successfully. In the third patient, who had a difficult 
bilateral placement due to adhesions in the uterine cavity, one device was expulsed 
into the uterine cavity. With ultrasound examination one device could not be made 
clearly visible. xpelvis showed an abnormal configuration of one device and on 
HSG there was tubal patency. After hysteroscopic removal of the microinsert a 
second device was correctly placed. Complications after Essure placement can be 
detected during the procedure itself or at follow-up. When, during the procedure, 
there is doubt about the position of a microinsert, a transvaginal ultrasound can 
be performed at that time. But one should realise that in case of perforation and 
expulsion, most incorrectly placed microinserts will migrate in the three-month 
period after the procedure. A majority of cases will not be detected during or directly 
after the procedure. We advise screening patients with apparent successful bilateral 
placement but with difficult placement procedures, other suboptimal conditions 
during the procedure, or abdominal pain in the first three months after the procedure. 
205Chapter 11  Summary
11
Initially this can be done with transvaginal ultrasound after the patient’s first period 
or withdrawal bleeding (approximately four weeks), and when in doubt, a pelvic 
X-ray can be performed. 
Because hysteroscopic sterilization is a rather new method, it is important that 
all pregnancies are reported and that cases are reviewed to determine the cause of 
unintended pregnancy. Some of the causes might be preventable. Understanding 
these causes can be helpful to improve the follow-up protocols and reduce the 
number of failures in the future. In chapter 6 we describe a retrospective analysis of 
10 unintended pregnancies after Essure sterilization in the Netherlands from August 
2002 till May 2008. In one case pregnancy already occurred before the procedure 
(luteal pregnancy). In three cases single placement was followed by HSG after three 
months and bilateral tubal occlusion was concluded. In the other six cases an abnormal 
position of a microinsert was recognized after termination of pregnancy although 
from one case data were lacking. In these five cases there was noncompliance to the 
protocol. A procedure with only a single device placement in a patient without a history 
of salpingectomy of the contralateral tube should be considered as unsuccessful and 
an HSG should not be performed.
Based on the information we collected from our earlier studies in the Netherlands we 
developed a revised protocol for the follow-up after Essure sterilization. The objective 
was to reduce the need for radiologic confirmation (X-ray examination and HSG), 
without compromising the effectiveness of Essure. In January 2005, this new protocol 
for follow-up of Essure sterilization was introduced in the Netherlands. With the new 
Dutch protocol, transvaginal ultrasound is used for the three-month confirmation of 
tubo-cornual location of the microinserts after an uncomplicated successful bilateral 
placement. The criteria for a normal successful bilateral procedure include procedure 
time of 15 minutes or less, microinsert visible after placement, fewer than nine coils 
protruding into the uterine cavity, and no unusual events during the procedure. In all 
other cases, HSG is still indicated. A procedure with only a single device placement 
in a patient without a history of salpingectomy of the contralateral tube should be 
considered unsuccessful, and HSG should be abandoned, because of a high risk of 
false positive confirmation of occlusion of the contralateral tube. When findings at 
ultrasound examination are inconclusive or abnormal location of a microinsert is 
suspected, HSG is indicated. 
In a multicenter study, described in chapter 7, we evaluated the revised protocol 
based on first-line confirmation using transvaginal ultrasound at three months after 
uncomplicated successful Essure sterilization and analyzed the placement success 
rate and effectiveness of the method. Data of 1,145 consecutive cases from five clinics 
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were collected and analyzed. The overall successful placement rate was 93.6% 
(1,072 of 1,145 intentions to treat). In 6% of patients with intention-to-treat, Essure 
sterilization was successfully completed; however, the procedure was not considered 
straightforward. According to the Dutch protocol, TVU was scheduled at four weeks 
after the procedure, and HSG at three months. In 4.5%, the ‘‘standard‘‘ three-month 
TVU was inconclusive; thus, HSG was scheduled as described in the protocol. In 
50 of these 52 patients, HSG confirmed bilateral occlusion with normal position of 
the devices. Only in two of these patients there was an abnormal positioning of one 
device: one expulsion and one perforation. Including patients with a successful second 
attempt and successful single placement overall 14.3% of patients (164 of 1,145) with 
intention to treat underwent HSG. In nine patients, HSG showed evidence of an 
abnormal position of one or two devices (two expulsions and seven perforations). 
Finally 1,037 patients were instructed to rely on the sterilization. The 24-months 
cumulative pregnancy rate was 3.86 per 1000 (4/1,037). None of these pregnancies 
were related to failure of the sterilization method. Two patients conceived with only 
one device in situ, one after bilateral placement and ultrasound confirmation, and 
one with bilateral tubal occlusion on HSG after single placement. In two cases there 
was a perforation of one device after a complicated procedure. in one case the device 
was absent or incorrectly positioned, and in three cases there was non-compliance 
with the protocol. The Dutch protocol for confirmation of Essure sterilization, 
with transvaginal ultrasound as first-line test, reduced the number of HSGs, thus 
reducing costs, inconvenience and discomfort, without influencing the effectiveness 
of the sterilization. In contrast with the FDA protocol, the Dutch control protocol is 
associated with high patient compliance. In cases of difficult placement, the extra 
TVU confirmation at 4 weeks did not reduce the number of HSGs. Thus, the need for 
routine TVU after a difficult hysteroscopic procedure should be abandoned, with sole 
reliance on the three-month HSG as a confirmatory test. 
After the success of occlusion of the fallopian tubes with microinserts for 
contraceptive use, a new indication was presented in 2005 to obstruct hydrosalpinges 
of subfertile woman to improve the results of IVF treatment as an alternative for 
salpingectomy to improve the chance of ongoing pregnancies in IVF-programs. 
Chapter 8 provides a prospective study to investigate the success-rate of proximal 
tubal occlusion with Essure devices in subfertile women with hydrosalpinges and to 
observe the results of subsequent treatment with IVF. Ten patients had successful 
placement of the Essure devices without any complications. Proximal tubal occlusion 
was confirmed by hysterosalpingography in 9 out of 10 patients. A 40% ongoing 
pregnancy rate was achieved with 20% life births after one IVF cycle and/or frozen 
embryo transfer. Our case series shows good pregnancy rates with IVF-ET following 
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Essure placement, and is consistent with others found after laparoscopic salpingectomy.
A significant concern for women with unintended pregnancies and subfertile 
women wishing to conceive with microinserts in situ, is the trailing of Essure coils 
into the uterine cavity and its possible effects on implantation as well as on pregnancy. 
Therefore we collected data of 50 pregnancies in 43 patients in the Netherlands who 
became pregnant with one or two Essure microinserts in situ. 
In Chapter 9 we analyzed the obstetric outcomes of 50 pregnancies in 43 women 
with one or two Essure microinserts in place and found a good outcome for ongoing 
pregnancies. Of 26 unintended pregnancies after hysteroscopic sterilization with 
Essure 17 (65.4%) were electively terminated, and 9 (34.6%) resulted in the birth of 
a healthy baby. Both of the two patients with sterilization-regret, treated with IVF-ET, 
conceived after the first single-embryo transfer. Both delivered a healthy baby. In the 
IVF-group with pre-procedure closure of hydrosalpinges 15 of 23 pregnancies (65%) 
were ongoing. Only two patients had a microinsert with five coils in the uterine 
cavity. In one of these patients, pregnancy ended in miscarriage. In the other patient, 
pregnancy ended with stillbirth. After removal of the microinserts, dramatically her 
next pregnancy ended with a second still birth. The number of miscarriages (35%) 
in the group who underwent IVF-ET after proximal closure of hydrosalpinges is not 
unexpectedly high and reflects findings reported in the literature. The number of 
ongoing pregnancies in this group is encouraging and congruent with the literature 
on pre-IVF salpingectomy or tubal occlusion. It is unlikely that the presence of Essure 
microinserts interferes with implantation and the developing amniotic sac and fetus. 
Chapter 10 is a general discussion on the findings of this thesis and provides the 
answers to the research questions posed in the outline of this thesis. Furthermore some 
future perspectives are discussed, including the introduction of new hysteroscopic 
sterilization devices and alternative non-ionising confirmation tests. A recommendation 
is made to register all data of patients seeking sterilization in the Patient Outcome 
Measurement Tool that has recently been introduced in the Netherlands. 
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Nederlandse samenvatting
Wereldwijd vertrouwen meer dan 100 miljoen vrouwen op sterilisatie als definitieve 
vorm van anticonceptie. Al meer dan 100 jaar worden vrouwen gesteriliseerd. Met 
de komst van de laparoscopische sterilisatie heeft deze techniek in veel Westerse 
landen lange tijd de voorkeur gehad, boven de meer invasieve technieken waarvoor 
een (min) laparotomie noodzakelijk was. Drie hysteroscopische sterilisaties 
technieken zijn afgelopen decennia met in Nederland geïntroduceerd. De Ovabloc 
Intratubal Device methode (1980) met injectie van een vloeistof met siliconen, 
waardoor zich een rubber plug vormt in de tuba. Waarbij controle plaats vindt 
door middel van twee röntgenfoto’s, direct na de ingreep en na drie maanden. De 
Essure methode (2002), waarbij veertjes met polyester vezels in de eileiders worden 
geplaatst , waarna afluiting ten gevolge van weefsel ingroei gecontroleerd wordt 
door middel vane een röntgenopname of Hysterosalpingogram na 3 maanden. Als 
laatste de Adiana Permanent Contraception Method (2009), waarbij een thermisch 
beschadiging wordt veroorzaakt van de mucosa van de tuba, waar na een poreuze 
silicone matrix ter hoogte van de laesie wordt achtergelaten. Na 3 maanden dient 
afsluiting van de tubae bevestigd te worden door middel van een HSG. Sinds maart 
2012 is na het verdwijnen van Ovabloc en Adiana alleen de Essure methode nog 
maar beschikbaar in Nederland. 
Hoofdstuk 1 geeft een historisch overzicht van de verschillende methoden van 
sterilisatie van de vrouw en beschrijft de doelstellingen en vraagstellingen van dit 
proefschrift. 
Hoofdstuk 2 beschrijft een systematisch literatuuroverzicht van cohortstudies 
over hysteroscopische sterilisatie bij de vrouw. Er werd gekeken naar de effectiviteit, 
betrouwbaarheid en veiligheid van de drie verschillende hysteroscopische sterilisatie 
methoden die in Nederland werden toegepast. 
In Hoofdstuk 3 worden een drietal casus beschreven, met abnormale positie van 
een Essure device. Bij een patiënte trad een perforatie op van het device, bij de tweede 
trad een expulsie naar het cavum uteri op en bij de derde trad complete expulsie van 
het device op. De röntgenfoto van de eerste patiënten toonde een abnormale positie 
en configuratie van het device op met deviatie van de het proximale einde van de 
buitenste veer (4th marker)
Hoofdstuk 4 beschrijft de resultaten van een studie, waarbij de betrouwbaarheid 
van de interpretatie en de interobserver variabiliteit van de beoordeling van een 
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röntgen bekkenfoto na Essure sterilisatie door 6 onderzoekers. In totaal werden 
47 foto’s beoordeeld door 3 gynaecologen met ruime ervaring van Essure plaatsing 
en drie radiologen met specifieke training in het lezen van röntgenfoto’s na Essure 
sterilisatie. Op basis van eerdere HSG’s waren drie foto’s afkomstig van patiënten 
waarbij de sterilisatie als onbetrouwbaar moest worden beoordeeld (1 perforatie, 1 
expulsie en 1 proximale positie). De testkarakteristieken en de reproduceerbaarheid 
van de beoordeling van de röntgenfoto’s ter bepaling van de correctheid van de 
positie van de microinserts was slecht. De interobserver agreement met behulp 
van Fleis’s statistiek (schaal 0,0 - 1,0) voor de gynaecologen was gering (κ = 0,09) 
en matig voor de radiologen (κ = 0,52). De negatief voorspellende waarden voor 
beide groepen was hoog (resp. 98% en 100%) hetgeen wil zeggen, dat een als 
betrouwbaar uitgeboekte foto overeenkomt met een betrouwbare sterilisatie. Echter 
de positief voorspellende waarde was laag (resp. 43% en 13 %) hetgeen betekent 
dat het niet kunnen bevestigen van een betrouwbare sterilisatie, niet wil zeggen 
dat deze ook onbetrouwbaar is. De radiologen beoordeelden correct de drie foto’s 
van patiënten met onbetrouwbare sterilisatie, echter in een groot aantal van de 
betrouwbare sterilisaties, was er minimaal 1 radioloog die een aanvullend HSG 
adviseerde. Twee gynaecologen beoordeelde de foto met perforatie als betrouwbaar 
en door 1 gynaecoloog werd de abnormale (proximale) positie van het device in het 
cavum uteri niet herkend.
Door alle zes de onderzoekers werd de foto van een patiënt met complete expulsie 
correct beoordeeld. Geconcludeerd wordt dat het niet is aan te bevelen een rontgen 
foto van het bekken als eerst test te verrichten na Essure sterilisatie. Slechts indien 
er verdenking is op expulsie of perforatie van een microinsert, en de echo is niet 
conclusief , is een x pelvis een nuttige aanvulling.
In Hoofdstuk 5 worden de resultaten besproken van een studie, waarbij de 
testkarakterieken van twee verschillende confirmatietesten werden bepaald en 
werden vergeleken. Bij 150 patiënten met succesvolle dubbelzijdige plaatsing van 
Essure, werd drie maanden na de procedure een vaginale echo ( transvaginale 
ultrasound, TVU) en HSG gemaakt. De eerste blanco opname van het HSG werd 
gelijk gesteld aan een X bekken. Transvaginale Ultrasound heeft een sensitiviteit 
van 50% en een specificiteit van 95% ten opzichte van de gouden standaard, het 
HSG. Voor het X bekken waren sensitiviteit en specificiteit respectievelijk 100% en 
99%. De voorspellende waarde van de transvaginale ultrasound dat de microinsert 
niet goed gepositioneerd is bedroeg 11%, terwijl de voorspellende waarde van een 
goed gepositioneerde microinsert 99% was. 
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Hoofdstuk 6 betreft een retrospectieve analyse van 10 ongewenste 
zwangerschappen na Essure sterilisaties in Nederland, die zijn ontstaan sinds de 
introductie in augustus 2002 tot mei 2008. In 1 geval bleek achteraf, dat patiënte 
al zwanger was ten tijde van de sterilisatie. In 3 gevallen was een dubbelzijdige 
plaatsing mislukt en toonde het HSG geen toe- en doorgankelijkheid van de 
eileiders en werd de sterilisatie als betrouwbaar beoordeeld. Van de overige 6 
patiënten betrof het in 5 gevallen een abnormale positie van het device, terwijl 
van 1 patiënt geen gegevens bekend zijn. In alle gevallen, behoudens de ene casus 
waarvan de gegevens ontbreken, was er sprake van verkeerde beoordeling van de 
confirmatietest of afwijking van het protocol. Geconcludeerd wordt dat bij patiënten 
zonder voorgeschiedenis van de verwijdering van een eileider, een enkelzijdige 
plaatsing geduid moet worden als mislukte sterilisatie en niet gevolgd moet gaan 
door een HSG.
Hoofdstuk 7 beschrijft de resultaten van een prospectieve multicenter cohort 
studie, waarbij een nieuw protocol met echoscopische controle na ongecompliceerde 
hysteroscopische sterilisatie door middel van Essure wordt geëvalueerd. Bij 90,3% 
(1034/1045) van de procedures was er sprake van een probleemloze dubbelzijdige 
plaatsing tijdens een eerste procedure. Bij 887 patiënten met een ongecompliceerde 
procedure kon na 3 maanden met echo (transvaginal ultrasound) worden 
geconcludeerd dat patiënten konden vertrouwen op de sterilisatie. Uiteindelijk, 
na een eventuele tweede procedure en/of HSG controle konden 1037 vrouwen 
vertrouwen op de sterilisatie. In totaal werd bij 14,3% van de vrouwen een HSG 
gemaakt. Bij 7 vrouwen bleek er sprake te zijn een perforatie en bij 2 werd 
een expulsie vastgesteld. In de eerste 24 maanden na de confirmatie traden 4 
zwangerschappen op. Het 2 jaar cumulatieve zwangerschapscijfer bedroeg 3,86 
/1000, terwijl er geen method-failures waren. Het vernieuwde Nederlands protocol 
met transvaginale ultrasound als eerste keuze voor confirmatietest vermindert het 
aantal noodzakelijke HSG’s en daarmede de kosten. Het is vriendelijker voor de 
patiënt en vermijd ioniserende straling, zonder dat het de betrouwbaarheid van de 
sterilisatie nadelig beïnvloed. In vergelijking met de Verenigde Staten, waar een 
HSG verplicht is, gaat het Nederlands protocol gepaard met een hoge therapietrouw 
(“patiënt compliance”).
Hoofdstuk 8 beschrijft de resultaten van een studie waarbij patiënten met 
tubaire infertiliteit een IVF behandeling ondergingen na afsluiting van 1 of 2 
hydrosalpingen door middel van Essure. Het onderzoek betrof 10 patiënten met 
1 of 2 hydrosalpingen en een contra-indicatie voor laparoscopische tubectomie. 
In alle gevallen kon een microinsert in de aangedane eileider worden geplaatst 
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en bij allen op één na werd met HSG bevestigd dat de hydrosalpinx proximaal 
werd afgesloten door de microinsert. Na 40% van de embryo-transfers trad een 
doorgaande zwangerschap op en het percentage levend geboren kinderen was 20% 
per behandelingscyclus.
In Hoofdstuk 9 worden de uitkomsten besproken van zwangerschappen bij 
vrouwen met 1 of 2 microinserts in situ. De gegevens werden verkregen door middel 
van een enquête onder Nederlandse gynaecologen, die Essure sterilisaties verrichten. 
In totaal werden gegevens verzameld van 50 zwangerschappen bij 43 vrouwen. Bij 
26 vrouwen trad de zwangerschap op na Essure sterilisatie en 21 zwangerschappen 
ontstonden na IVF behandeling bij 15 vrouwen met hydrosalpingen, die waren 
afgesloten door middel van microinserts. Van de ongeplande zwangerschappen 
eindigde er 17 door middel van zwangerschapsafbreking. Van de 9 doorgaande 
zwangerschappen eindigde er 8 met de geboorte van een gezond kind, terwijl 
van 1 zwangerschap de gegevens ontbreken. Van de 22 zwangerschappen na IVF 
vooraf gegaan doorafsluiting hydrosalpingen met microinserts eindigde er 8 in een 
miskraam en waren er 14 doorgaand. Twee zwangerschappen eindigde met een 
partus immatures, Deze twee casus worden besproken. Beide vrouwen werden 
opnieuw zwanger na een volgende IVF behandeling. De overige 12 zwangerschappen 
leidde tot de geboorte van 13 gezonde kinderen, waaronder een tweeling geboren 
bij 34 weken. Bij 2 vrouwen betrof het een zwangerschap na IVF na spijt van de 
sterilisatie. Beide vrouw baarden een gezond kind.
De resultaten van de studie komen overeen met eerdere bevindingen dat het 
onwaarschijnlijk is dat de aanwezigheid van microinserts een negatieve invloed 
heeft op de implantatie en ontwikkeling van vruchtvliezen en fetus.
In Hoofdstuk 10 worden algemene conclusies, resultaten en tekortkomingen 
van dit proefschrift beschreven. Nieuwe ontwikkelingen op het gebied van 
hysteroscopische sterilisatietechnieken en alternatieven confirmatietesten worden 
besproken. Toekomstig onderzoek dient zich te richten op een analyze van de 
oorzaak van mislukte sterilisaties en de noodzaak van een eventuele confirmatietest. 
Een aanbeveling wordt gedaan voor een landelijke registratie van alle uitgevoerde 
sterilisaties en de opgetreden complicaties, inclusief zwangerschappen in POMT 
(Patient Outcome Measurement Tool).
Hysteroscopische Sterilisatie
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List of Abbreviations
2D  2 Dimensional
3D  3 Dimensional
AE  Advers Event
ART   Artifical Reproduction 
Techniques
BSN Burgerservicenummer
CE   Conformité Européene
CF  Continous Flow
CI   Confidence Interval
CIS  Contrast Infusion Sonography 
CREST   Collaborative Review 
of sterilization 
CS  Conscious Sedation
D&C  Dilatation & Curettage
EASE   Evaluation of the Adi-
ana System for Tran-
scervical sterilization 
ET   Embryo Transfer
FDA  Food and Drug Administration
Fr   French (Gauge)
GA   General Anesthesia
HSG  Hysterosalpingography
HyCOSy  Hysterosalpingo  
Contrast Sonography
HyFOSy  Hysterosalpino Foam  
infusion Sonography
ITD  Intra Tubal Device
IUD  Intra Uterine Device
IVF-ET   In Vitro Fertilization 
EmbryoTransfer
IVS  Intravenous Sedation
MBDT  Methylene Blue Dye Test
NPV  Negative Predictive Value
OR  Operation Room
PB   Paracervical Block
PET  Polyethylene Terephthalate
PID  Pelvic Inflammatory Disease
 
 
POMT   Patient Outcome  
Measurement Tool
PPV  Postive Predictive value
RCT  Randomised Controlled Trial
RF   Radio-Frequency
SAE  Serious Adverse Event
SD  Standard Deviation
Se   Sensitivity
SF   Single Flow
SIS  Saline Infusion Sonography
Sp   Specificity
STI  Sexual Transmitted Disease
TVU  Transvaginal Ultrasound
VAS Visual Analogue Scale
VOP Violation of Protocol
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Hysteroscopic 
sterilization with 
Essure
Bilateral normal 
procedure?
Microinsert visible 
Number of coils ≤8 
Procedure time ≤15 min
After 3 months, TVU
Satisfactory
Successful 
sterilization 
Successful 
sterilization 
Successful 
sterilization 
Satisfactory
Bilateral occlusion?
Expulsion?
Perforation?
Second fallopian tube 
removed
Satisfactory
After 3 months,
hysterosalpingographya
After 3 months,
hysterosalpingographyb
After 4 weeks, pelvic 
radiography or TVU
ATTENTION!
Pelvic radiography
Microinserts
Distance
Location
Symmetric
Position fourth marker
Alignment
Placement of 
2 microinserts?
Placement of 
1 microinsert?
Unsuccessful 
sterilization 
Unsuccessful 
sterilization 
Unsuccessful 
sterilization 
Consider surgical 
intervention
yes yes
no
?
no
nonono
no
nono
no
yes yes yes
yes
yes
yes
yes yes
Time Schedule
T0  = Essure procedure 
T4  = T0 + 4 weeks
T12 = T0 + 12 week
T0 
T0 T4 
T4 
T0 
T12 T12
T12
Dutch protocol: Flowchart of Essure sterilization in the Netherlands ( SV, MV; 2005)
*  Begin Hysterosalpingography with plain scan (without contrast medium) 
 If patient uses NSAID, corticoids or cytostatics perform hysterosalpin-
gography after 6 months
Hysteroscopic 
sterilization with 
Essure
Bilateral normal 
procedure?
Microinsert visible
Number of coils ≤ 8
Procedure time ≤ 12 min
No Post-Procedure Pain
No other risk factor
Successful 
sterilization 
Successful 
sterilization 
Successful 
sterilization 
Successful 
sterilization 
Satisfactory Satisfactory
Bilateral Occlusion?
Normal Position
After 3 months
TVU* or X-ray
Second test        Pelvic 
X-ray or TVU* 
Hysterosalpingog-
raphy*
Placement of two
Microinsert?
Placement of One
Microinsert?
( No salpingectomy or 
Ut unicollis)
Unsuccessful 
sterilization 
Unsuccessful 
sterilization 
yes
yes
yes
yes yes yes
no no
nono nono
no
yes
Time Schedule
T0  = Essure procedure 
T12 = T0 + 12 week
T0 
T12 T12 T12
T0 
Revised Flowchart of Essure follow-up without standard confirmation (SV; 2014) 
*  TVU: Transvaginal Ultrasound 
Begin Hysterosalpingography with plain scan (without contrast medium) 
If patient uses NSAID, corticoids or cytostatics perform hysterosalpingogra-
phy after 6 months
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Dankwoord
Wat jammer dat het af is. Het bereiken van dit resultaat geeft voldoening, maar 
de weg er naar toe nog veel meer. Het was een lange weg , maar het heeft me veel 
gebracht, waarvoor ik dankbaar ben. De afgelopen jaren hebben velen mij geholpen 
en hun bijdrage geleverd.
In de eerste plaats gaat mijn dank uit naar alle vrouwen in Nederland, die 
gemotiveerd waren om zich met een nieuwe hysteroscopische techniek te laten 
steriliseren. Nieuwe methoden, brengen nieuwe onzekerheden en complicaties 
met zich mee. Ik ben er van overtuigd dat we in Nederland de juiste weg hebben 
gevonden en uw vertrouwen niet hebben geschaad. Heel veel dank. Zonder u was 
deze dissertatie niet mogelijk geweest.
Niet in de laatste plaats ben ik dank verschuldigd aan vele collega’s in het land, met 
in het bijzonder: Caroline Koks, Hugo van Eijndhoven, Andreas Thurkow, Huub van 
der Vaart en Michel Vleugels. Mede dankzij jullie inbreng en bereidheid om data 
uniform te registreren heb ik mijn analysis kunnen doen. Dank voor jullie inzet.
De leden van de beoordelingscommissie dank ik voor het kritisch beoordelen van 
het manuscript. De leden van de promotiecommissie dank ik voor de mogelijkheid 
om mijn proefschrift ten overstaan van hen te mogen verdedigen.
Beste Michel, nadat ik in 2003 bij jou had meegekeken naar een door jou in 
Nederland geïntroduceerde nieuwe techniek van hysteroscopische sterilisatie was 
ik overtuigd dat het een prima alternatief was voor de laparoscopische sterilisatie. 
Toen ik je een jaar later vroeg of je het goed vond dat ik een proefschrift aan dit 
onderwerp ging wijden, was je direct enthousiast. Je had zelfs al een concept 
protocol klaar liggen. Je geduld is beloond. De inzet en gedrevenheid die jij bij al 
je projecten toont dwingen diepe respect af. Ik wens je veel succes bij je grootste 
project: het ontwikkelen van instrumenten met haptic feedback.
Beste Hans via Michel kwam ik bij jou. Voor mij een niet meer dan logisch keuze, 
omdat een hysteroscopisch onderwerp thuis hoort bij een hoogleraar met expertise 
op dit gebied. Dat je je ook nog eens hoogleraar was in de VU, waar ik ben opgeleid, 
maakte het helemaal compleet. De wijze waarop jij mij ( waarschijnlijk je oudste 
promovendus) de afgelopen jaren mijn gang hebt laten gaan, was bijzonder. Steeds 
als ik erom vroeg was je beschikbaar en gaf je me de juiste raad en stond je me bij. 
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Behalve het proefschrift waren er ook altijd veel andere zaken die werden besproken 
en hebben we ongelooflijk met elkaar gelachen. Je hebt niet alleen voor mij maar 
voor heel gynaecologisch Nederland een cruciale rol vervuld als voortrekker om 
het deelgebied benigne gynaecologie met haar complexe (chirurgische) uitdagende 
kanten tot een volwaardig aandachtsgebied te brengen.
Beste Peter, mijn verzoek aan jou om onze krachten te bundelen werd door jou 
direct positief beantwoord. Het was voor mijn onderzoek een zeer waardevolle 
aanvulling. Hoe bijzonder is het dat ik na al die jaren weer terug mocht komen op 
het “oude nest”. Heel veel dank. 
Beste Kim, Roel, Mark-Hans en Velja, dank voor de prettige wijze waarop we 
hebben kunnen samenwerken. Het afsluiten van de eileiders kan om meerdere 
reden zinvol zijn. Dank, dat wij twee hoofdstukken van dit proefschrift , gezamenlijk 
hebben kunnen vormgeven.
Alle mede auteurs, heel veel dank voor jullie inbreng.
Beste Hetty, Carla, Oscar en Miebeth (Clinical Librarians). De wijze waarop jullie 
mij telkens weer hebben geholpen met het verkrijgen van de juiste literatuur en 
de hulp bij de searches is heel belangrijk geweest voor het volbrengen van mijn 
proefschrift. Het St. Antonius mag zich gelukkig prijzen met zo’n enthousiast team 
bij het verwezenlijken van onze wetenschappelijke ambities. 
Beste Hans en Ellen, dank voor jullie hulp bij de statistische analyses. Het waren 
voor jullie niet de moeilijkste opgaven, maar jullie hulp was voor mij essentieel.
Beste maten: Erik v. Beek , Adrienne Blankhart, Peppino Graziosi, Arne van 
Heusden, Michael Kars, Joost Lange, Jessica vdr Leij, Jur Oosterhuis , Lucie Ribbert, 
Jules Schagen van Leeuwen, Sien The, Elly Vernooij, Gerard Wennink en Wilma 
Monincx,. Het project waar maar geen eind aan kwam is volbracht. Dank voor jullie 
steun en ruimte die ik daarvoor gekregen heb.
Beste Andrea, je zei nooit nee, als ik je iets vroeg om voor mij te regelen of af te 
handelen waar ik geen tijd (zin) in had. Samen met Coby en Kitty hebben jullie me 
vanaf het begin enorm geholpen. 
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Beste Claire, nadat we eerst samen hebben gewerkt binnen de commissie richtlijn 
“sterilisatie van de vrouw”, heb ik het genoegen gehad om samen met je de review 
te schrijven. Jouw punctualiteit en souplesse, maakten het tot een genot om met 
je te werken.
Beste Kathy en Coby, wij kunnen ons geen betere R&D nurses wensen. Jullie 
hebben echt fantastisch werk geleverd met de invoer van alle data en afhandeling 
van veel administratieve handelingen. Ik ben jullie heel veel dank verschuldigd.
Beste Annemiek, vanaf het begin heb jij je ingezet voor een goede planning en 
controle van de patiënten die kozen voor hysteroscopische sterilisatie. Ik ben jou 
en al je collega’s die hebben meegeholpen (poli gyn: Ardien , Deli, Gerda, Mary 
en Petra; Endoscopie: Angela, Anja, Heleen, Liesbeth, Linda, Marlous en Nina) 
veel dank verschuldigd. Nu maar eens kijken wat we van de nieuwe “schuur” in 
Leidsche Rijn kunnen maken. 
Lieve Idje en Daan. hoe leuk is het als je in de familie professionals hebt die je 
kunnen helpen met layout en design. Ik hoop dat jullie mijn professionele hulp niet 
nodig hebben over enkele maanden.
Simone, lieve zus. Dank voor je vertrouwen. Ik ben net zo trots op jou.
Lieve Marlies, na de middelbare school kruisten onze wegen opnieuw. Sindsdien 
lopen ze parallel. Al meer dan 30 jaar werken we samen en zijn we twee handen 
op één buik. Het is zo heerlijk om een professioneel “maatje” te hebben om mee te 
sparren of door terug gevloten te worden. Jij had ook in de leescommissie kunnen 
plaats nemen of kunnen opponeren, maar je verkoos om samen met Repke mij 
terzijde te staan. Samen gaan we nog mooie dingen beleven.
Repke, mijn allerbeste vriend vanaf de kleuterschool. Vanaf ons 5e jaar waren we 
onafscheidelijk tot en met de studie geneeskunde in Utrecht. We deelden lief en 
leed. Het kon geen toeval zijn dat we beiden in het St. Antonius terecht kwamen, 
nu alweer meer dan 20 jaar. Als we niet samen hadden gestudeerd had ik hier 
waarschijnlijk nooit gestaan. 
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Lieve Diederik, dierbare broer. Toen jij pottenbakker wilde worden, wilde ik dat 
ook. Dierenarts? Ik ook!. Uiteindelijk ging je geneeskunde studeren. Ik ook. Jij werd 
gynaecoloog, ik ook. Van grote broer en collega werd je uiteindelijk mijn vriend. Het 
verschil in leeftijd leek ooit een hele generatie, maar is verdwenen. Soms vragen 
collega’s of wij een Tweeling zijn. Ik wel, een zogenaamde juni-tweeling. Jij niet. 
Hoewel ik wars ben van astrologie heb jij je als Ram om mij bekommerd en in het 
begin de weg gewezen. 
Lieve Martha. Dit proefschrift was er nooit geweest zonder jouw onvoorwaardelijke 
liefde, steun en vertrouwen in mij. Ik prijs mijzelf gelukkig met jou en Tim en 
Nils. Twee zonen, die het mooiste zijn wat mij ooit is overkomen. Jullie hebben 
me geweldig geholpen met de laatste loodjes. Het schijnbaar gemis aan dochters 
wordt ruimschoots gecompenseerd met twee geweldige schoondochters: Caroline 
en Minou.
Lieve Moeder, Ooit spraken we af dat wij samen mijn promotie zouden gaan 
beleven. Ik heb het uiterste van je gevraagd, maar wij hebben het volbracht. 
Woorden schieten hier tekort. Aan jou aan wie ik alles te danken heb, draag ik dit 
proefschrift op.
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Curriculum Vitae
Sebastiaan Veersema was born on 1 June 1957 in Eindhoven, the Netherlands. 
After attending Nutsschool Reigerlaan primary school and the Lorentz Lyceum in 
Eindhoven he received his medical degree in 1980 from the University of Utrecht. 
Subsequently he started a residency in the department of Gynaecology and Obstetrics 
of the St. Lambertus Hospital in Helmond. For three years he participated in a 
research project aimed at early detection of EPH-gestational disease, led by O.T. 
Uttendorfsky en D. Veersema. Own research was conducted on hemodynamic 
changes during pregnancy. In 1985 gynecological training commenced in VU 
Academic Hospital in Amsterdam (under respectively prof. J.G. Stolk, prof. N. 
Arts, prof. J. Janssens, prof. P. Kenemans). He had his 15 minutes of fame in 1988, 
when the results of the TOAST-study were published in The New England Journal 
of Medicine. The last year of (non academic) training was completed in the St 
Elisabeth Gasthuis in Haarlem, followed by registration as medical specialist on 1 
April 1989. Thereafter he started a fellowship in Reproductive Endocrinology and 
Fertility Research at the Vrije Universiteit Academic Hospital, supervised by prof. 
J. Schoemaker. In this period research was conducted on the relationship between 
Human Placental Proteins and Endometrium Staging. 
Since 1991 he has been a consultant in the department of Obstetrics and 
Gynaecology at the St. Antonius Hospital in Nieuwegein. From 1996 to 2013 he 
was medical manager for respectively Care Units ‘Surgery’, ‘Mother and Child’, 
and ‘Man, Woman and Child’. He was board member for the NVOG (Dutch Society 
for Obstetrics and Gynaecology) from 2001 to 2006. In addition he has held 
numerous managing positions within the NVOG: VAGO (Society for Obstetrics and 
Gynaecology Residents), Dutch Working Party Gynaecological Endoscopy (WGE) 
and Committees on Manpower Planning, Patient Education and Gynaecongres. He 
is the inventor of the BasIQ, a surgical instrument for performing episiotomies 
and of a hybrid shaft for ambulant hysteroscopy. He is married to Martha Serkei, 
together they have two sons: Tim and Nils.  
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Sebastiaan Veersema werd geboren op 1 juni 1957 in Eindhoven. Na de Nutsschool 
Reigerlaan en het Lorentz Lyceum te Eindhoven behaalde hij in 1980 zijn artsexamen 
aan de Rijks Universiteit te Utrecht. Aansluitend begon hij als arts-assistent op 
de afdeling Gynaecologie en Verloskunde van het St. Lambertus Ziekenhuis te 
Helmond. Gedurende drie jaar participeerde hij in een onderzoeksproject gericht 
op de vroege detectie van EPH gestose onder leiding van O.T. Uttendorfsky en 
D. Veersema. Een eigen onderzoek was gericht op de haemodynamische veranderingen 
in de zwangerschap. In 1985 werd begonnen met de opleiding tot gynaecoloog in het 
Academisch Ziekenhuis VU te Amsterdam (resp. opleiders: prof. J.G. Stolk, prof. 
N. Arts, prof. J. Janssens, prof. P. Kenemans). In 1988 beleefde hij zijn ‘15 minutes 
of fame ‘ met de resultaten van het TOAST onderzoek, die gepubliceerd werden in 
The New England Journal of Medicine. Het laatste (niet academische) jaar van de 
opleiding werd volbracht in het St Elisabeth Gasthuis te Haarlem met als opleider 
J. Kleinhout, waarna inschrijving in het specialistenregister bij de MSRC plaats 
vond op 1 april 1989. Hierna volgde een fellowship Voortplantingsendocrinologie 
en Vruchtbaarheidsonderzoek in het Academisch Ziekenhuis der Vrije Universiteit 
onder leiding van prof. J. Schoemaker. In deze periode werd onderzoek verricht 
naar de relatie tussen Human Placental Proteins en Endometrium Staging. Vanaf 
1991 tot op heden is hij lid van de maatschap Gynaecologie en Obstetrie van het 
St. Antonius Ziekenhuis te Nieuwegein en Utrecht. Vanaf 1996 tot 2013 was hij 
medisch manager van respectivelijk de Zorgeenheid Heelkunde, de Zorgeenheid 
Vrouw en Kind en de Zorgeenheid Man, Vrouw en Kind en van 2001 tot 2006 was 
hij lid van het Bestuur van de NVOG. Daarnaast heeft hij diverse andere bestuurlijke 
functie vervuld binnen de NVOG: VAGO, Commissie In- en Uitstroom, Commissie 
Patiëntenvoorlichting, Commissie Gynaecongres en Werkgroep Gynaecologische 
Endoscopie (WGE). Hij is uitvinder van de BasIQ, een chirurgisch instrument voor 
het verrichten van een episiotomie en van een hybride schacht voor ambulante 
hysteroscopie. Hij is getrouwd met Martha Serkei. Samen hebben zij twee zonen: 
Tim en Nils.
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